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Abstract 
Background: 
Currently available prosthetic small calibre vascular grafts have poor medium and long term 
outcomes due to the development of neo-intimal hyperplasia caused by their non-compliant 
properties and lack of an endothelial cell lining.  
Here a nanocomposite based on polyhedral oligomeric silsesquioxane (POSS) attached by 
direct reaction onto a urethane segment was employed as a potential vascular graft material. 
It has been demonstrated to have similar viscoelastic properties to a native artery and be 
resistant to degradation. 
Initially Human Umbilical Vein Endothelial Cells (HUVEC) were employed as the cell 
source of choice after which investigations were carried out into the suitability of human 
peripheral blood derived circulating endothelial cells (CEC) and endothelial progenitor cells 
(EPC) for graft seeding.  
Aim: 
The aim of this study was to develop a system with the potential to deliver an EPC/CEC-
seeded bypass graft in a realistic time-frame. 
Methods: 
The cytocompatibility of the nanocomposite was initially investigated using HUVEC as a cell 
source. Surface modification of the nanocomposite to improve cell adhesion and proliferation 
was then attempted using UV exposure. Seeded nanocomposite grafts were then exposed to 
flow and the effect of preconditioning investigated. Following this the use of human 
peripheral blood derived EPC and CEC as a potential cell seeding source was investigated. 
Studies were also carried out into the sterilization of the nanocomposite. 
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Results: 
The nanocomposite was able to support the attachment and growth of both HUVEC and 
EPC/CEC. Nanocomposite grafts were successfully seeded and exposed to flow with cells 
being retained on the graft surface following exposure to flow. 
Conclusions: 
The results obtained suggest that the nanocomposite graft and the use of EPC/CEC derived 
from human peripheral blood process has potential both for a realistic and achievable two-
stage seeding process for vascular bypass grafts.  
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EtOH (10 mins and 24 hrs), Autoclave and gamma irradiation.  With each spectra is a 
summary of any changes in key peak intensities (n=6, p<0.05).   
Figure 7.3: The percentage change (compared with unsterilized control) in number average 
(Mn, top) and weight average (Mw, bottom) molecular weight of POSS-PCU and POSS-
PCL, both cast and porous samples after sterilization via a 10-min incubation in EtOH, 24 h 
incubation in EtOH, autoclaving, and gamma irradiation (mean ± SD, n=3). The molecular 
weights of the unsterilized controls were as follows: POSS-PCU (Mw = 108 500, Mn = 
42,600), POSS-PCL (62 800, Mn = 31,200). 
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Figure 7.4: Cell viability after 7-day incubation, as determined by Alamar blueTM assay.   
Results (mean ± SD) are presented as a percentage of the control cells grown on tissue culture 
plastic (n=4, * = p<0.001).  Gamma irradiation appeared to reduce the number of viable cells 
by approximately 50% on POSS-PCU whereas no significant differences were observed in 
cell growth on casted POSS-PCL samples.  No cell growth was seen on the coagulated 
samples of POSS-PCL. 
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1 
1 Introduction 
 
Cardiovascular disease has become an increasing health issue with a significant economic 
impact (Mozaffarian et al., 2016). The World Health Organisation estimates that in 2012 17.5 
million people died from cardiovascular disease worldwide. In the USA for example 38% of 
all deaths recorded were due to cardiovascular disease (World Health Organisation, 2016). It 
is believed that over 800,000 coronary artery bypass procedures are carried out annually 
(Cleveland Clinic 2011) and the overall demand for vascular grafts is growing substantially 
with an estimated annual growth of 8.4% in the USA for example (Freedonia Group 2011). 
For the past five decades, there has been considerable interest in the development and use 
of synthetic vascular grafts as an integral part of vascular surgery. Initial work in the 1950’s 
focused on the use of autologous vein segments for small (less than 4mm) to medium (less 
than 7mm) vessel peripheral vascular bypass in distal limbs. While the use of autologous 
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grafts has been successful (Klinkert et al., 2004; Klinkert et al., 2003; Chamiot-Clerc et al., 
1998) it is limited by the fact that in approximately one third of patients a suitable autologous 
vein is not available either because the existing veins are in poor condition or suitable ones 
have been used in previous procedures (Veith et al., 1979; Kerdjoudj et al., 2007; Twine and 
McLain, 2010).  
There are a number of features and challenges which must be taken into consideration 
when designing the ideal vascular conduit such as minimizing patient waiting time for a 
suitable conduit, ensuring that the conduit has adequate mechanical properties (suture 
retention strength, burst pressure, resistance to degradation and compliance similar to native 
vessels), low permeability at arterial pressures to limit transmural bleeding and seroma 
formation, minimal thrombogenicity and consistency between production runs all of which 
must be addressed. 
One possibility is to use natural biological scaffolds as a basis for a vascular conduit. 
These can be either autologous or derived from human or animal donors. There are two major 
advantages to these natural scaffolds compared to synthetic models, firstly that they can be 
infiltrated more easily by host cells than synthetic materials such as polytetrafluoroethylene 
(PTFE) giving the potential to be repopulated with autologous cells from the host and 
secondly that the scaffold itself is composed of proteins and other components of the 
extracellular matrix necessary to support cell adhesion and growth unlike synthetic scaffolds 
(Nemeno-Guanzon et al., 2012).  The difficulty with these biological scaffolds is the issue of 
immune-mediated rejection which is difficult to overcome (Schuurman et al., 2003; 
Seetharam et al., 2010). In order to try to reduce the effect of this decellularization of allo- or 
xeno-grafts is usually performed to remove the antigenic cellular components while leaving 
the extra-cellular matrix structure intact (Mathapati et al., 2011).  Such decellularized 
scaffolds have shown promise as implantable biomaterials or as the basis for tissue-
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engineered constructs (L'Heureux et al., 2007; Fiore et al., 2011). However, while 
decellularizing the scaffold reduces the risk of immune-mediated rejection the methods used 
to accomplish this such as the use of organic solvents, detergents or ionic solutions (Dahl et 
al., 2003; Mangold et al., 2015) and the mechanical techniques such as agitation, sonication 
or freeze-thawing (Wilshaw et al., 2012; Azhim et al., 2011; Pellegata et al., 2012) may have 
a detrimental effect on scaffold integrity following implantation (Moroni and Mirabella, 
2014). Investigations into these effects are complicated by the fact that there is no generally 
agreed method for achieving decellularization in part due to the varied composition of the 
extracellular matrix in different tissues.  
As a result, it has been necessary to employ synthetic vascular graft replacements for 
those patients who cannot provide a suitable autologous vein (Veith et al., 1979; Desai et al., 
2011). To date the outcome of using the various synthetic vascular grafts employed clinically 
has been poor with low long-term patency rates resulting in high re-intervention rates, 
increased morbidity and low quality of life when compared to grafts employing an 
autologous vein (Baiguera and Ribatti, 2013).  The reasons for this decrease in patency are 
varied with issues such as the thrombogenicity and mechanical characteristics of the material 
surface (Sarkar et al., 2007a), lack of a suitable endothelial cell (EC) layer (Kannan et al., 
2005a) and increased rates of infection (Chiesa et al., 2002) which can be life-threatening 
(Harish and Allon, 2011) all being implicated. 
Considering that according to a recent report by Hirsch et al cardiovascular diseases still 
account for more than 20% of global mortality and are the primary cause of death worldwide 
this is an issue which still needs to be addressed (Hirsch et al., 2012). 
One of the first studies to look at a successful suitable synthetic replacement for an 
autologous vein was that of Voorhees’ and Blakemore published in 1954 which used tubes 
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constructed from Vinyon “N” cloth initially in thirty canine subjects followed by a clinical 
trial in eighteen human subjects (Blakemore and Voorhees, 1954). Ten of the human subjects 
survived the trial with a maximum follow up of ten months. All the survivors were symptom 
free and had functional prosthesis.  
These early studies encouraged further investigation into other textiles including Nylon 
and Orlon. The major difficulty encountered with these textiles was that over time they lost 
tensile strength and failed. The next major breakthrough was the introduction of Dacron in 
1957 by DeBakey (Debakey et al., 1957). Dacron consists of polyester fibres bundled into 
multi-filament yarns and has been either woven or knitted into a fabric material. Woven 
Dacron tends to result in narrow spaces for tissue in-growth while knitted Dacron is looser 
and favours tissue in-growth. However knitted Dacron is prone to low bursting strength and a 
tendency to deform when placed under stress.  Dacron was demonstrated to have much 
improved post-implantation mechanical properties and rapidly became the material of choice 
for synthetic aortic aneurysm repair which has not been bettered since. Some improvements 
have been made to the initial Dacron prosthesis including adding a velour coating to the inner 
and outer surface to encourage cell attachment and growth as well as making the prosthesis 
easier to pre-clot. A further addition was external support to the prosthesis to prevent 
prosthesis kinking when crossing joints. 
Unfortunately, when employed in low flow small diameter vessel replacement the 
positive outcomes seen in large calibre high flow vessels were not observed. The major 
reason for this failure was twofold, firstly the low flow experienced in the smaller vessels and 
the inherent thrombogenicity of the Dacron lead to thrombotic occlusion and secondly 
neointimal hypoplasia was a significant problem at the anastomotic sites. These issues 
resulted in a poor long-term patency for small diameter Dacron prosthesis and resulted in 
other materials being investigated for this application. 
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The next breakthrough in peripheral artery bypass came in 1959 with the introduction of 
PTFE by Edwards (Edwards, 1959). PTFE is a durable inert fluorocarbon polymer which can 
be extruded to increase the number of micropores as extended PTFE Polytetrafluoroethylene 
(ePTFE). PTFE has high flexibility, demonstrates good resistance to biodegradation and has 
an anti-thrombogenic electronegative luminal surface. It has been used as an haemodialysis 
vascular access conduit (Baker et al., 1976) and synthetic membranes. It has also been used 
in cosmetic and reconstructive surgery (Liu et al., 2016). In 1973 PTFE was successfully 
used for small calibre artery replacement  (Matsumoto et al., 1973). Studies such as those by 
Raithel (Raithel and Groitl, 1980)  and Veith (Veith et al., 1979) came to the conclusion that 
PTFE was as effective as autologous vein when employed for infrainguinal bypass. However 
medium to long term usage of PTFE grafts suffered from the development of neointimal 
hypoplasia resulting in graft occlusion (Echave et al., 1979) which may result either from 
changes in matrix and cytokine constituents (Sarkar et al., 2006) and from the relative 
stiffness of the material compared to native vessels. These issues are exacerbated in small 
diameter conduits (Kannan et al., 2005a).  PTFE also does not support cell seeding very well 
with extensive cell loss when exposed to physiological flow (Carr et al., 1996; Rosenman et 
al., 1985). 
Another material with low compliance which has been considered for use in small 
diameter vascular prosthesis is polypropylene, a thermoplastic polymer made from the 
monomer propylene. Polypropylene has a crystalline structure which gives it strength and is 
relatively resistant to chemical degradation. It also has a low thrombogenicity and 
inflammatory reaction rarely being rejected by the body. These properties lead to studies 
using polypropylene as a small calibre vascular prosthesis. Initial results based on medium 
term implantations suggested that polypropylene was superior to PTFE (Greisler et al., 1992) 
but further long term studies demonstrated that the long term biostability of polypropylene in 
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vivo was less successful with surface cracking, erosion and serious wall weaknesses 
developing in grafts implanted for a number of years (Mary et al., 1998) resulting in 
polypropylene falling out of favour as a potential prosthesis base. 
Various reasons have been suggested for the development of neointimal hyperplasia in 
small calibre PTFE and Dacron grafts. A study by Kidson and Abbott made a direct 
association between the lack of compliance of PTFE and Dacron and neoinitimal hyperplasia 
particularly in small diamer (<6mm) grafts (Kidson and Abbott, 1978). The mechanism of 
intimal hyperplasia was investigated in depth by Sottiurai in 1999 who demonstrated that 
intimal hyperplasia consisted principally of multiple layers of extracellular matrix (ECM) and 
cells. Adjacent to the lumen the cells were mesenchymal type cells, deeper in the lumen 
myofibroblasts were more prominent (Sottiurai, 1999). Earlier studies by the same group had 
already demonstrated that physical stresses on smooth muscle cells (SMC) result in the 
synthesis of ECM (Sottiurai et al., 1983). More recent studies have shown that the geometry 
of the anastomosis affects the occurrence of initmal hyperplasia (Kannan et al., 2005a) as 
does the lack of compliance demonstrated by PTFE, Dacron and polypropylene (Sarkar et al., 
2006). 
As a result, there has been considerable interest in the possibility of utilizing materials 
with a compliance more similar to natural veins to reduce the likelihood of neointimal 
hyperplasia developing in long term implanted small diameter vascular prosthesis. To date 
two major groups of material have been investigated, silicones and polyurethanes. 
Silicone has several advantages as a potential graft material. It is very elastic resulting in 
potentially good compliance, a property it retains even after implantation and tissue 
incorporation   (White et al., 1987). It is also largely inert (Habal, 1984). Silicone has a long 
history of use for medical devices as diverse as breast implants and feeding tubes with long 
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term implantation (Moss et al., 1990) {153} and biostability (Christenson et al., 2005). While 
silicone has low leucocyte and complement activation (Kottke-Marchant et al., 1987) one 
major disadvantage is that the hydrophobicity of pure polysiloxane results in a high affinity 
for fibrinogen resulting in unacceptable levels of thrombogenicity. In an attempt to overcome 
this either the use of hydrophilic copolymer coploymerisation (Julio et al., 1994) or the 
attachment of organic groups (Whalen et al., 1992) has been investigated. 
The use of silicone in breast implants has, however, lead to a reconsideration of the long 
term stability of silicone in the body due to reports of silicone breast implants rupturing and 
migrating (Puckett et al., 2004) due to the degradation of silicone in vivo following the 
breakdown of silicone bonds by oxidation and hydrolysis as reported by Garrido et al 
(Garrido et al., 1993). As a result of these issues the use of silicone for long-term implants 
has become problematical. 
Another potential material to address the need for conduits which has been explored are 
the polyurethanes. Polyurethanes are more compliant than Dacron and PTFE resulting in a 
reduction in compliance mismatch between the conduit and the native vasculature (Sarkar et 
al., 2006). Polyurethane conduits can be produced via two methods, either fibrillar in which 
fibres of polyurethane are woven, knitted, spun electrostatically or wound into a conduit or 
foam which can be produced by phase inversion, foam flotation and dip coating. Initial 
studies reported issues with high rates of aneurysm and thrombogenicity compared to Dacron 
or ePTFE (Brothers et al., 1990) but these issues have been addressed using modified forms 
of polyurethane which demonstrate biostability (Salacinski et al., 2002b), improved 
thrombogenicity (Kannan et al., 2006) and the potential for successful cell seeding (Punshon 
et al., 2005; Vara et al., 2008).  
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It was recognised very early on that apart from the deficiencies of the various materials 
explored as potential vascular conduits one of the other major issues was the lack of an EC 
layer on the conduit either at implantation or through spontaneous in-growth post-
implantation.  The lack of an endothelial layer which can interact with circulating blood to 
provide an anti-thrombogenic surface preventing the initiation and development of the 
process of intimal hyperplasia is a major factor in graft failure. 
Many studies have demonstrated that spontaneous formation of an endothelial layer along 
the full length of the vessel does not occur in humans either by in-growth through the vessel 
wall or in-growth from the adjacent vessel. There is some limited in-growth in a narrow zone 
limited to the immediate anastomotic area in humans (Pennel et al., 2013; Berger et al., 
1972). Even after numerous studies the maximum transanastomotic growth in grafts 
implanted for a number of years has been found to be no more than 1 to 2 cm (Pennel et al., 
2013) which, given that the usual graft length is 50 to 60 cm. is inadequate. Several animal 
models have been utilized to study EC seeding but these are somewhat compromised by the 
fact that many animal species demonstrate rapid and extensive transanastomotic 
endothelialisation and is further complicated by the fact that relatively young animals are 
used in studies compared to the human patient population requiring intervention (Zilla et al., 
2007). 
Other than relying on the spontaneous in-growth of an endothelial layer from the 
anastomotic region there are two main strategies for creating an endothelial layer on vascular 
prosthesis. The first method investigated was to seed the conduit with EC’s prior to 
implantation. There have been two approaches with this method, ‘single-stage’ seeding in 
which cells are extracted and immediately seeded on the conduit without expansion in culture 
and ‘two-stage’ seeding where cells are harvested from a suitable source followed by culture 
and expansion in the laboratory prior to conduit seeding and implantation. These two 
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approaches have their own advantages and disadvantages when potentially used in a clinical 
situation.  
‘Single-stage’ seeding requires the patient to undergo a single operation during which 
cells are extracted and the conduit seeded and implanted which seemed an ideal way to 
produce a seeded conduit. 
 Early studies by Herring in 1978 (Herring et al., 1978) looked at single-stage seeding in a 
canine model replacing the infrarenal aorta with a Dacron conduit which was seeded 
immediately pre-implantation with endothelium scraped from the saphenous vein and 
resulted in the successful development of an endothelial layer after six weeks’ implantation. 
Graham in 1980, again in a canine model, reported on a series of twenty-eight subjects which 
underwent thoracoabdominal bypass using a 6mm Dacron conduit (Graham et al., 1980b; 
Graham et al., 1980a). The cell source in this study was autologous external jugular vein 
extracted by enzymatic digestion using trypsin and collagenase. Extracted cells were 
similarly seeded immediately pre-implantation of the conduit and the implanted conduits 
examined between one and twenty-eight days’ post-implantation. Again, the seeded conduits 
demonstrated an endothelial coverage (greater than 80% by day twenty-eight) and showed an 
increase in clot-free surfaces compared to unseeded conduits. Building upon his earlier 
canine work Herring in 1984 reported on a trial in human subjects which looked at single-
stage seeding (Herring et al., 1984). 186 operations were carried out on 161 patients over the 
course of the four-year study and again Dacron was the conduit of choice. In eleven patients’ 
axillary-femoral and axilliary femoral-femoral bypasses were carried out (six seeded and five 
unseeded) with 28 patients undergoing femoral-femoral bypasses (thirteen seeded and fifteen 
unseeded). Femoral-popliteal conduits were implanted in 147 limbs (112 vein, 18 seeded and 
17 unseeded). Unfortunately, the results of this trial were not encouraging. For femoral-
femoral and femoral-popliteal bypasses there was no significant difference in patency 
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between seeded and unseeded conduits. There was an increase in patency in axillary-popliteal 
seeded conduits compared to unseeded conduits. Vein grafts were significantly better than 
both seeded and unseeded Dacron grafts (p = 0.016). Interestingly this study also reported on 
the effect of smoking on the patency of conduits and suggested that patients who smoked had 
worse outcomes than those that did not. 
A later study reported in 1989 by Fasol et al looked at the effect of single-stage seeding 
using PTFE conduits and compared unseeded conduits, seeded with autologous EC conduits 
or reversed saphenous vein conduits with a one-year follow-up period (Fasol et al., 1989). 
Assessment was by scanning electron microscopy (SEM) of circulating platelets to determine 
active platelet levels. It was demonstrated that there was a significant increase in activated 
platelets in PTFE conduits regardless of seeding when compared to patients with reversed 
vein implantation suggesting that the cell seeding had failed to develop a functional EC layer 
on the conduits. 
Studies such as the ones above lead to a consideration of the difficulties inherent in the 
single-stage seeding process. It is very difficult to extract sufficient cells to provide a realistic 
seeding density (Tiwari et al., 2003a; Ivarsson et al., 1998) compounded by the fact that as 
the cells have a very limited time to attach to the conduit there are substantial losses when the 
conduit is implanted and exposed to physiological blood flow post-implantation (Salacinski 
et al., 2000). As mentioned previously the issue of self-endothelialisation which was not so 
apparent at the time also affected the value of the animal studies on which this work was 
based. 
As a result, interest moved on to two-stage seeding which by comparison allows the 
production of substantial numbers of cells over a number of week’s culture which can be 
seeded on the conduit prior to implantation.  
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One of the earliest clinical studies into two-stage seeding was reported in 1992 by 
Magometschnigg   who carried out a prospective non-randomised clinical trial on 26 human 
subjects all of whom had chronic end stage peripheral vascular disease and required repeat 
reconstruction. EC were extracted between 4 and 7 weeks prior to implantation, expanded in 
culture, and seeded onto PTFE conduits for 13 patients. The other 13 patients were given 
unseeded PTFE conduits. Initial patency after 30 days was 92% for the seeded group 
compared to 53% for the unseeded group. After an 18 month follow-up the amputation rate 
was 15% for the endothelialised conduit group whereas for the control group the amputation 
rate was 31%. This study therefore suggested that EC seeding in a two-stage process was a 
potential method to improve clinical outcomes in human patients (Magometschnigg et al., 
1992). 
In 1994 Zilla et al reported a study carried out on 49 human subjects who did not have 
suitable saphenous vein’s available for harvest (Zilla et al., 1994). EC were harvested from 
the external jugular vein and cultured to provide an adequate cell number to endothelialise 
PTFE conduits coated with fibronectin glue. 33 patients were provided with an 
endothelialised conduit and 16 with an unseeded conduit. The efficiency of seeding was 
measured using angiography, platelet labelling studies, assessment of the ankle-brachial 
index and duplex sonography for up to 32 months’ post-implantation. To obtain the 16 
million EC required to produce a confluent layer on a 70-cm length 6 mm conduit took an 
average of 25 days’ post-harvest with a 27% failure rate where the harvested cells failed to 
grow. The results for the successfully seeded conduits were impressive with an 84% patency 
at 32 months compared to only 55% for the unseeded conduits demonstrating a significant 
difference (p<0.041) while there was also a significant lowering of the ankle-brachial index at 
24 months (p<0.0023) and a significant reduction in platelet uptake at all time points 
measured. 
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A similar study in humans by Leseche et al (Leseche et al., 1997) using EC harvested 
from autologous vein followed by cell culture to increase cell numbers prior to PTFE conduit 
seeding at high density comprised 32 patients. In 11 patients (34%) insufficient cells were 
obtained to seed the conduit due to failed isolation or culture (nine patients), preoperative 
infarction (one patient) or contamination of the isolated cells (one patient). In the remaining 
21 patients it took an average of 23.5 days to achieve sufficient EC for seeding from an 
average vein segment 10.5 cm long. All the patients underwent above-knee femoro-popliteal 
bypass with a 7mm PFTE conduit. Immediately post-operation there were no complications 
reported. Two patients died of non-related causes after 2 and 36 months respectively. One 
patient required the conduit to be removed after 75 days due to the development of an abscess 
in the femoral triangle and three patients suffered bypass failure (at 3, 10 and 53 months). 
The cumulative patency rates for the implanted conduits were 95% at 3 months, 89% at 48 
months and 67% at 76 months. While no direct comparison was made with unseeded 
conduits these rates demonstrated that such seeding was viable and may result in improved 
patency. 
The long-term outcome of such two-stage seeding techniques has also been examined by 
Deutsch et al who reported on a fifteen-year study partly based on their previous work 
mentioned earlier (Zilla et al., 1994) and two later investigations in 1997 (Meinhart et al., 
1997) and 1999 (Deutsch et al., 1999).  This involved 318 non-acute patients 310 of whom 
received a total of 381 endothelialised PTFE grafts (308 femoropopliteal and 33 
femorodistal). The source of the EC was short segments of subcutaneous veins (80% 
cephalic, 11% basilica, 2% external jugular and 7% saphenous) with an average culture time 
of 19 days. The expanded cells were then seeded onto fibronectin coated PTFE conduits 
(6mm diameter 64%, 7mm diameter 36%). In only 2.5% of cases growth failure prevented 
successful seeding which was a considerable improvement on the approximately 30% failure 
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rate in the studies mentioned earlier. Reported outcomes of primary patency were 69% for the 
femoropopliteal conduits at 5 years with a 61% patency at 10 years, for the femorodistal 
conduits was 52% after 5 years and 3% at 10 years. This study demonstrated that two-stage 
endothelialisation for vascular conduits was a viable routine procedure with significant 
benefits for the patients involved and patency rates resembling those of vein grafts assuming 
that they could wait for the EC to be extracted and grown up. 
Such seeded conduits can further be subjected to regimes such as pre-conditioning (in 
which seeded conduits are exposed to a gradually increasing flow in an in vitro flow circuit 
which has been demonstrated to improve cell retention on conduits when exposed to 
physiological flow) to improve cell adhesion when the conduit is implanted in the patient 
(Vara et al., 2008).   
Despite the apparent success of the two-stage seeding method it has failed to be adopted 
clinically generally and remains limited to very few groups. The process exposes the patient 
to the necessity for two procedures (one to extract the cells and a second to implant the 
conduit) with the associated risk to the patient of the procedures themselves. There is also the 
possibility that the cell extraction and expansion may fail resulting in the patient undergoing 
an additional operation and not having a suitable seeded conduit for implantation anyway. 
Such a process also has significant cost implications both from the expense of carrying out 
two procedures per patient rather than one for an un-seeded conduit or a ‘single-stage’ 
process and the additional cell culture facilities and staff required to expand and seed the 
conduits which may be the main reason behind the failure of this process to be adopted more 
widely despite it’s apparent advantages. Finally the fact that it can take several weeks to 
expand the cells means that this approach is not suitable if the patient cannot wait for a 
seeded conduit to be produced. 
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Given the problems encountered with the various synthetic conduit materials another 
approach which has gained considerable interest over the last twenty-five years is that of a 
tissue engineered vascular graft. As a concept, such tissue engineered vascular conduits 
would have mechanical properties which mimicked those of native vessels with a diameter 
matched to that of the site of the anastomosis and have a viable endothelium present on the 
inner surface. This would be achieved without the use of either synthetic materials (such as 
PTFE or Dacron) or foreign materials (such as allo- or xeno-grafts} to provide an initial 
scaffold thus ideally avoiding the issues with chronic inflammatory responses. 
One of the first proponents of the tissue-engineered approach was the group of Bell who 
reported a living blood vessel developed in vitro developed using a cell-seeded collagen gel 
tube system in 1986 (Weinberg and Bell, 1986). The resulting conduit demonstrated a 
multilayered structure resembling that of an artery with SMC in the vessel wall and EC’s 
lining the lumen. That the endothelial layer was functional was demonstrated by the 
production of von Willebrand factor and prostacyclin. Unfortunately, however, the resulting 
conduit was not mechanically strong enough to withstand implantation at physiological 
pressures and flow rates resulting in the necessity to incorporate a Dacron sleeve to 
strengthen the conduit and re-introducing the problems associated with synthetic materials. 
Following this pioneering works other groups have looked at using collagen  or fibrin (Bu 
et al., 2010; Sgarioto et al., 2012; Assmann et al., 2013; Filova et al., 2014) based or coated 
conduits but the issues with achieving a conduit with a clinically acceptable burst pressure 
have remained.  The issues with the burst pressure of such conduits are multiplied when such 
conduits are implanted as they are also susceptible to attack and degradation by the immune 
system weakening them further. 
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Given these challenges with either using permanent synthetic materials or tissue-
engineered conduits without synthetic materials a variation on the process has been 
increasingly investigated in which the synthetic material used in the conduit is composed of 
resorbable polymers. The concept behind this system is that the polymer gives the conduit the 
initial strength to allow implantation under physiological flow conditions to occur while over 
time the resorbable nature of the polymer results in the polymer gradually degrading in a 
controlled manner to be replaced by native tissue which maintains structure (Weber et al., 
2011). In animal models this method has proved successful but it has proved less so in 
humans where there are complications resulting from the reproducibility and safety of the 
manufacturing process which must be taken into account unlike in animal models. 
In conclusion, there is still a considerable challenge to be addressed in developing a 
widespread clinically acceptable process for overcoming the lack of a suitable autologous 
vessel for use as a vascular conduit. The amount and variety of research carried out to date 
suggests that no single approach will be successful and that in order to develop a clinically 
viable system numerous obstacles must still be overcome.  
Financially the costs related to the use of cells in a proposed conduit must be addressed 
and the long-term potential cost savings of improved outcomes investigated. Any such 
system will require commercialization both to fund research into the field and to overcome 
the high production costs involved. However, the fact that there is a large potential market 
and that the treatment is potentially life-saving or limb saving suggest that financing a 
potentially successful process may be viable. 
Clinically the long lead time associated with many of the approaches taken to date for 
systems involving cell seeding which can require weeks or even months of preparation to 
produce a viable conduit also need to be considered. To some extent these can be reduced by 
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appropriate patient management but this has to date been one of the major reasons why such 
methods are not routinely employed clinically. There have been some investigations into this  
of invasive versus medical therapy in elderly patients suffering from chronic symptomatic 
coronary-artery disease with some studies showing no difference in either myocardial 
infarction or mortality between patients receiving either optimum medical treatment or 
surgical intervention while the benefits of improved patency may also outweigh the increased 
risk associated with a longer waiting time to produce an improved conduit (Simoons and 
Windecker, 2010). By contrast systems which focus on improving the materials from which 
conduits are made and not involving cellularization avoid the problems associated with long 
waiting times and reliability and reproducibility of cellularization systems but generally have 
worse outcomes. 
Finally, there are a number of regulatory and ethical issues which must be considered 
both for cell-based conduits and synthetic materials. The model of regulation used in organ 
transplantation may be the most appropriate basis for such regulation which is still in a 
development phase in tissue engineering where much of the regulatory practice is based on 
the mass production of pharmaceuticals which does not tailor well with the relatively small 
scale nature of tissue engineered vascular conduits. 
The work presented in this thesis was carried out over a number of years during which 
there were exciting developments in the field of vascular tissue engineering.  
Initially the concept was to look at the potential of a novel material, POSS-PCU, to 
support EC seeding and improve blood compatibility. In order to demonstrate this initially the 
cytotoxicity of POSS-PCU was investigated thoroughly using HUVEC following which 
investigations were performed into optimising seeding of a POSS-PCU conduit and exposing 
the seeded conduit to simulated physiological flow to investigate the effect of pre-
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conditioning on cell retention. Additional studies included looking at surface modification of 
the POSS-PCU to improve cell adhesion and growth and investigating the blood 
compatibility of the unseeded POSS-PCU. 
During the course of this work it became apparent that there was the potential to 
investigate new sources of EC’s for use in vascular tissue engineering. Traditional studies had 
used primary cell sources such as autologous vein or various types of fat (omentum and 
subcutaneous) which were difficult to obtain and failed to result in adequate cell numbers for 
successful conduit seeding without extensive cell culture prior to implantation. As a result, 
many studies looked at HUVEC which, while easier to obtain and expand, were not suitable 
for use in a clinical situation. 
The potential of stem cells extracted from bone marrow, embryonic tissue or umbilical 
cord blood lead to considerable interest in the use of stem-cell derived EC’s for vascular 
tissue engineering. However, these sources of cells have some drawbacks either from ethical 
considerations (for embryonic tissue), difficulty in obtaining samples for research (bone 
marrow) and lack of clinical relevance (cord blood with its immune compatibility issues) 
were all potential drawbacks.  As a result, other potential sources of EPC have been 
considered such as lipoaspirates. Marchal et al reported extracting and culturing multi-potent 
endothelial-like cells from 15 patients using liposuction-derived subcutaneous adipose tissue 
(Marchal et al., 2012). 
Asahara’s paper in 1997 demonstrating that EPC could be extracted from human 
peripheral blood was interesting in that it postulated a source of cells which would be readily 
available for research (taking blood samples being considerably less invasive than collecting 
bone marrow samples), free from any ethical considerations other than informed consent and 
clinically relevant in that patients could have a conduit seeded with autologous cells collected 
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from their own peripheral blood (Asahara et al., 1997). Peripheral blood derived EPC have 
subsequently been used in a number of areas such as vascular stents (Banerjee et al., 2012), 
human pulmonary valves (Cebotari et al., 2006) and prosthesis (Liu et al., 2014; Goh et al., 
2014).  
It thus became apparent that it might be possible to combine the clinically proven success 
of the ‘two-stage’ seeding system reported by Deutch and Zilla with this new cell source to 
produce a seeded graft which would overcome some of the disadvantages of the ‘two-stage 
system’. Peripheral blood could be extracted from the patient without the need for an 
operation, EPC and circulating EC’s extracted and either the conduit seeded immediately and 
implanted or the cells expanded and differentiated then seeded on the conduit. Such a system 
would remove the need for the patient to undergo two operations with the associated risks 
and expense, not require expansion and culture of the extracted cells if sufficient cells could 
be extracted from blood without culture and still provide all the benefits of an EC seeded 
conduit with no tissue compatibility issues as well. There are still some drawbacks with using 
peripheral blood as a source of cells such as the low numbers of EPC which can be isolated 
from peripheral blood which may be exacerbated in elderly patients or those with high 
morbidity associated with vascular disease (Stauffer et al., 2008; Singh et al., 2012) and the 
lack of a generally accepted method of isolation and characterisation (Igreja et al., 2007; 
Punshon et al., 2011) but it is possible that these can be overcome by further research in the 
field. 
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1.2 Aim of the Thesis 
Current techniques for vascular grafting have many limitations but there has been some 
progress using EC seeding. The aim of this thesis is to explore possible solutions to this 
clinical challenge. A variety of approaches to this problem, using culture and seeding of 
peripheral blood derived EPC and circulating EC’s was investigated to further the 
development of two-stage seeding process for vascular conduits. 
1.3 Ethical Approval and Informed Consent 
All of the work carried out in this study had ethical approval from the UCL Research Ethics 
Committee. When the studies in this thesis were carried out informed consent was not 
required for the collection of human umbilical cords used as a cell source in Chapters 2, 3 and 
5. Under current legislation for research access to human cells and tissues as developed under 
the Human Tissue Authority (HTA), informed consent from the mother is required for all 
donations of human umbilical cord tissue and should be obtained prior to donation. This also 
dictates development of appropriate traceability, storage, audit and disposal policies. In the 
case of the use of human blood used for the extraction of peripheral blood derived stem cells 
in Chapters 4, 6 and 7, informed consent was obtained from the volunteer donors under the 
procedures relevant at the time. Nowadays, such procedures equally must form part of any 
HTA-related research access in the institutes undertaking the research. Full details on HTA 
policies and procedures can be seen at https://www.hta.gov.uk/. 
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2 
2 Endothelial Cell Cytocompatibility of the Nanocomposite 
 
2.1 Introduction 
 
 The biomaterials available for clinical applications such as stents or bypass grafts are 
largely made from two different  polymers, poly(ethylene terephthalate) (PET or Dacron) and 
polytetrafluoroethylene (PTFE) (Seifalian et al., 2002; Kannan et al., 2005a). Dacron is very 
reactive towards both surrounding tissue and blood when used for cardiovascular applications 
, and this results in neo-intimal proliferation and inflammation  when used for both grafts 
(Zenni et al., 1994; Greisler et al., 1996a) and stents (Peng et al., 1996; Murphy et al., 1992). 
PTFE is the other commonly employed polymer in applications such as cardiovascular grafts 
and stents as it displays a relatively high bio-stability and is tolerated reasonably well by the 
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human body. However, in a similar manner to Dacron there is a high adherence of platelets 
and blood proteins to the surface of the graft or stent (Kannan et al., 2005d). 
 As a result, a number of alternatives to polymers have been investigated in an attempt to 
overcome these difficulties. One such alternative is Polyurethanes which have been 
investigated for applications in cardiovascular biomedical devices and have advantages in 
both their durability and their ability to extrude flexibly. In an artificial bypass graft their 
properties can simulate the viscoelastic properties found in native arterial wall, which can be 
a significant factor in improving the patency of cardiovascular devices (Salacinski et al., 
2001). In comparison to Dacron and PTFE, Polyurethanes demonstrate a lower level of 
surface thrombogenicity. This reduction in thrombogenicity can be enhanced by the fact that 
the surface of polyurethanes can be modified with smart bio-molecules such as Arginine-
Glycine-Aspartate (RGD) or heparin (Kidane et al., 2004). 
 An bypass graft based on poly(carbonate-urea)urethane (PCU) was developed in the 
Division of Surgery at UCL where it underwent testing and assessment. This material is 
currently marketed as an access graft (Salacinski et al., 2002a; Salacinski et al., 2002b) in 
kidney patients who require an access graft for a short period while they are waiting for a 
suitable kidney donor. This material has some issues with thrombogenicity, but to a lesser 
extent than other polyurethanes due to its soft segment being based on carbonate linkages 
rather than ester or ether as in the majority of conventional polyurethanes. It was felt that 
there remained a need for a material which did not require surface modification that 
employed a carbonate amorphous segment in order to reduce the issues associated with 
surface thrombogenicity. Ideally such a polymer should be able to demonstrate both anti-
platelet and protein inhibitory qualities together with the ability to allow cells to grow on its 
surface due to showing good   cytocompatibility. In an attempt to achieve these requirements 
a polymer based on polyurethane and bridged monomers of silsesquioxane (pendant nano-
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bridge); poly(carbonate-silsesquioxane-bridge-urea)urethane (PCBSU) nanocomposite was 
developed. By the incorporation of these bridged monomers into polyurethanes anti-
thromogenic qualities may occur in the resultant polymer. Due to their inorganic nature 
silsesquioxanes do not have the issues and complexities which occur when drugs and 
biomaterials such as heparin are incorporated into the material. The silesquioxane being 
bridged and pendant on the polymer surface allows the anti-platelet and anti-coagulant 
function to occur and may reduce the cytotoxic effects often associated with materials 
containing silicon. This should allow EC’s to grow on the material surface as ideally required 
in tissue engineered cardiovascular medical devices.  
 
 Previous studies into the cytocompatibility of similar materials have investigated the 
effect on cells of either contract directly with the material or via indirect contact using cell 
culture medium exposed to samples of the material for a period prior to exposure to cells. 
Techniques used to evaluate cytocompatibility include examining cell morphology by light 
microscopy and SEM, [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
(MTT) metabolic activity assays, Neutral Red viability staining and cell counting by using 
Tryphan Blue (Ramires et al., 2000; Belanger et al., 2000; Marois et al., 1996; Armitage et 
al., 2003).  
 
In this Chapter the direct and indirect outcome of exposing HUVEC to nanocomposite is 
investigated to determine if it may provide a suitable material for cell seeding. This was 
ascertained by looking at the total amount of DNA present in the cells using a Pico Green 
assay system, examining cell metabolism using an Alamar blueTM (AB) metabolic assay and 
looking at cell damage by measuring Lactate Dehydrogenase (LDH) release. Cell 
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morphology was studied by staining with Toluidine blue in the case of indirect contact and 
carrying out SEM studies in the case of direct contact. 
 
2.2. Materials and Methods 
 
2.2.1. Polymer production 
 
 The synthesis of poly(carbonate-bridged silsesquioxane-urea)urethane nanocomposite 
was carried out as follows. The inorganic urethane is made from 4,4’-methylenebis(phenyl 
isocyanate) (MDI), poly(hexamethylene carbonate)diol, and silsesquioxane dissolved in 
tetrahydrofuran here bis[3-(trimethoxysilyl)propyl]amine and chain extended with DMAC. 
 Nanocomposite graft material was cast by pouring 3ml of polymer (diluted 1:1 in DMAC) 
solution into a 10cm diameter glass dish and leaving for 18 hours in a circulating air oven at 
55-65oC. Following casting graft material was thoroughly washed with phosphate buffered 
saline (PBS) prior to use. 
 
2.2.2. Endothelial cell culture 
 
 HUVEC were isolated from human umbilical cord vein following a previously described 
method (Seifalian et al., 2001). Cell numbers were amplified by tissue culture in Cell Culture 
Medium (CCM) which was prepared as follows: 157 ml M199 medium, 4.5 ml Sodium 
Bicarbonate (7.5%), 1.5 ml Penicillin/Streptomycin (10,000 U/ml and 10 mg/ml 
respectively), 40 ml Fetal Bovine Serum and 3.6 ml 200 mM L-Glutamine (Invitrogen Ltd, 
Paisley, U.K.). At confluence cells were removed using 0.25% Trypsin-EDTA (Sigma-
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Aldrich Company Ltd, Poole, U.K.) and split in a 1:2 ratio. Confluent cultures at passage 
three were used in all experiments. 
 
2.2.3 Assessment of Cytocompatibility 
 
2.2.3.1 Indirect effect of nanocomposite on HUVEC 
 
 A sample of the nanocomposite was powdered using a Mikro Dismembartor U (B. Braun 
Biotech International, Melsungen, Germany). Following powdering nanocomposite samples 
were sterilised by autoclaving. Powdered nanocomposite was then added at concentrations of 
1, 10 and 100mg/ml to CCM and shaken for seven days at 37oC on a shaker. Following 
exposure to powdered nanocomposite the treated CCM samples were centrifuged to remove 
the powdered nanocomposite. 
 24-well plates were seeded with 1ml HUVEC at a concentration of 2x105 cells/ml for 24 
hours. Cells were then exposed to the following treatments: Untreated CCM (CCM0), 1mg/ml 
treated CCM (CCM1), 10mg/ml treated CCM (CCM10), 100mg/ml treated CCM (CCM100) 
and, in order to show the efficiency of the assays used, 1μM Staurosporine (CCMST) which is 
a potent inhibitor of phospholipids/calcium-dependant protein kinase and causes cell death. 
LDH, AB and Pico Green assays were carried out 24 and 96 hours post-exposure. 
 
2.2.3.2 Direct effect of nanocomposite on HUVEC 
 
 Sections of nanocomposite material were cut into 16mm diameter discs and autoclaved to 
sterilise them. The discs were then placed into a 24-well plate (Helena Biosciences, 
Sunderland, U.K). Twelve nanocomposite discs were seeded with 1ml HUVEC at a 
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concentration of 2x105 cells/ml for 24 hours (nanocomposite-seeded). Twelve wells 
containing discs of nanocomposite were left unseeded with only CCM in them as a control 
(nanocomposite-unseeded). LDH, AB and Pico Green assays were carried out 24 and 96 
hours post-seeding and samples of nanocomposite sent for SEM studies. 
 
2.2.3.3 Assessment of cell proliferation on nanocomposite 
  
 Thin films of nanocomposite were cast in 60mm x 120mm glass Petri dishes and 
sterilized by autoclaving. 2 x 105 HUVEC were then seeded in six dishes with a further six 
being left unseeded as a control. As a comparison, uncoated dishes were seeded with the 
same number of cells. At 1, 3, 6, 10, 13 and 16 days post-seeding a 4-hour AB assay was 
carried out on all samples. 
 
2.2.4. Lactate dehydrogenase assay to assess cell damage on nanocomposite 
  
 LDH was measured using a CytoTox 96® Non-Radioactive Cytotoxicty assay kit 
(Promega, Southampton, U.K.). LDH is a stable cytosolic enzyme released upon cell lysis 
into the CCM. The amount of LDH released is measured using a 30-minute coupled 
enzymatic assay based on the conversion of a tetrazolium salt INT (2-p-iodophenyl-3-p-
nitrophenyl-5-phenyl tetrazolium chloride) into a red formazin product, with the amount of 
colour formed being proportional to the number of lysed cells. 
 50µl CCM from each sample was transferred to a 96-well plate (Helena Biosciences, 
Sunderland, U.K). 50µl Substrate Mix (1 vial substrate plus 12mls assay buffer) was added to 
each well and the plate covered in foil to prevent light access. Samples were then incubated at 
room temperature for 30 minutes after which the reaction was stopped by the addition of 50µl 
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stop solution (1M acetic acid). Absorbance was then read at 450nm using a Multiscan MS 
UV visible spectrophotometer (Labsystems, Ashford, U.K.). 
 
2.2.5. Alamar blueTM assay to assess cell viability and metabolism on nanocomposite 
  
 AB (Serotec, Kidlington, U.K.) is a commercially available assay which aims to measure 
quantitatively cell proliferation, cytotoxicity and viability. This is achieved by incorporating 
resazurin and resarfurin as colourimetric oxidation reduction indicators. These indicators 
respond to chemical reduction resulting from cell metabolism by changing colour. This 
colour change may be measured by monitoring absorbance at 570 and 630 nm. The 
advantages of this assay are that it is soluble in media, stable in solution, minimally toxic to 
cells and produces changes that are easily monitored (Seifalian et al., 2001). 
 
 AB was added to CCM at a concentration of 10% (v/v). At each AB assay timepoint 
grafts/wells were washed with 1 ml PBS and 1 ml of the AB/CCM mixture added to each 
graft/well. 1 ml AB/CCM mixture was placed into each of 6 empty wells as a negative 
control. After 4 hours’ a 100μl sample of the AB/CCM mixture was removed and the 
absorbance at 570 nm and 630 nm measured in a 96-well plate (Helena Biosciences, 
Sunderland, U.K.) using a Multiscan MS UV visible spectrophotometer (Labsystems, 
Ashford, U.K.). The absorbance at 630 nm (background) was subtracted from that at 570 nm.  
 
2.2.6 Pico green assay to assess cell quantity on nanocomposite 
  
 The Pico green assay (Molecular Probes Europe BV, Leiden, The Netherlands) quantifies 
double stranded DNA in solution using an ultrasensitive fluorescent nucleic acid stain. Stock 
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standard DNA solution (100µg/ml) was diluted in tris-EDTA (TE) assay buffer to provide a 
standard curve of 0 to 1000ng/ml DNA. Cell samples were trypsinised as above and the cell 
disrupted by being passed through a small-bore needle three times. 100µl of standard/sample 
was added to a 96-well plate and 100µl of diluted Pico Green (Pico Green Dimethylsulfoxide 
stock solution diluted x200 in TE assay buffer) was added to each standard/sample well. 
Plates were then incubated for 5 minutes in the dark. Standards/samples were then excited at 
480nm and the flouresence emission intensity measured at 520nm using a Fluroskan Ascent 
FL spectrofluorometer (Thermo Life Sciences, Basingstoke, U.K.). 
 
2.2.7 Assessment of cell morphology on nanocomposite 
 
2.2.7.1 Toluidine blue staining 
 
 Cells were washed with PBS and then fixed in formaldehyde for 10 minutes at room 
temperature. 500µl of an 0.1% solution of Toluidine blue in distilled H2O (Sigma Chemical 
Company, Poole, Dorset, U.K.) was then added to each well and incubated for 30 minutes at 
room temperature. Cells were then destained in water and photographed. 
 
2.2.7.2 Scanning Electron Microscopy 
 
 Sections of unseeded nanocomposite and nanocomposite seeded with HUVEC were 
washed 3 times with PBS and prepared for SEM. The specimens were then attached to 
aluminium stubs and an SC500 (EM Scope) sputter coater used to coat them with gold. The 
stubs were then examined and photographed using a Phillips 501 SEM. 
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2.2.8. Data analysis and statistical methods 
 
 Data are presented in meanSD. Comparison between groups was made by One Way 
ANOVA (Kruskal-Wallis) test with post comparison using Bonferroni’s Multiple 
Comparison test. *indicates P< 0.05 and *** that P< 0.001. 
 
2.3. Results 
 
2.3.1. Indirect effect of nanocomposite on HUVEC 
 
2.3.1.1. Lactate dehydrogenase assay 
  
 After 24 hours’ indirect exposure there was no significant difference (P>0.05) between 
the CCM0 group and any of the nanocomposite treated CCM groups. Cells treated with 
CCMST had a significantly higher level of LDH activity compared to the CCM0 group 
(p<0.001) (Fig. 2.1a). 
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Fig. 2.1a. LDH assay test on HUVEC exposed to nanocomposite-treated CCM for 24 hours. 
Absorbance was measured in arbitrary units at 450nm wavelength. Data are mean ± SD(n=6).  
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2.3.1.2. Alamar blueTM assay 
 Indirect exposure to nanocomposite for 24 hours showed no significant difference 
between the CCM0 group and the three nanocomposite-treated CCM groups. The cells treated 
with CCMST showed significantly less AB activity than the CCM0 group (p<0.001) (Fig. 
2.1b). In the case of the indirectly exposed 96 hour cells there was no significant difference in 
AB activity between the CCM0 cells and the CCM1 or CCM10 groups, however there was a 
significant reduction in AB activity in the case of the CCM100 sample (p<0.05). After 96 
hours exposure to CCMST no viable cells were present (Fig. 2.1c). 
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Fig. 2.1b. Alamar blueTM viability assay test on HUVEC exposed to nanocomposite-treated 
CCM for 24hours. Absorbance was measured in arbitrary units at 570nm wavelength and 
background at 630nm subtracted. Data are mean ± SD(n=6).  
 
53 
 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Blank
CCM0
CCM1
CCM10
CCM100
CCMST
***
*
Treatment
A
b
s
o
rb
a
n
c
e
(5
7
0
-6
3
0
n
m
)
 
Fig. 2.1c. Alamar blueTM viability assay test on HUVEC exposed to nanocomposite-treated 
CCM for 96 hours. Absorbance was measured in arbitrary units at 570nm wavelength and 
background at 630nm subtracted. Data are mean ± SD(n=6). 
 
2.3.1.3. Pico Green assay 
  
 After 24 hours’ indirect exposure to nanocomposite treated CCM between 780.1±55.3 and 
916.9±38.0 µg/ml DNA was extracted, with no significant difference being observed between 
the CCM0 cells and any of the test groups (Fig. 2.1d). In the case of the 96hr indirect 
exposure experiment again there was no significant difference between the CCM0 cells and 
the three different concentrations of nanocomposite-treated medium exposed cells. However, 
there was significantly less DNA in the staurosporine exposed group (Fig. 2.1e). 
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Fig. 2.1d. Pico Green assay test on HUVEC exposed to nanocomposite-treated CCM for 24 
hours. Data is presented as DNA amount in µg/ml. Data are mean ± SD(n=5).  
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Fig. 2.1e. Pico Green assay test on HUVEC exposed to nanocomposite-treated CCM for 96 
hours. Data is presented as DNA amount in µg/ml. Data are mean ± SD(n=5).  
 
2.3.1.4. Toluidine Blue staining 
 
 The results from the Toluidine Blue staining can be seen in Fig. 2.2. It can be seen that at 
both 24 and 96 hours post exposure to CCM100 cell appearance and numbers are comparable 
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to cells exposed to untreated CCM (Fig. 2.2a, 2.2b, 2.2d and 2.2e). However, exposure to 
CCMST clearly results in cell damage at both time points (Fig. 2.2c and 2.2f). 
 
Fig 2.2a. Toluidine Blue staining of HUVEC exposed to 24 hours nanocomposite-treated 
CCM0 (Magnification X20). 
 
Fig 2.2b. Toluidine Blue staining of HUVEC exposed to 24 hours nanocomposite-treated 
CCM100 (Magnification X20). 
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Fig 2.2c Toluidine Blue staining of HUVEC exposed to 24 hours nanocomposite-treated 
CCMST (Magnification X20). 
 
 
Fig 2.2d. Toluidine Blue staining of HUVEC exposed to 96 hours nanocomposite-treated 
CCM0 (Magnification X20). 
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Fig 2.2e. Toluidine Blue staining of HUVEC exposed to 24 hours nanocomposite-treated 
CCM100 (Magnification X20). 
 
Fig 2.2f. Toluidine Blue staining of HUVEC exposed to 24 hours nanocomposite-treated 
CCMST(Magnification X20). 
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2.3.2. Direct effect of nanocomposite on HUVEC 
 
2.3.2.1. Lactate dehydrogenase assay 
 
After 24 hours direct exposure a significantly higher level (p<0.001) of LDH activity was 
found from the nanocomposite-seeded group compared to the CCM0 group (Fig. 2.3a).  
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Fig.2.3a. LDH assay test on HUVEC seeded directly onto nanocomposite for 24 hours. 
Absorbance was measured in arbitrary units at 450nm wavelength. Data are mean ± SD(n=6).  
 
2.3.2.2. Alamar blueTM assay 
 
 Direct exposure to nanocomposite for 24 hours showed viable cells present, though at a 
lower level of AB activity compared to the CCM0 group (p<0.001) (Fig. 2.3b). After 96 hours 
direct exposure viable cells were still present on the PCBSU-seeded, again at a lower level 
compared to the CCM0 cells (p<0.001) (Fig. 2.3c).  
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Fig. 2.3b.  Alamar blueTM viability assay test on HUVEC seeded directly onto nanocomposite 
for 24 hours. Absorbance was measured in arbitrary units at 570nm wavelength and 
background at 630nm subtracted. Data are mean ± SD(n=6).  
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Fig. 2.3c. Alamar blueTM viability assay test on HUVEC seeded directly onto nanocomposite 
for 96 hours. Absorbance was measured in arbitrary units at 570nm wavelength and 
background at 630nm subtracted. Data are mean ± SD(n=6). 
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2.3.2.3. Pico green assay 
 
 24 hours direct exposure to nanocomposite resulted in the presence of 417.3±50.4 µg/ml 
DNA. After 96 hours direct exposure 323.6±232.9 µg/ml of DNA was extracted from the 
graft samples.  
 
2.3.2.4. SEM studies 
  SEM studies showed that the surface of the nanocomposite graft material was uniform 
and demonstrated that EC were present on the graft material at both 24 and 96 hours post-
seeding (Fig. 2.4). 
  
Fig. 2.4a: Unseeded nanocomposite 24 hours(Magnification x640). 
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Fig. 2.4b: Unseeded nanocomposite 96 hours(Magnification x 160) 
 
Fig. 2.4c: HUVEC seeded nanocomposite 24 hours(Magnification x 160). 
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Fig 2.4d: HUVEC seeded nanocomposite 96 hours(Magnification x160) 
 
2.3.3. Assessment of cell proliferation on nanocomposite 
 Fig. 2.5 shows the results from the proliferation study. It can be seen that the HUVEC 
exhibit a typical growth curve on both nanocomposite and glass, with confluence being 
reached at day 10. Again, the AB results are lower for the cells seeded on nanocomposite 
compared to those seeded on glass. 
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Fig.2. 5. Alamar blueTM viability assay test on HUVEC seeded directly onto nanocomposite 
for 16 days. Absorbance was measured in arbitrary units at 570nm wavelength and 
background at 630nm subtracted. Data are mean ± SD(n=6).  
 
2.4. Discussion 
 
 A greater understanding of the importance and need to improve the surface 
thrombogenicity of biomaterials has become a vital field of research. Studies in tissue 
engineering have demonstrated that silicon and its analogues (for example oxides) can have 
the effect of reducing both protein adsorption and platelet adhesion (Zhang et al., 2001). It 
has been suggested that this reduction is related to the surface charge on the material 
(Nylander et al., 2001; Amaral et al., 2002) which can result in structural changes to blood 
proteins (Xu et al., 2003; Buijs et al., 2003) with fibrinogen (Lasseter et al., 2004) being one 
example. One property of silicon is that it is very un-reactive and as a result research has been 
focused on moieties such as siloxane, in particular poly(dimethysiloxane) (PDMS) either by 
itself or in conjunction with either rubbers or polyurethanes (Chen et al., 2002; Prokopowicz 
et al., 2003; Cunningham et al., 2002). However, PDMS by itself or combined with rubbers 
64 
 
is mechanically very weak and as a result is generally unsuitable for use in biomedical 
devices.  Therefore, a number of different methodologies have been investigated with the aim 
of combining it with a polyurethane. The outcomes in vivo have not been good as  a result of 
the dramatic losses in bio-stability caused by the non-reaction of PDMS with either the soft 
or hard segments of the polyurethane resulting in a tendency to form two separate polymers 
(Martin et al., 2000; Park et al., 1999). Silicon and siloxane based materials have also been 
demonstrated to have poor growth characteristics when seeded with human cells such as EC’s 
(Peters et al., 2004) resulting in an inability to seed a prospective biomedical device based on 
these materials. 
 There is still therefore a requirement for a polyurethane containing silicon which would 
be mechanically strong, able to demonstrate bio-stability and also possesses the advantageous 
properties of reduced protein and platelet adsorption. This material should also permit the 
seeding and growth of cells such as EC without deleterious cytotoxic effects.  
 
 The material used in this investigation, a polyurethane containing silsesquioxane, was 
developed for its potential to become an inorganic-polymer which would possess all the 
required properties described above (Duchateau et al., 2004).  
 
 In the clinical scenario, the choice of a material to be used for cardiovascular prostheses 
must incorporate cytocompatibility to EC in two areas; indirect and direct contact of EC with 
the material. In this study in the case of indirect contact an initial exposure for 24 hours to 
CCM treated with powdered nanocomposite produced no significant effect on either cell 
metabolism or cell numbers compared to the CCM0 as shown by the results of the AB and PG 
assays. The use of Staurosporine as a positive control proves the principle that these assays 
are capable of demonstrating cell damage and further suggests that the toxicity of the 
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nanocomposite is low. A longer 96-hour exposure again produced no significant change in 
cell numbers though metabolism was reduced significantly in the case of the CCM100 group. 
In contrast by 96 hours’ post-exposure the CCMST group showed no cell metabolism and 
extremely low cell numbers. This indicated that toxicity by nanocomposite on EC was not 
apparent other than mildly at CCM100. 
 
 24 hours post-seeding of EC onto nanocomposite showed the presence of viable EC from 
the Pico Green DNA analysis results and SEM analysis and that the cells were metabolising. 
Whilst both the cell numbers and metabolism were significantly less than for the CCM0 cell 
group this may be due to improved seeding and attachment on TCP (which is optimal for cell 
attachment and growth) compared to nanocomposite and is similar to the results obtained in 
previous studies on ePTFE and compliant polyurethane (CPU) (Seifalian et al., 2001). There 
was a significantly increased level of LDH activity compared to the CCM0 cells suggesting 
that seeding efficiency on nanocomposite was lower than on TCP or glass or that initial cell 
damage had occurred. Extended 96-hour direct exposure showed similar results to the 24-
hour period and again demonstrated the presence of viable cells on the material. The cell 
proliferation study showed that HUVEC can be maintained on nanocomposite for an 
extended period (16 days) and that the growth pattern is similar to that for HUVEC grown on 
a glass surface. 
 
2.5. Conclusion 
 
 In conclusion, it can be said that the results presented in this chapter demonstrate that 
indirect exposure to nanocomposite does not result in serious damage to EC at concentrations 
likely to be encountered in a clinical situation. Furthermore, the nanocomposite can be 
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successfully seeded with EC and, once seeded, the EC remain viable and proliferate for a 
period of days. This combined with its other advantages suggests that the nanocomposite is 
suitable for further development in cardiovascular devices.  
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3 
3 Ultra violet Surface Modification of Nanocomposite 
 
3.1 Introduction 
In clinical usage at present the vast majority of medical devices such as bypass grafts 
and stents are manufactured from two polymers, either polytetrafluroethylene (PTFE) or 
poly(ethylene terephthalate) (PET or Dacron) (Seifalian et al., 2002). Dacron has a long 
history of clinical employment, being first used as a vascular graft in 1957 (Hess, 1985) but is 
highly reactive both to blood and the surrounding tissues producing inflammation and neo-
intimal proliferation in both grafts (Zenni et al., 1994; Greisler et al., 1996b) and stents (Peng 
et al., 1996; Murphy et al., 1992). PTFE was first introduced in the 1960’s for use as artificial 
heart valves and, due to its properties such as biostability and tolerance in the body, has been 
extensively used since then and indeed is still the most popular choice for bypass grafts 
today. However, the long-term patency of PTFE, especially in small diameter grafts, is poor 
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and there is a high adherence of platelets and blood proteins to the surface (Kannan et al., 
2005a).  
A variety of different types of polymer have been studied as alternatives to PTFE and 
Dacron in an attempt to develop an improved device (Xue and Greisler, 2003). Our group 
initially developed a poly(carbonate-urea)urethane in collaboration with an industrial partner 
which was demonstrated to be cytocompatible (Salacinski et al., 2000; Tiwari et al., 2002) 
and resistant to degredation (Salacinski et al., 2002b; Salacinski et al., 2002a; Seifalian et al., 
2003). In order to further improve the anti-thrombogenicity of the material a number of 
nanocomposites based upon polyurethane and incorporating silsesquioxane (Kannan et al., 
2005b) were then developed. One uses bridged monomers of silsesquioxane (pendant nano-
bridge); poly(carbonate-silsesquioxane-bridge-urea)urethane (PCBSU) nanocomposite. The 
cytocompatibility of the nanocomposite has been demonstrated in a previous study which 
showed that EC are not significantly damaged by indirect exposure to nanocomposite at 
concentrations likely to be encountered in a clinical situation (1 to 100g/ml) and that cast 
nanocomposite films can be successfully seeded with EC which remain viable and proliferate 
for a period of days (Punshon et al., 2005).. Another is poly(carbonate-urea)urethane with 
silsequioxane nano-cages namely herein a mixture of two polyhedral oligomeric 
silsequioxanes. This nanocomposite has been demonstrated to be resistant to degradation. 
 
The other major area of investigation in this field is the potential modification of the 
surface of the polymer to improve the biocompatibility of the material. One approach to this 
is to coat or incorporate a variety of moeties such as heparin or Arginine-Glycine-Aspartate 
(RGD) onto or into the polymer (Kidane et al., 2003; Kidane et al., 2004). A variety of 
chemical  modfication techniques have also been investigated which have been believed to 
have potential in this area such as exposure of materials to plasmas (Tseng and Edelman, 
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1998), ion beams (Lee et al., 2004), electrons (Lappan et al., 1999), synchrotron and γ 
radiation (Sato et al., 2003) or UV light (Heitz et al., 2003). In general these methods rely 
upon creating new chemical groups on the polymer surface favouring cell adhesion. Previous 
studies have demonstrated that the biocompatibility of PTFE could be markedly improved by 
exposure of the polymer to UV-light at a wavelength of λ < 200 nm in a reactive NH3 
atmosphere (Heitz et al., 2003; Heitz et al., 2004; Mikulikova et al., 2005). 
 
This chapter examines the possibility of applying a UV-light based surface 
modification technique previously shown to be successful to the nanocomposite with the aim 
of demonstrating successful surface modification and improving cell attachment and 
proliferation on the nanocomposite surface.  
 
3.2 Materials and methods 
 
3.2.1 Nanocomposite synthesis and graft preparation 
 
 Polycarbonate polyol and trans-cyclohexanediolisobutyl-silsesquioxane (Figure 2.1) were 
placed in a reaction flask equipped with stirrer and nitrogen. The mixture was heated to 
dissolve the nanocage. To this, methylene di-isocyanate (MDI) was added and then reacted at 
70 ºC for 90 minutes to form a pre-polymer. Then DMAC was added. Chain extension of the 
pre-polymer was carried out by the addition of ethylenediamine and diethylamine in DMAC. 
1-butanol in DMAC was added to the mixture to form a 2% polyhedral oligomeric 
silsesqioxane-poly (carbonate-urea) urethane solution. All chemicals and reagents were 
purchased from Aldrich Limited, Gillingham, UK.  
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3.2.2 Nanocomposite Preparation  
 
 Nanocomposite foils with a thickness of approximately 10 µm were cast from a DMAC 
solution. 1.5 g of the nanocomposite was dissolved in 12 g of DMAC. 10.25 g of this solution 
was poured into a metal mould (10 x 10 x 0.5 cm) and the nanocomposite solidified in a 
polymer drying oven at 51oC for 30 hours. In all subsequent discussions, the polymer will be 
addressed as nanocomposite to avoid confusion once it is diluted for casting. 
 
Figure 3.1 Structure of nanocomposite 
 
3.2.3 UV-modification of the nanocomposite 
 
The foils were irradiated by means of a Xe2
*-excimer lamp (Heraeus-Noblelight, 
Hanau, Germany) for times of between 30 seconds and 30 minutes. The lamp was emitting 
quasi-continuously with a centre wavelength of 172 nm, a spectral bandwidth of 
approximately 16 nm and an intensity of approximately 17 mW/cm2. The samples were 
flushed with a moderate flow of NH3 at a total pressure of 5 mbar. The NH3 gas employed 
during irradiation had a purity of 99.995%. (Linde, Höllriegelskreuth, Germany). The 
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distance between the sample surface and the chamber window was 5 mm. The time intervals 
between surface modification and the biological experiments were between 1 and 9 weeks. 
Between modification and biological experiments, the samples were stored covered by 
aluminium foils under atmospheric conditions without special provisions. Investigations 
involved untreated and 30 second, 5 minute, 10 minute, 15 minute and 30 minutes’ surface 
modified nanocomposite foils. Prior to cell seeding nanocomposite films were cut into discs 
to fit 24-well plates and sterilized by autoclaving. 
 
3.2.4 Nanocomposite characterisation methods  
 
The sample morphology was investigated by contact mode atomic force microscopy 
(AFM) in air (Resolver, Quesant Instrument, Agoura Hills, CA) and by SEM (JSM-6400 
Scanning Microscope, Joel, Tokyo, Japan). Measurements of advancing water contact angle 
were performed according to a standard procedure  (Adamson and Gast, 1997). In brief, a 
small drop of de-ionised water (volume about 10 µl) was put onto the flat sample surfaces 
using a syringe in such a way that the drop volume at the surface expands. The resulting 
advancing contact angle was evaluated by optical methods using a digital camera. The 
measurements were performed in an air-conditioned laboratory at 22° C. For each sample the 
measurement was repeated 12 times. The chemical composition of the surface of 
nanocomposite samples was investigated by means of X-ray induced photo-electron 
Manchester, UK). The typical analysed depth was about 7 nm and the analysed area 0.3 x 0.7 
mm. Attenuated total reflection – fourier transformed infrared spectroscopy (ATR-FTIR) was 
employed to analyse infrared active bonds in the surface of the samples. In this case an FTIR 
spectrometer (Equinox, Bruker, Karlsruhe, Germany) with a single reflection attenuated total 
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reflectance (ATR) diamond system (Golden Gate, Specac, Orpington, UK) was employed. 
The analytical depth of this methodology depends on the refractive index of the material 
under investigation and the position in the spectrum. For a typical nanocomposite we 
estimated a penetration depth of 0.2 µm at 7500 cm-1 and 4.6 µm at 370 cm-1, respectively. A 
spectra library (Mentor Pro, Biorad, Hercules, CA) together with an heuristic approach was 
used to identify the peaks and the corresponding bond vibrations. 
 
3.2.5 Cell Seeding of nanocomposite foils 
 
 Experiments for evaluation of cell adhesion and proliferation were performed using 
HUVEC at passage 3. HUVEC were isolated from human umbilical cord vein following a 
previously described method (Jaffe et al., 1973). Cell numbers were amplified by tissue 
culture in Cell Culture Medium (CCM) which was prepared as follows: 157 ml M199 
medium, 4.5 ml Sodium Bicarbonate (7.5%), 1.5 ml Penicillin/Streptomycin (10,000 U/ml 
and 10 mg/ml respectively), 40 ml Fetal Bovine Serum and 3.6 ml 200 mM L-Glutamine 
(Invitrogen Ltd, Paisley, U.K.). At confluence cells were removed using 0.25% Trypsin-
EDTA (Sigma-Aldrich Company Ltd, Poole, U.K.) and split in a 1:2 ratio.  
 
3.2.6 Determination of optimal seeding density 
 
In order to determine the optimum seeding density for HUVEC unmodified 
nanocomposite foils (n=4) were placed in standard polystyrene 24-well tissue culture plates 
(Helena Biosciences, Sunderland, U.K.) and seeded with cells at a density of 0.5, 1.0, 2.0 and 
4.0 x 105 cells/well in 0.5 ml culture medium for two hours. Following the two-hour seeding 
period seeding the cell culture medium was removed and frozen at -20oC for total DNA 
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analysis to assess the number of cells which did not attach and the seeded cells were extracted 
for total DNA analysis.  
 
 LDH was measured using a CytoTox 96® Non-Radioactive Cytotoxicty assay kit 
(Promega, Southampton, U.K.). LDH is a stable cytosolic enzyme released upon cell lysis 
into the cell culture medium. The amount of LDH released is measured using a 30-minute 
coupled enzymatic assay based on the conversion of a tetrazolium salt INT (2-p-iodophenyl-
3-p-nitrophenyl-5-phenyl tetrazoliumchloride) into a red formazin product, with the amount 
of colour formed being proportional to the number of lysed cells. 
 
 50µl cell culture medium from each sample was transferred to a 96 well plate (Helena 
Biosciences, Sunderland, U.K). 50µl Substrate Mix was added to each well and the plate 
covered in foil to prevent light access. Samples were then incubated at room temperature for 
30 minutes after which the reaction was stopped by the addition of 50µl stop solution (1M 
acetic acid). Absorbance was then read at 450nm using a Multiscan MS UV visible 
spectrophotometer (Labsystems, Ashford, U.K.). 
 
 The Pico green assay (Molecular Probes Europe BV, Leiden, The Netherlands) quantifies 
double stranded DNA in solution using an ultrasensitive fluorescent nucleic acid stain. Stock 
standard DNA solution (100µg/ml) was diluted in tris-EDTA (TE) assay buffer to provide a 
standard curve of 0 to 1000ng/ml DNA. Cell samples were trypsinised as above and the cell 
disrupted by being passed through a small-bore needle three times. 100µl of standard/sample 
was added to a 96 well plate and 100µl of diluted Pico Green (Pico Green Dimethylsulfoxide 
stock solution diluted x200 in TE assay buffer) was added to each standard/sample well. 
Plates were incubated for 5 minutes in the dark. Standards/samples were then excited at 
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480nm and the flouresence emission intensity measured at 520nm using a Fluroskan Ascent 
FL spectrofluorometer (Thermo Life Sciences, Basingstoke, U.K.). 
 
 
3.2.7 Nanocomposite seeding to determine the effect of UV modification of nanocomposite 
 
Untreated polymer foils and foils of 5 minute, 10 minute, 15 minute and 30 minutes 
irradiation times were placed in a 24-well untreated tissue culture plates (n=4). Foils were 
seeded with HUVEC at a concentration of 1 x 105 cells/well in 0.5ml cell culture medium for 
either 1 or 2 hours. Following seeding the medium was removed and used for LDH analysis. 
The initially seeded cells were initially examined by Alamar blueTM assay and again after 24, 
48 and 72 hour's culture. 
 
3.2.8 Assessment of cell viability and metabolism on UV modified nanocomposite 
 
  AB (Serotec, Kidlington, U.K.) is a commercially available assay which aims to measure 
quantitatively cell proliferation, cytotoxicity and viability. This is achieved by incorporating 
resazurin and resarfurin as colourimetric oxidation reduction indicators. These indicators 
respond to chemical reduction resulting from cell metabolism by changing colour. This 
colour change may be measured by monitoring absorbance at 450 nm. AB was added to cell 
culture medium (CCM) at a concentration of 10% (v/v). At each AB assay timepoint 
grafts/wells were washed with 1 ml PBS and 1 ml of the AB/CCM mixture added to each 
graft/well. 1 ml AB/CCM mixture was placed into each of 6 empty wells as a negative 
control. After 4 hours’ a 100μl sample of the AB/CCM mixture was removed and the 
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absorbance at 450 nm measured in a 96-well plate (Helena Biosciences, Sunderland, U.K.) 
using a Multiscan MS UV visible spectrophotometer (Labsystems, Ashford, U.K.).  
 
 
3.2.9 Statistical Evaluation 
 Data are presented in meanSD. Comparison between groups was made by One Way 
ANOVA (Kruskal-Wallis) test with post comparison using Bonferroni’s Multiple 
Comparison test. *indicates P< 0.05 and *** that P< 0.001. 
 
3.3 Results 
 
3.3.1 Atomic Force Microscopy/Scanning Electron Microscopy of nanocomposite 
 
Figure 3.2 shows an SEM micrograph of the top side of a nanocomposite sample cast 
from DMAC solution. The surface appearance consists of a bulky round rough structure with 
a periodicity of about 5 µm and ribbon-like finer layered structure which is not distributed 
homogeneously over the whole sample area. Also visible are fine inclusions. The surface 
morphology accessible by the SEM investigation is independent of the UV-irradiation. The 
sample in Figure 2 has been irradiated for 30 minutes by the UV-lamp in 5 mbar NH3 (the 
longest irradiation time used in this study), but shows the same features as an untreated 
surface demonstrating that the process of irradiation does not affect the surface. The fine 
inclusions were investigated in more detail by AFM measurements. Figure 3.3 shows the 
micrograph of nanocomposite samples UV-irradiated for 0 to 30 minutes in NH3. The 
pronounced cage-like features are the mixture of silsequioxane nano-cages. Again, the 
features were similar for untreated and irradiated samples. 
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Figure 3.2 SEM image of nanocomposite: nanocomposite exposed to 172 nm UV-light in 5 
mbar NH3 for 30 minutes. For recording of the SEM image, a thin Au layer was deposited 
onto the surface by sputter deposition. 
 
3.3.2 Chemical and Surface Analysis 
 
Atomic Force Microscopy (AFM). Scans were performed with an 'Quesant 
Instruments Corp' AFM Serial Number: 752010 and the results are shown in Figure 3.3 
which are set out in the series below. 
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i) O minutes irradiation 
 
ii) 5 minutes 
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iii) 10 minutes 
 
iv) 15 minutes 
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v) 30 minutes 
 
Figure 3.3 AFM image of nanocomposite: nanocomposite exposed to 172 nm UV-light in 5 
mbar NH3 for i) 0 minutes (untreated), ii) 5 minutes, iii) 10 minutes, iv) 15 minutes and v) 30 
minutes. The image shows an area of 4 x 4 µm, while the colour-scale encodes the height 
information. Due to an image processing artefact, the largest features are accompanied by 
slightly deeper stripes in horizontal and vertical direction. 
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3.3.3 Contact Angle Analysis 
 
The UV-treatment of the nanocomposite samples in NH3 resulted in increased 
hydrophilicity of the originally amphiphillic surface. Figure 3.4 shows the advancing water 
contact angle (CA) as function of the irradiation time. It decreased from 87.5 ° on untreated 
nanocomposite to about 37 ° on UV-treated samples. For longer irradiation times than 5 
minutes a saturation effect for the CA was observed. 
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Figure 3.4 CA of UV-irradiated nanocomposite: advancing water contact angle at 
nanocomposite versus irradiation time (exposure to 172 nm UV-light in 5 mbar NH3). 
 
81 
 
3.3.4 X-ray Induced Photo-electron Spectroscopy  
 
Figure 3.5 shows XPS spectra of untreated and irradiated nanocomposite samples 
which were UV-irradiated for 30 seconds, 5 minutes and 30 minutes in NH3. For the 
untreated nanocomposite (Figure 5a) the spectrum consists of peaks which are assigned to 
oxygen (O), carbon (C) and silicon (Si). No nitrogen (N) peaks could be detected even 
though the nanocomposite and polyurethane matrix includes N-containing urea and urethane-
groups. A possible explanation for that is the short penetration depths of XPS (7 nm) along 
with surface effects during solidification. In addition traces of chlorine could be detected as 
in all other spectra in Figure 3.5.  
The chlorine content is from the mixture of nano-cages used in the synthesis one of 
which contains chlorine. The 172 nm UV-irradiation resulted in the introduction of new N- 
and O-containing groups into the surface. The quantitative evaluations of these spectra are 
listed in Table 3.1 showing examples for an untreated nanocomposite sample and a 
nanocomposite sample exposed for 30 minutes to the 172 nm UV-irradiation in 5 mbar NH3. 
Detailed spectra of the element peaks (not shown) allow the determination of the chemical 
bindings of the elements. For the C 1s , O 1s and N 1s electron the intensity of the sub-peaks 
and their identification are also listed in the Table.  
In addition, the sub-peaks and identifications of the Si 2p doublet are listed. For C-
groups, the irradiation resulted in the nanocomposite surface showing a strong depletion of C-
C bonds (suggesting a reduction of CH2 groups) and the formation of C=C double bonds and 
of various C-O and C-N bonds. For Si-groups, higher values of binding were detected in the 
samples irradiated for 5 and 30 minutes than in the unirradiated sample. This can be 
interpreted as an oxidation of the Si-atoms in the surface layer. The newly found N-peaks can 
be assigned to C-bond N-H groups, mainly near C=O groups, or to Si-N bonds. The detailed 
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analysis in the N-region of the sample of Figure 2.5b revealed a peak, which could be 
interpreted as N+ (for example from ammonium groups). The other features of the spectra of 
the samples irradiated for 30 seconds and 5 minutes are qualitatively similar to those of the 
spectrum of irradiated for 30 minutes, but less pronounced. 
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Figure 2.5 XPS spectra of nanocomposite: (a) nanocomposite untreated, (b) nanocomposite 
exposed to 172 nm UV-light in 5 mbar NH3 for 30 seconds, (c) nanocomposite exposed for 5 
minutes and (d) nanocomposite exposed for 30 minutes. 
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Sample Peak Conc.  Subpeak Pos.  Conc. Binding 
  at %   eV  % 
UN C  61.4  C 1s 1 285.0 94.5 C-C 
   C 1s 2 286.5 5.5 C-O 
 O 22.9  O 1s 1  530.9 1.7  O-Si 
   O 1s 2  532.3  87.2  O-Si,O= 
  O 1s 3  533.1  11.1    -O- 
 Si 14.9 Si 2p3/2 1 102.6  66.7 Si-C 
   Si 2p1/2 1 103.2  33.3 Si-C 
IN C  38.5  C1s 1 284.6  43.0  C 
   C1s 2 285.0  13.4  C-C 
   C1s 3 285.7  14.2  C-N, C- 
   C1s 4 286.5  15.1  C-O 
   C1s 5 287.8  10.0  O-C-O,C=O,N-CO 
   C1s 6 288.9  4.2          O=C-O 
 O 35.1  O 1s 1  530.9 6.3     O-Si 
   O 1s 2  532.4  89.1  O-Si, O= 
   O 1s 3  533.8  4.6  -O- 
 Si 13.6 Si 2p3/2 1 101.9  3.4       Si-C 
   Si 2p1/2 1 102.6  1.7 Si-C 
   Si 2p3/2 2 103.1  63.3 Si-O 
   Si 2p1/2 2 103.8  31.7 Si-O 
  N 11.7 N 1s 1  398.6  22.8 Si-N, C-N- 
   N 1s 3  399.9  77.2 N-C=O 
 
Table 3.1: Detailed evaluation of XPS spectra. Key: UN; Untreated Nanocomposite, IN; 
Irradiated Nanocomposite (30 minutes exposure to 172nm UV-light in 5 mbar NH3) 
 
3.3.5 Attenuated Total Reflection- Fourier Transformed Infra Red Spectroscopy 
 
Figure 3.6 shows the ATR-FTIR spectra of untreated nanocomposite and 
nanocomposite samples irradiated for 30 seconds, 5 minutes or 30 minutes. In Figure 3.7 the 
identified peaks are marked by labels indicating the corresponding vibrations. The peaks of 
the untreated sample could be correlated to vibration modes of the components of the 
nanocomposite polymer (Figure 2.7a). The peak at 3340 cm-1 could be identified as N-H 
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vibration, probably from the urea and urethane groups in the polymer. The large peak at 2960 
cm-1 was assigned to C-H vibrations from methylene segments in the polymer chain, the side 
peak at 2865 cm-1 to C-H vibrations from CH3-groups bonded to phenol groups in the 
carbonate segments. The peak at 1735 cm-1 was identified as C=O vibration, probably from 
carbonate or urethane segments. The small peaks between 1430 and 1625 cm-1 were assigned 
to ring vibrations of phenol groups.  
 
The peak at 1250 cm-1 was assigned either to C-C or O-CO-O vibrations in the 
polymer backbone. The peak at 1085 cm-1 could be assigned to Si-O-Si vibrations from the 
silsequioxane groups. The identification of the peak at 945 cm-1 was to some extent 
ambiguous, but may be the vibration of an Si-O group bond to a phenol ring. Compared to 
untreated nanocomposite, the main difference in the spectra of the irradiated samples was the 
appearance of a broad peak between 2630 and 3690 cm-1 (Figure 3.7b), which was more 
pronounced for the samples with longer irradiation times.  
 
This peak can be assigned to a combination of various O-H, N-H and N-H2 vibrations. 
Besides the peak at 1085 cm-1, an additional peak at 1050 cm-1 appeared in the irradiated 
samples. Both could be associated with Si-O-Si vibrations. 
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 Figure 3.6 ATR-FTIR spectra of nanocomposite: nanocomposite untreated and 
nanocomposite exposed to 172 nm UV-light in 5 mbar NH3 for 30 seconds, 5 minutes and 30 
minutes, respectively. For sake of clarity, an off-set is added to the spectra of irradiated 
samples. 
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 Figure 3.7 Peak assignment in ATR-FTIR spectra: peak assignment in spectrum of (a) 
untreated nanocomposite and (b) nanocomposite exposed to 172 nm UV-light in 5 mbar NH3 
for 30 minutes. Ph is the abbreviation of phenol-ring. 
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 3.3.6 Determination of optimal seeding density 
 
 Figure 3.8a) shows the amount of DNA extracted from adherent cells on unmodified 
nanocomposite after a two-hour seeding period for four cell concentrations. It can be seen 
that as the seeding density increases there is a significant (p<0.001 vs. Previous column) 
increase in the amount of DNA (and hence cell numbers).  
 
 The percentage of cells seeded after two hours is shown in Figure 3.8b). 
Approximately 40% to 50% of the total number of cells appear to be attached after two hours. 
 The relative LDH release following two hours’ cell seeding is shown in Figure 3.8c). 
It can be seen that there was no significant difference in LDH release for any of the 
treatments over the period examined. 
 
 Based on the above results it was determined to use a 1 x 105 seeding density and 
seeding periods of one and two hours to determine if UV modification of the nanocomposite 
improved initial cell adhesion or growth. 
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Figure 3.8a Pico green assay for total DNA amount from cells seeded on unmodified 
nanocomposite graft after two hour seeding with 0.5, 1, 2 and 4  x 105 HUVEC/ml (n=4).  + 
indicates p<0.001 vs. previous column. 
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Figure 3.8b Percentage of cells seeded on nanocomposite after two hour seeding with 0.5, 1, 
2 and 4  x 105 HUVEC/ml (n=4).  
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Figure 3.8c LDH activity for unmodified (0), 5, 10, 15 and 30 minutes irradiated at 5mbar 
NH3 atmosphere modified Prep 11 graft after 2 hours seeding (n=4). Cell seeding density 1 x 
105 cells/well. 
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3.3.7 Assessment of cell viability and metabolism on UV modified nanocomposite 
 The results of the assessment of cell viability and metabolism for the initially seeded 
cells and after 24, 48 and 72 hours’ incubation for each seeding time are shown in figures 
3.9a) to d). 
 It can be seen that there was little difference between any of the groups at the time 
points investigated for either a one hour or two hour seeding period. The nanocomposite 
irradiated for 10 minutes appears to be slightly worse at most time points in the two-hour 
seeding experiment. 
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Figure 3.9: AB assay for unmodified (0), 5, 10, 15 and 30 minutes irradiated at 5mbar NH3 
atmosphere modified nanocomposite a) after initial seeding, b) 24 hours; c) 48 hours and d) 
72 hours after initial 1 hour and 2 hour seeding (n=4). Cell seeding density 1 x 105 cells/well. 
* indicates p<0.05 vs. 2 hour unmodified. 
 
 
3.4 Discussion 
 
The XPS results of the unmodified sample are consistent with the nanocomposite 
composition except the lack of N explainable by the low penetration depth of the XPS assay 
method NMR studies (data not shown) and ATR measurements demonstrated that this lack of 
N is not representative of the bulk material . XPS and ATR-FTIR spectra showed an 
increasing amount of N for the irradiated nanocomposite samples. Photochemical surface 
modification of the polymer is responsible for this increase, comparable with the 
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incorporation of N into the surface of other polymers as described previously (Heitz et al., 
2004; Gumpenberger et al., 2003). The new N-containing groups could be NH, NH2 or NH3
+. 
The irradiated nanocomposite samples showed higher O-contents as compared to the 
untreated nanocomposite. This increase in O could be due to residual O in the irradiation 
chamber or to oxidation of remaining radicals in the sample surface during exposure to air 
after the treatment (Heitz et al., 2004). Another source could be O-groups from within the 
nano-cages themselves.  
 
This is supported by the fact that the Si at the surface arising from the nano-cages is 
oxidized to a degree as is indicated in the XPS results as well as in the ATR-FTIR. For 
untreated nanocomposite, one peak at 285 eV is dominant in the detailed XPS spectra in the 
C-region. This is commonly associated with CH groups. With increasing irradiation time the 
C peak becomes more complex consisting of several subpeaks. This indicates that carbon is 
involved in the chemical reactions or that the surface composition changes during 
modification.  
 
The width of the XPS C-peak is relatively large for the irradiated samples, 
indicating a broad variation of the chemical surrounding of the C-atoms under consideration. 
This would be consistent with photoreactions in the nanocomposite chain being induced due 
to UV-irradiation. The appearance of a broad peak between 2630 and 3690 cm-1 the ATR-
FTIR clearly shows that there are new N- or O- containing groups incorporated in to the 
surface which are polar. Therefore, the photochemical surface modification is in accordance 
with the observed considerable reduction of CA resulting in a change from an amphiphillic 
surface to a more hydrophilic surface. 
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No obvious changes to the surface morphology of the nanocomposites were observed 
by SEM and AFM investigations. However small changes could occur due to irradiation that 
may influence the interaction of the cells with the surface and structural changes well below 
100 nm can be of great significance. 
 
The cell adhesion and proliferation results show clearly that there is little 
improvement in HUVEC adhesion and proliferation on the photochemically modified 
nanocomposite surfaces under the circumstances investigated. Interestingly further study 
using a HUVEC EA.hy926 cell line which was derived from HUVEC (Edgell et al., 1983; 
Bouis et al., 2001) did demonstrate an improvement in cell adhesion and proliferation for the 
5 and 15 minute UV modified surfaces (Olbrich et al., 2007). 
 
It was anticipated that the potential enhancement of the adhesion and proliferation 
on the photochemically modified regions may be due to the improved hydrophillicity of the 
modified surface. This is supported by the change of polarity/wettability demonstrated by the 
CA measurements. The improved wettability facilitates the adsorption of cell adhesion-
mediating proteins, present in the serum of the culture media, in an amount, spectrum and 
conformation favourable for the binding of specific amino acid sequences of these proteins to 
the integrin receptors of the cells (Arnold et al., 2004). On the modified nanocomposite 
samples there is a relatively high content of positively chargeable amine groups. These are 
reported to have a good interaction with the mainly negative charged cell membrane and this 
could be favourable for cell adhesion. In addition the new chemical groups include functional 
groups typically found in amino acids suggesting that cell adhesion may be supported by 
direct cellular interaction with these newly formed chemical groups on the surface.  
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3.5 Conclusion 
 A decrease in contact angle from 87.5O for the untreated nanocomposite to 
approximately 37O for the UV-treated samples shows a significant increase in hydrophilicity 
which is supported by the ATR-FTIR and XPS analysis. The difference in outcome for the 
primary HUVEC cells reported in this chapter which were largely unaffected by the surface 
modification and the HUVEC cell line used in the follow up study demonstrates the 
difficulties involved in extrapolating results obtained using cell lines to primary cells.  In 
conclusion, it can be said that the successful modification of the nanocomposite investigated 
in this study by UV-irradiation in an ammonia atmosphere has been demonstrated by the 
results obtained and that the technique may have potential for future employment to develop 
an EC seeded prosthesis. 
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4 
4 Human Peripheral Blood derived Endothelial Cell Seeding of 
Nanocomposite. 
 
4. 1 Introduction 
 The use of prosthetic grafts in vascular surgery has increased since the introduction of a 
fabric arterial graft in mid twentieth century. Although much work has been carried out since 
then to improve the prosthetic grafts employed in this field, cardiac and peripheral vascular 
disease remain the major causes of death in the Western world. In UK, it is estimated that one 
in three deaths could be attributed to diseases of the circulatory system or heart and this is 
likely to be a continuing problem in the future as the life expectancy of the population 
increases. In an ideal situation, an autologous vein or artery is the most suitable conduit 
choice for bypass operations (the internal mammary being employed for coronary bypass and 
the saphenous for lower limb arterial bypass) and these results in a 5-year patency rate of 
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around 75%. In around 30% of cases a suitable autologous conduit is not available for lower 
limb bypass and a similar situation occurs for coronary bypass (Kannan et al., 2005a) leading 
to a requirement to use an artificial conduit (Rashid et al., 2004). 
 There are two major types of prosthetic graft in clinical usage currently, based on either 
expanded polytetrafluoroethylene (ePTFE) or polyethylene terephthalate (Dacron®). Current 
prosthesis employed have low patency rate due to the low compliance and thrombogenicity 
of the materials used.  
 
 Several approaches have been taken to attempt to improve the patency of prosthetic 
grafts, including surface modification of existing grafts, endothelial seeding and recently 
development of tissue engineering bypass graft (Baguneid et al., 2006; Sarkar et al., 2007b; 
Isenberg et al., 2006) and development of new compliance prosthesis with active 
biomolecules and endothelialisation (Kidane et al., 2004). 
 
 The most interesting material our group has been working on is an novel nanocomposite 
based on polyhedroligomeric silsesquioxane-poly (carbonate-urea)urethane nanocomposite. 
The potential advantages of the UCL-Nano™ have been reviewed previously (Kannan et al., 
2005a). The nanocomposite has been demonstrated to have similar viscoelastic properties to a 
native artery and be resistant to degradation (Kannan et al., 2005c). Several previous studies 
have also indicated that the nanocomposite can sustain HUVEC seeding (Punshon et al., 
2005; Vara et al., 2006). 
 
 Another aspect which has been investigated to overcome this problem is seeding the 
artificial material with EC’s to improve the blood compatibility of the device. This idea was 
first reported by Herring et al (Herring et al., 1978; Stanley et al., 1985) in 1978 and has 
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since attracted considerable interest with numerous studies being carried out in this area. 
Sources of material from which to obtain suitable cells to attempt seeding include the 
patient’s own veins (Herring et al., 1978; Stanley et al., 1985)  omentum or subcutaneous fat 
and peritoneal lavage (Tiwari et al., 2003a) all of which have the disadvantages of being 
invasive to obtain (requiring an operation) and difficult to extract cells from in adequate 
numbers. These factors limit their potential in both a research and clinical situation. 
 
 In a clinical context two-stage seeding, in which EC are extracted from tissue then 
cultured for a period of time in the laboratory has been demonstrated to be successful in a 
number of studies with a significant increase in graft patency. One study by Zilla et al and 
published in 1994 (Zilla et al., 1994) seeded autologous EC from the external jugular vein 
onto 70 cm long 6 mm internal diameter PTFE grafts coated with fibrin glue in 33 patients 
with either disabling claudication or critical ischemia. The average culture time required after 
vein incision was 25 days and growth failure occurred in 27% of the cases. Cases were 
followed up by angiography, platelet adhesion studies, assessment of the ankle-brachial index 
and duplex sonography. After 32 months’ the patency of the endothelialised grafts was 85% 
compared to 55% for the unseeded control grafts thus demonstrating an improvement in 
patency similar to that found when employing autologous grafts. These results were 
confirmed by further long-term studies by the same group reporting similar results (Deutsch 
et al., 1999; Meinhart et al., 2001).  
 
 Despite this demonstration of the potential of the two-stage seeding technique developed 
by this group such techniques have not, to date, been taken up in widespread practice. There 
are several reasons why uptake of this technique has been limited. Firstly, it requires the 
patient to undergo an extra operation to collect the tissue required to extract EC prior to 
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culture in the laboratory. This exposes the patients to additional risk in undergoing an extra 
surgical procedure to obtain tissue and has considerable cost implications over and above 
those for the cell culture stage where a dedicated facility is required. Secondly the period 
required to grow up the cells and seed the device is considerable (three to four weeks) and, in 
a number of cases, the cells fail to multiply sufficiently to seed the graft.  
 
 There has been much interest in the potential for using human stem cells to treat a wide 
variety of medical conditions in the future (Sales et al., 2005). Much of this research is based 
on using embryonic stem cells, cells obtained from bone marrow or cells obtained from 
umbilical cord blood. Whilst the potential for such work is great it is associated with grave 
problems from the ethical viewpoint when working with human tissue in the case of 
embryonic stem cells, difficulty in obtaining adequate samples for research in the case of 
bone marrow or clinical practicality in the case of umbilical cord blood. 
 
 It has recently been demonstrated however that human peripheral blood contains both 
circulating EC’s and EPC, a type of stem cell with the potential to expand. The first report on 
the isolation of progenitor cells from peripheral blood was made by Ashara et al in 1997 
(Asahara et al., 1997)  using magnetic beads to separate CD34+ cells. Further studies by 
groups such as Hill et al demonstrated that it was possible to extract progenitor cells without 
the use of magnetic beads and correlated the numbers in blood with cardiovascular risk 
factors (Hill et al., 2003). Several other studies have demonstrated the potential of progenitor 
cells isolated from this source (Shirota et al., 2003; Hur et al., 2004; Ingram et al., 2004).  
 
 In view of the above the aim of this chapter was to develop a system with the potential to 
deliver an EC-seeded bypass graft in a realistic time-frame and in a manner such that general 
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uptake of the process would be possible. This could be achieved by building on the proven 
clinical success of two stage seeding whilst attempting to overcome the potential pitfalls of 
cell source by employing peripheral blood as a source of cells and using nanocomposite as a 
scaffold for seeding. 
    
4.2 Materials and Methods 
 
4.2.1 Preparation of nanocomposite polymer films 
 The synthesis of the nanocomposite inorganic urethane is made from 4,4’-methylenebis 
(phenyl isocyanate) (MDI), poly (hexamethylene carbonate)diol, and silsesquioxane 
dissolved in tetrahydrofuran here bis [3- (trimethoxysilyl)propyl]amine and chain extended 
with DMAC. 
 Glass Petri dishes (40mm diameter) were then coated with 4mls of nanocomposite (15 % 
in DMAC) and cured overnight at 55oC. The resulting films were then thoroughly washed 
with sterile PBS and sterilized by immersion in 70% ethanol followed by air-drying. 
 
4.2.2 Blood Collection 
 Blood samples were collected following consent from healthy adult human volunteers. 
20ml samples were collected by venepuncture in EDTA blood tubes (Sarstedt, U.K.). 
Following collection samples were mixed and used for cell isolation within one hour of 
collection.  
 
4.2.3 Cell Isolation 
 The mononuclear fraction of the blood was then isolated using Lymphoprep (Axis-Shield, 
U.K.). Briefly 20ml of blood was transferred to a 50 ml centrifuge tube (Falcon, U.K.) and 
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gently mixed with 20ml Hank’s Balanced Salt Solution (HBSS) (Invitrogen, U.K.). 5ml 
Lymphoprep was then added to each of eight 12ml polystyrene centrifuge tubes (Falcon, 
U.K.) and 5ml of the blood/HBSS mixture then layered carefully on top. The tubes were then 
centrifuged at 1500 rpm and 20oC for 25 minutes. The mononuclear fraction was then 
separated from each and placed equally into two 30 ml universal tubes (Falcon, U.K.). 10ml 
of HBSS was then added slowly to each tube and the contents mixed. The tubes were then 
centrifuged at 1500 rpm and 20oC for 15 minutes. The supernatant was then discarded and the 
cells resuspended in 2 ml HBSS. The volume was then made up to 10ml and the cells 
centrifuged at 1200 rpm and 20oC for 15 minutes to remove red blood cells. The supernatant 
was again discarded and the cell pellet resuspended in 10ml HBSS. A final centrifugation 
step at 1500 rpm and 20oC for 15 minutes was then performed. Finally, the supernatant was 
again discarded and the cells resuspended in 5ml cell culture medium (CCM): RPMI 1640 
supplemented with 20% fetal bovine serum and penicillin/streptomycin (Invitrogen U.K.). 
The cells were then counted using a haemocytometer. 
 
4.2.4 FACS analysis for CD133+/VEGFR2+ EPC 
 100μl of initial cell isolation was incubated with a murine IgG, for 15 minutes at 4°C to 
block non-specific binding/specific binding via FcR, followed by incubation with a novel 
cocktail of antibodies comprising FITC-conjugated mouse anti-human CD2, CD13 and CD22 
(BD Biosciences), PE-conjugated mouse anti-human VEGFR2 (R&D Systems, U.K) and 
biotin-conjugated mouse anti-human CD133 (Miltenyi Biotec, U.K) monoclonal antibodies 
for 10 minutes at 4°C, then washed. Following this, streptavidin-PeCy7 (Beckman Coulter, 
U.K) was added and the samples further incubated for 10 minutes at 4°C. Red cells were 
lysed and the samples were fixed using the Coulter TQ-prep system (Beckman Coulter, U.K). 
The samples were resuspended in HBSS and fluorescent particles (Sphero™Accucount 
103 
 
fluorescent particles (ACFP-100-3), 10 μm; Spherotech Inc, U.K) were added to calculate 
absolute cell numbers. The calculation was performed as follows: 
 Samples included the count of 10,000 fluorescent particles to give a total of 0.5–1×106 
mononuclear events. The samples were analysed immediately on a FACScan using CellQuest 
3.1 software (Becton Dickinson, U.K.).  
 
 The instrument was standardised daily with Calibration beads (FluoroSpheres 6-Peak; 
DakoCytomation, U.K) and thoroughly cleaned before data acquisition to exclude any trace 
amounts of cellular debris or residual cells from a previous tube. The cleaning process 
comprised of sequential tubes with water, bleach and water again for about 30 minutes. 
 
4.2.5 Cell Culture 
 Isolated cells were cultured for an initial two days in a 6-well plate (Falcon, U.K) at a 
seeding density of 9.2x106 cells/well following which the supernatant (containing the non-
attached cells) from two wells was transferred to a nanocomposite film coated Petri dish. 
Cells were then cultured in CCM for a further five days. The supernatant was then removed 
from the UCL-Nano™ film coated Petri dishes and the remaining adherent cells cultured in 
CCM with the medium being changed every two to three days for a total of 35 days. Cells 
were also cultured on 8-well slides (Falcon, U.K.) for characterisation studies. Experiments 
were repeated between three and five times. 
 
4.2.6 Measurement of Cell Metabolism 
 Cell metabolism was assessed by Alamar blueTM (AB) (Serotec, U.K.) assay at Day 7, 14, 
21, 28 and 35. Medium was removed from the nanocomposite film coated Petri dishes and 
4ml 10% AB in CCM added. After a 4-hour incubation, duplicate 100μl samples of AB/CCM 
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were removed and measured on a Fluroskan Ascent FL (Thermo Labsystems, U.K.) 
fluorescent plate reader (excitation 530nm, emission at 620nm). Unseeded nanocomposite 
film coated Petri dishes were used as a control. The AB/CCM mixture was then removed and 
replaced with fresh CCM. 
 
 
4.2.7 RNA Isolation and Investigation 
 RNA was extracted from initial cell isolates, confluent cell cultures on 6-well plates and 
Day 35 confluent cell cultures seeded on nanocomposite by using an “RNeasy” kit (Qiagen 
Ltd, U.K.). The RNA concentration and purity was calculated by measuring the absorbance at 
260nm and 280nm using an Eppendorf Biophotometer (EppendorfAG, Germany). The quality 
of the RNA was assessed by 2% agarose gel electrophoresis and the mRNA obtained was 
used for polymerase chain reaction (PCR) for CD14, CD34, CD133, PECAM-1 and vWF. 
RT-PCR was performed using an One-Step PCR kit (Qiagen Ltd, U.K.). A master mix 
containing 10 μl 5x Qiagen One-Step RT-PCR buffer, 10 μl 5x Q-Solution, 400 μM from 
each of the deoxynucleoside triphosphate’s, 2 μl Qiagen One-Step RT-PCR enzyme mix and 
0.5 μM from each of the primers (Table 4.1) was added. 0.25 μg of template RNA was used 
for each PCR reaction. RNase free water was added to give a total volume of 50 μl. Cycle 
conditions were as follows: CD14 30 cycles at 94oC, 57oC and 72oC; CD34 35 cycles at 
94oC, 54oC and 72oC; CD133 35 cycles at 94oC, 52oC and 72oC; VEGFR2 35 cycles at 94oC, 
59oC and 72oC; vWF 35 cycles at 94oC, 50oC and 72oC; PECAM-1 35 cycles at 94oC, 50oC 
and 72oC and amplification was carried out using a MasterCycler Gradient PCR machine 
(EppendorfAG, Germany). In the case of vWF and PECAM-1 RNA extracted from HUVEC 
was used as a positive control. PCR products were then analysed by 2% agarose gel 
electrophoresis and a GeneGenius darkroom with ‘GeneSnap’ version 6.02. (Syngene, U.K.).  
105 
 
Marker Sense (5’ to 3’) Antisense (5’ to 3’) 
CD14 
 
CCTCCCAAGTTTTAGGACAA CAGCTGGTGATAAGGGTTAG 
CD34 CCTCCCAAGTTTTAGGACAA CAGCTGGTGATAAGGGTTAG 
CD133 CAGTCTGACCAGCGTGAAAA GGCCATCCAAATCTGTCCTA 
VEGFR2 
 
GTGACCACATGGAGTCGTG CCAGAGATTCCATGCCACTT 
CD31 GCTGTTGGTGGAAGGAGT GAAGTTGGCTGGAGGTGCTC 
vWF TGCTGACACCAGAAAAGTGC AGTCCCCAATGGACTCACAG 
 
Table 4.1: Primer sequences for CD14, CD34, CD133, VEGFR2, CD31 and vWF gene 
expression analysis. 
 
4.2.8 Giemsa Staining 
 CCM was removed from the cell sample to be stained. Cells were then washed thoroughly 
with 5mls PBS. 500μl ice-cold methanol was then added for 5 minutes to fix the cells. 
Following fixing the methanol was removed and the cells air-dried. 200μl Giemsa stain 
(Invitrogen, U.K.) was then added and the cells left to stain for 15 minutes at room 
temperature. The stain was then removed and the cells destained with PBS as required then 
examined microscopically. Cells were stained at Day 5, Day 14, Day 21 and Day 35. 
 
4.2.9 Scanning Electron Microscopy 
 Seeded nanocomposite at Day 35 was examined by SEM to visualise whether cells were 
still present on the nanocomposite surface. 
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4.2.10 Immunohistochemistry for CD34, CD133 and vWF 
 
4.2.10.1 Preparation of Cells for Staining 
 Cell samples were collected from the initial cell isolation and cytospun onto polylysine-
coated slides (VWR, U.K.) at 500 rpm for 5 minutes. Confluent cell cultures were grown on 
8-well slides. Slides were then fixed in ice-cold methanol (VWR, U.K.) for 10 minutes, air-
dried and stored at 4oC until stained. 
 
4.2.10.2 CD34 Staining of Initial Cell Isolations and Confluent Cells 
 CD34 staining was carried out using an FITC conjugated CD34 antibody (Milteyni, U.K). 
10µl CD34-FITC antibody was added to 90µl buffer (Phosphate buffered saline (PBS) 
containing 0.5 % bovine serum albumin (BSA) and 2 mM EDTA). Diluted antibody was then 
added gently to the cell sample and incubated at 4oC in the dark for 10 minutes. Excess 
antibody was then removed by washing with 10 to 20 times volume of buffer following 
which the cells were covered with a drop of mounting medium (Vector, U.K.) and examined 
microscopically. 
 
4.2.10.3 CD133 Staining of Initial Cell Isolations and Confluent Cells 
 CD133 staining was carried out using a biotin conjugated CD133 primary antibody and 
visualized using an anti-biotin Allophycocyanin (APC) secondary antibody (both Miltenyi, 
U.K.). Briefly 20µl CD133-biotin antibody was added to 80µl buffer (PBS containing 0.5 % 
BSA and 2 mM EDTA). Diluted antibody was then added gently to the cell sample and 
incubated at 4oC in the dark for 10 minutes. Excess antibody was then removed by washing 
with 10 to 20 times volume of buffer. 10µl Anti-biotin-APC in 100µl buffer was then applied 
with a further incubation for 10 minutes at 4oC. Excess antibody was then again removed by 
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washing with 10 to 20 times volume of buffer following which the cells were covered with a 
drop of mounting medium and examined microscopically. 
 
4.2.10.4 von Willebrand Factor Staining of Initial Cell Isolations and Confluent Cells 
 Staining for von Willebrand Factor (vWF) was carried out using a mouse monoclonal 
primary antibody to vWF and visualized using a goat polyclonal to mouse IgG H&L (FITC 
conjugated) secondary antibody (ABCAM, U.K.). Briefly cells were permeabilized by 
incubating for 10 minutes in PBS with 0.25% Triton X-100 (Sigma Chemical Company, 
U.K.). Cells were then washed 3 times with 1ml PBS after which cells were incubated for 30 
minutes with 1% BSA PBST (PBS plus 0.2% Tween-20 (Sigma Chemical Company, U.K.) 
to block unspecific binding. Cells were then incubated in diluted primary antibody (3µl to 
100 µl 1% BSA PBST) for 1 hour at room temperature. Cells were then washed 3 times with 
1ml PBS after which cells were incubated in diluted secondary antibody (3µl to 100µl 1% 
BSA PBST) in 1% BSA PBST for 1 hour at room temperature in the dark. Cells were then 
washed a further three times in PBS, mounted as above and examined microscopically. 
 
4.2.10.5 PECAM-1 (CD31) Staining of Initial Cell Isolations and Confluent Cells 
 CD31 staining was carried out using an APC conjugated CD31 antibody (Milteyni, U.K.). 
Briefly 10µl CD31-APC antibody was added to 90µl buffer (PBS containing 0.5 % BSA and 
2 mM EDTA). Diluted antibody was then added gently to the cell sample and incubated at 
4oC in the dark for 10 minutes. Excess antibody was then removed by washing with 10 to 20 
times volume of buffer following which the cells were covered with a drop of mounting 
medium and examined microscopically. 
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4.3 Results 
4.3.1 Number of Cells Isolated 
 The total numbers of cells isolated for 22 isolations (11 from the same test subject) from 
20mls blood are shown in Figure 4.1. In general, the average number of cells isolated was 
37.5x106±2.414 (SEM) cells/20ml blood (maximum 54x106, minimum 19x106). For the 11 
extractions from the same subject the average number of cells isolated was 42.18x106±3.440 
(SEM) cells/20ml blood (maximum 54x106, minimum 21x106 cells/ml). Cells were 
successfully isolated from all blood samples taken. 
 
Figure 4.1: Cell isolations by density centrifugation from 20ml human blood. Cells counted 
by haemocytometer and number adjusted for volume of blood taken. Alphanumeric on the X 
axis refer to extract codes. 
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4.3.2 FACS analysis for CD133+/VEGFR2+ EPC 
 Figure 4.2 shows the number of CD133+ cells per ml of initial cell isolation (all isolations 
5ml) as determined by FACS analysis was 131±13.53 cells per ml of cell isolation. For 
CD133+/VEGFR2+ (EPC) cells 13.65±6.21 were produced per ml of cell isolation. 
 
Figure 4.2: FACS analysis of initial cell isolations. Number of CD133+ and 
CD133+/VEGFR2+ (EPC) cells shown per ml of cell isolation. 
 
4.3.3 Assessment of Cell Metabolism of Cells Seeded on Nanocomposite 
 Cell metabolism was measured over a 35-day period on seeded nanocomposite films. 
Cells were present at all time-points measured and there was no significant reduction in cell 
metabolism over the course of the investigation (Figure 4.3). 
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Figure 4.3: Cell metabolism determined by an Alamar blueTM assay up to 35 days (n=5). 
 
4.3.4 RNA Isolation and Investigation of Initial Cell Isolations, Confluent Cells and Day 
35 Confluent Cells Seeded on Nanocomposite 
 Figure 4.4a) demonstrates a 2% agarose gel of three initial cell isolations (A, B and C) 
examined by RT-PCR for CD14, CD34, CD133 and VEGFR2. All isolations were positive 
for CD14, CD34, CD133 and VEGFR2. Figure 4.4b) similarly shows a 2% agarose gel of 
three confluent cell cultures (A, B and C) examined in the same way. CD14, CD34 and 
VEGFR2 were still detected while CD133 was not found to be present. All negative controls 
showed no PCR product present. Figure 4.4c) shows a 2% agarose gel of an initial cell 
isolation (A) and two Day 35 nanocomposite seeded confluent cell samples (B) and (C). The 
results are similar to those obtained from confluent cells on 6-well plates. Figure 4.4d) shows 
a 2% agarose gel of two HUVEC cell samples (A and B), two initial cell isolations (C and D) 
and two Day 35 nanocomposite seeded confluent cell samples (E and F) examined for 
PECAM-1 and vWF. All the isolations are positive for both genes. 
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Figure 4.4a) 2% agarose gel of RT-PCR for three initial cell isolations (A, B and C) with 
CD14, CD34, CD133 and VEGFR2 
 
 
Figure 4.4b) 2% agarose gel of RT-PCR for three confluent cell isolations A, B and C with 
CD14, CD34, CD133 and VEGFR2 
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Figure 4.4c) 2% agarose gel of RT-PCR for an initial cell isolation A and two Day 35 
nanocomposite confluent seeded samples B and C with CD14, CD34, CD133 and VEGFR2 
 
 
Figure 4.4d) 2% agarose gel of RT-PCR for two HUVEC cell isolations A, B, two initial cell 
isolations C, D and two Day 35 nanocomposite confluent seeded samples E, F for PECAM-1 
and vWF 
 
4.3.5 Giemsa Staining of Cells Seeded on Nanocomposite 
 Cells seeded on nanocomposite were stained with Giemsa stain at Day’s 5, 14, 21 and 35. 
At Day 5 several Hill Colonies were present. By Day 14 the majority of the nanocomposite is 
covered by cells with some dense areas of cells where Hill Colonies had developed and this 
was maintained to Day 35 (Figure 4.5). 
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Figure 4.5a): Cells seeded on nanocomposite and stained with Giemsa at Day 5 (x10 
magnification) 
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Figure 4.5b): Cells seeded on nanocomposite and stained with Giemsa at Day 14 (x10 
magnification) 
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Figure 4.5c): Cells seeded on nanocomposite and stained with Giemsa at Day 21 (x10 
magnification) 
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Figure 4.5d): Cells seeded on nanocomposite and stained with Giemsa at Day 35 (x10 
magnification). 
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4.3.6 Scanning Electron Microscopy 
 Cells were observed in a confluent layer on the nanocomposite (Figure 4.6). 
 
Figure 4.6: Cells were observed in a confluent layer on the nanocomposite at day 35 
demonstrated with SEM. 
 
4.3.7 CD34 and CD133 Staining of Initial Cell Isolations, Hill Colonies and Confluent 
Cells 
 Figure 4.7 shows staining for CD34 and CD133 on an initial cell isolation sample. All 
views are of the same cell population. Figure 4.7a) shows a large mixed cell population 
present with two basic cell types, small round cells and larger round cells. Figure 4.7b) shows 
cells staining positive for CD34 (FITC (green)). All the larger cells present are stained 
positive for CD34 whereas only a small proportion of the smaller cells stain CD34+ve. Figure 
4.7c) shows cells staining positive for CD133 (Allophycocyanin (red)). All of the larger 
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CD34+ve cells appear to be CD133-ve whereas again a small proportion of the smaller cells 
appear to be CD133+ve. Figure 4.7d) shows dual staining for CD34 and CD133. A low 
proportion of the smaller cells can clearly be seen to be both CD34+ve and CD133+ve. 
 
 Figure 4.8 shows three different Hill Colonies i) unstained, ii) stained for CD34 and iii) 
stained for CD133. All three colonies show clear evidence of CD34+ve and CD133+ve cells. 
 
 Figure 4.9 shows staining for CD34 and CD133 on a confluent cell culture sample. All 
views are of the same cell population. Figure 3.9a) shows a fairly consistent cell population. 
Figure 4.9b) shows cells staining positive for CD34 (FITC (green)). The majority of cells 
present are stained positive for CD34. Figure 4.9c) shows cells staining positive for CD133 
(Allophycocyanin (red)). Again, the majority of cells express CD133, with a few cells 
expressing high levels. Figure 4.9d) shows dual staining for CD34 and CD133. The majority 
of the cells appear to be both CD34+ve and CD133+ve at confluence. 
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Figure 4.7. Initial cell isolation stained for CD34 and CD133. a) unstained, b) CD34 stained, 
c) CD133 stained and d) dual stained. All views are of the same cell population 
(magnification X100). 
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a) 
 
 
b) 
 
 
 
c) 
 
Figure 4.8: Staining of Hill Colonies: three views each stained for i) no fluorescence ii) 
CD34 (FITC(green)) and iii) CD133 (Allophycocyanin(red)).  
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b
Figure 4.9: Confluent cell culture stained for CD34 and CD133: a) unstained, b) CD34 
stained, c) CD133 stained and d) dual stained. All views are of the same cell population 
(magnification X100). 
 
4.3.8 von Willebrand Factor Staining of Initial Cell Cultures and Confluent Cells 
 Staining for vWF is demonstrated in Figure 4.10. Figure 4.10a) and c) shows an initial 
cell isolation stained for vWF with a mixed cell population of small and larger cells. The 
larger cells are stained strongly positive for vWF. There is also some staining in the smaller 
cell population in addition. Figure 4.10b) and d) show confluent cell cultures stained for vWF 
and demonstrates that the majority of the cells are vWF positive. 
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c d
Figure 4.10: Initial cell isolation and confluent cells stained for vWF: a) initial isolation 
unstained b) confluent cells unstained, c) initial isolation stained for vWF and d) confluent 
cells stained for vWF (magnification X100). 
 
4.3.9 PECAM-1 (CD31) Staining of Initial Cell Isolations and Confluent Cells 
 Initial cell isolations stained for CD31 have a small minority of cells stained positive 
(Figure 4.11a) and c). Confluent cultures demonstrate a low overall level of staining (Figure 
4.11b) and d). 
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c
b
d
Figure 4.11: Initial cell isolations and confluent cells stained for PECAM-1: a) initial 
isolation unstained b) confluent cells unstained, c) initial isolation stained for PECAM-1 and 
d) confluent cells stained for PECAM-1 (magnification X100). 
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4.4 Discussion 
 
 Recent research on adult stems cells has focused upon turning bone marrow cells into a 
variety of cell types. This is a promising area of study but has many potential pitfalls and the 
mechanisms involved are complex. More practical at this time from the viewpoint of 
developing a functional EC-seeded vascular prosthesis may be the use of the EPC first 
isolated and differentiated into EC by Asahara in 1997 (Asahara et al., 1997). This chapter 
investigates isolating these cells and their culture on a novel nanocomposite material 
previously shown to be an excellent candidate for vascular grafts. The results presented in 
this chapter demonstrate that not only can this material support colonies of EPC but also that 
they will differentiate into EC then grow to near confluence on the graft and remain viable for 
a considerable period of time on the nanocomposite surface. 
 
 To characterise the initial cell extract a variety of techniques were employed. FACs 
analysis for CD133+/VEGFR2+ cells which is the current standard for FACs analysis of EPC 
{74} demonstrated that EPC were present in the initial cell isolation in numbers similar to 
those obtained in other studies (George et al., 2006). RNA analysis confirms that in the initial 
cell extract the monocyte marker CD14 and the EPC/ mature EC marker CD34 are strongly 
expressed. The stem cell marker CD133 is also expressed to a lesser extent. PECAM-1, 
VEGFR2 and vWF were also expressed in the initial cell isolations. CD34, CD133, vWF and 
PECAM-1 were also examined by immunohistochemistry. The initial cell isolation was dual 
stained for CD34 and CD133 which also indicates the presence of EPC. Initially a mixed 
population of cells can be seen with some larger cells among a larger number of small cells. 
When stained for CD34 with the larger cells are clearly positive with a low proportion of the 
smaller cells also staining positive. When dual stained for CD133 the larger cells which were 
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positive for CD34 are clearly negative for CD133 (and may thus perhaps be identified as 
CEC) while the low proportion of the smaller cells which were CD34 positive are also 
CD133 positive (potentially identified as EPC). When the initial cell extract was stained for 
vWF again the larger cells are clearly vWF positive (supporting the suggesting that they are 
CEC) with some fragmentary staining of the smaller cell population. Taken together the 
above results in this study this suggests that the isolation of EPC from peripheral blood was 
successfully achieved in line with reports from other groups. 
 
 The process for culturing EPC once isolated is currently a matter for debate and 
experimentation. Many groups use a ‘pre-plating’ stage after which non-adherent cells are 
collected and cultured to remove rapidly adhering cells (such as CEC, monocytes and 
macrophages) which varies from one hour (Asahara et al., 1997; Shirota et al., 2003) to 48 
hours (Hill et al., 2003; George et al., 2006). Others omit a ‘pre-plating’ stage and allow cells 
to seed for a variety of times ranging from 24 hours (Ingram et al., 2004) to three days 
(Zhang et al., 2006a) or six days (Hur et al., 2004). In this study a 48-hour pre-plating period 
was employed. Some samples of the initially adherent cells were continued in culture but 
failed to prosper (data not shown). Following the pre-plating period cells were left for five 
days to adhere after which non-adherent cells were disposed of. Again, some samples of the 
non-adherent cells after five days seeding were continued in culture but did not grow to any 
extent (data not shown).  
 
 All isolations cultured produced viable cell populations and developed a number of 
colonies with Hill Colony characteristics when seeded on the nanocomposite. Cultures on 
nanocomposite achieved confluence in 14 days and resulted in cells with a cobblestone 
appearance by day 21. Cultures were maintained at confluence for a total of 35 days. AB 
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studies confirmed that metabolically active cells were present over the 35-day period of the 
study. While the level of cell metabolism does not increase greatly in the initial period this 
may be due to a combination of monocytes dying off with EPC and CEC proliferating at the 
same time leading to little net change in the overall level of cell metabolism. 
 
 RNA analysis of confluent cells confirms that CD14, CD34 and VEGFR2 expression was 
maintained though CD133 expression was lost which may be attributed to the conversion of 
EPC to EC over time. PECAM-1 and vWF expression was also maintained and increased in 
comparison to that in the initial cell isolations. Immunostaining for CD34 and CD133 again 
showed that the majority of confluent cells expressed both markers and, in addition, also 
expressed vWF and PECAM-1. Thus, the conditions employed in this study may be optimal 
for differentiation (due to the presence of growth factors in the FBS) but not for prolonged 
division. 
 
 The results obtained in this chapter suggest that it is possible to obtain a confluent layer of 
cells with endothelial-like properties on the nanocomposite after 14 days of culture following 
extraction from human blood. All the extractions produced viable cells. Previous work has 
demonstrated that HUVEC attach to the nanocomposite and (particularly with the 
employment of pre-conditioning) survive on the nanocomposite when exposed to 
physiological flow (Vara et al., 2006). Thus, the cell extraction method employed compares 
favourably with the 25 day time-period and failure rates quoted by the clinical studies in two-
stage seeding with the added advantage of the ease of blood collection compared to the 
difficulty of obtaining cells from other sources and the requirement for an additional 
operation. While it is possible that a mixed population of cells may ensue from the extraction 
method employed (including monocytes, EPC and CEC) this should not be a major problem 
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in the application envisaged as the long-term studies carried out in humans suggest that with 
9 year patencies EC must be renewing on the graft either by infiltration from the anastomosis 
or by EPC or CEC attaching from the blood. Thus the initial presence of a seeded layer of 
cells would seem to be the significant factor in producing a successful graft and improving 
patency (Asahara et al., 1997; Salven et al., 2003). 
 
4.5 Conclusion 
 
  In conclusion, the results presented in this chapter demonstrate that the 
nanocomposite employed in this study can be successfully seeded with cells derived from 
human peripheral blood with a confluent layer of cells being observed after 14 days’ culture. 
The cells remained viable and confluent on the nanocomposite for 35 days over the course of 
the study. These results suggest that this process has potential both for a realistic and 
achievable two-stage seeding process for vascular bypass grafts or for the potential 
development of a device with the aim of achieving in-situ seeding once implanted. Further 
optimisation and development of the technique may result in a clinically successful method 
for improving the patency of vascular bypass grafts in the future.  
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5 
5 The effect of shear stress on human endothelial cells seeded on 
cylindrical nanocomposite conduits 
 
 
5.1. Introduction 
 Physiological fluid mechanical stimuli are important modulators of vascular cell 
phenotype and function (Dolan et al., 2011). The major biomechanical forces that have been 
characterised are a) shear stress, which is the frictional force applied by flowing blood on the 
inner vessel wall tangential to the vessel wall and b) cyclic stretch (tensile stress), which 
results from pulsatile pressure (blood pressure) acting perpendicular to the vessel wall (Sarkar 
et al., 2006). Although the entire vessel wall, including EC’s, SMC and the extracellular 
matrix (ECM) (collagen, elastin, proteoglycans), is subjected to stretch as a consequence of 
pulsatile pressure, the shear stress is received principally at the EC surface. Experimental 
studies have been widely carried out where mechanical force-induced changes in cell 
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function have been measured in vitro, using EC cultured mainly on glass or plastic (Boo et 
al., 2002; Chien, 2008). Shear stress is experimentally generated in vitro by flowing fluid 
across an EC monolayer under controlled kinematic conditions, usually in a laminar flow 
regime. Flow circuits have been used as an in vitro system to investigate the responses of 
cultured EC to hemodynamic forces at the cellular and molecular level (Illi et al., 2003; 
Wasserman and Topper, 2004; Chen et al., 2001). EC exposed to shear stress undergo 
changes in cell shape, alignment and microfilament network remodelling in the direction of 
flow.  
 
The patency rate of small diameter (<6 mm) cardiovascular grafts has been poor due to 
the development of anastomotic intimal hyperplasia (IH) and thrombus formation (Kannan et 
al., 2005a). The formation of an EC layer is a critical factor in the development of a tissue 
engineered vascular graft (Heyligers et al., 2005) as the endothelium provides a 
thromboresistant barrier between circulating blood and the surface of the graft. It also 
controls blood flow and vessel tone (Furchgott et al., 1984; Furchgott and Zawadzki, 1980), 
platelet activation, adhesion and aggregation (Cucina et al., 2003), leukocyte adhesion 
(Iiyama et al., 1999) and SMC migration and proliferation (Ward et al., 2001). Currently 
attempts to seed EC on vascular prosthesis materials are problematic with the major concern 
being the low number of EC that remain on the graft surface after exposure to in vivo shear 
stress. In an effort to improve cell retention, one approach has been to condition the seeded 
EC by applying in vitro shear stress prior to implantation. Exposure of EC seeded grafts to 
shear stress has been shown to increase cell retention (Baguneid et al., 2004) and decrease 
cell loss post implantation (Dardik et al., 1999). There has been considerable interest in 
studying the effect of applying shear stress to vascular prosthesis seeded with cells and 
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recently the importance of examining gene expression in this situation has become very 
apparent.  
 
 The development of a polymer containing silsesquioxane in the form of nano-bridges; 
poly(carbonate-silsesquioxane-bridge-urea)urethane nanocomposite intended for the 
development of cardiovascular devices (Seifalian et al., 2005) has been reported and 
patented. This nanocomposite has been characterized and further studies have also 
demonstrated that it can be successfully seeded with EC and that, once seeded, the EC remain 
viable for a period of days (Punshon et al., 2005). 
 
 EC in vivo are highly robust and can resist disruption by haemodynamic shear stress at 
levels that far exceed physiological conditions. In cell culture, EC rapidly lose many of their 
differentiated features, and when seeded on vascular graft material they are not sufficiently 
adherent or differentiated to resist physiologic shear stress. Studies have found that EC 
exposed to shear stress in vitro, applied in a stepwise fashion over days, are induced to 
become tightly adherent to the substratum and exhibit more differentiated features (Baguneid 
et al., 2004; Ballermann et al., 1998; Dardik et al., 1999). Therefore, it has long been 
postulated that the pre-conditioning of EC seeded on vascular grafts with shear stress in vitro 
could be used to improve EC retention and differentiation for subsequent in vivo use and 
avoid or reduce the problems associated with rapid cell loss observed when cells are exposed 
to physiological shear stress without a prior period of preconditioning. 
 
 It has been previously shown that preconditioning prior to exposure to physiological shear 
stress using a flow circuit developed in-house can significantly enhance EC retention, 
viability and morphology (Tiwari et al., 2003b). Significantly studies showed the 
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development of a functional and stable endothelium on the prosthetic vascular graft in 
response to low shear stress (1-2 dyne/cm2) (Baguneid et al., 2004; Dardik et al., 1999). One 
potential mechanism for this observed improvement has been suggested to be regulated by 
the expression of growth factors and matrix enhancing factors (Passerini et al., 2003). To 
attempt to elucidate the molecular basis of the behaviour of EC when exposed to shear stress 
examined the gene expression of EC seeded on a nanocomposite conduit demonstrated that 
transforming growth factor beta-1 (TGFβ-1), collagenase-1 (COL-1) and platelet endothelial 
cell adhesion molecule-1 (PECAM-1) gene expression was upregulated after 4 hours of 
physiological shear stress (Vara et al., 2006).  
 
 The aim of this Chapter was to initially examine the application of shear stress for 1 and 4 
hours on EC seeded nanocomposite conduits. To provide a comparison to the nanocomposite 
and validate the methods employed initially identically sized and seeded glass conduits were 
also examined.  
 
 Following this initial investigation, the impact of low flow preconditioning on EC 
adhesion and retention on cylindrical nanocomposites prior to exposure to physiological flow 
rates and pressures was examined. Further the effect of a period of recovery under static 
conditions between the preconditioning episode and the exposure to physiological shear 
stress is examined and finally potential changes in gene expression which may explain the 
effects observed monitored. 
 
 To examine the effect of preconditioning on cell retention and adherence EC seeded 
conduits were exposed to a variety of preconditioning regimes with appropriate static and 
non-preconditioned controls. Conduits were preconditioned by exposure to a low shear stress 
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of 1-2 dynes/cm2 for a period of 1 or 4 hours with or without a 24 hour recovery period and 
then subjected to physiological shear stress of 15 dynes/cm2 for 4 hours. Cell retention and 
adherence was then measured using an AB metabolic activity assay and examination by 
SEM.  
 
5.2. Methods 
5.2.1. Preparation of Nanocomposite Polymer Conduits 
 The inorganic urethane is made from 4,4’-methylenebis(phenyl isocyanate) (MDI), 
poly(hexamethylene carbonate)diol, and bridged silsesquioxane here bis[3-
(trimethoxysilyl)propyl]amine and then chain extended with ethylene diaminell in DMAC.  
 An automated bio-processor was used to extrude the nanocomposite into conduits with an 
internal diameter of 5mm and length of 5cm. Conduits were sterilised by autoclaving prior to 
use.  
 
5.2.2. Glass Conduits 
 Glass conduits of 5cm length and 5mm internal diameter were manufactured to order 
(Scientific Laboratory Supplies, Wilford, U.K.). Conduits were sterilised by autoclaving prior 
to use. 
 
5.2.3. Human Umbilical Vein Cell Culture 
 HUVEC were isolated from human umbilical cord vein following a previously described 
method (Jaffe et al., 1973). Cell numbers were amplified by tissue culture in culture medium; 
prepared as follows: 157 ml M199 medium, 4.5 ml Sodium Bicarbonate (7.5%), 1.5 ml 
Penicillin/Streptomycin (10,000 U/ml and 10 mg/ml respectively), 40 ml Foetal Bovine 
Serum and 3.6 ml 200 mM L-Glutamine (Invitrogen Ltd, Paisley, U.K.) at 37° C and 5 % 
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CO2/95 %O2. At confluence cells were removed using 0.25% Trypsin-EDTA (Sigma-Aldrich 
Company Ltd, Poole, U.K.) and split in a 1:2 ratio. Confluent cultures at passage three were 
used in all experiments. 
 
5.2.4 Optimisation of Conduit Seeding 
HUVEC were cultured to passage three and seeded in five-centimetre length, five-
millimetre internal diameter tubular nanocomposite conduits. Following trypsinisation, and 
resuspension in complete tissue culture medium, a cell count was obtained and diluted in 1ml 
of complete medium to three cell seeding concentrations; 0.5 x 106 cells, 1 x 106 cells and 2 x 
106 cells per conduit. Cells were added as a suspension to each graft segment, the ends of the 
graft plugged, and the graft segments rotated 90° every 15 minutes for the first two hours to 
achieve an even covering of HUVEC on each graft. To assess the efficiency of cell adhesion 
on the nanocomposite, grafts were incubated for four, eight, 12 and 24 hours at 37°C. 
Unseeded grafts were placed with complete medium and incubated at 37°C. As a comparison 
and to ensure each technique was carried out accurately the same densities of cells were 
seeded onto 6-well polystyrene tissue culture plates as above. 
 
5.2.5 Estimation of Cell Damage during Seeding 
To assess cell damage over seeding conditions, LDH levels were examined in the 
media following cell seeding. Fifty microliters cell culture medium from each sample was 
transferred to a 96-well plate. Fifty microliters substrate mixes (1 vial substrate plus 12 mls 
assay buffer) was added to each well and the plate covered in foil to prevent light access. 
Samples were then incubated at room temperature for 30 minutes after which the reaction 
was stopped by the addition of 50 μl stop solution (1 M acetic acid). Absorbance was then 
read at 450 nm using a Multiscan MS UV visible spectrophotometer. 
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5.2.6 Conduit Seeding for Exposure to Physiological Flow 
 Glass and nanocomposite conduits were seeded with HUVEC at 1 x 106 cells per conduit. 
Cells were added as a suspension to each conduit, the ends of the conduit plugged, and the 
conduits rotated 90° every 15 minutes for 2 hours to achieve an even covering of HUVEC on 
each conduit. Conduits were then left overnight at 37° C and 5 % CO2/95 %O2 for efficient 
cell adhesion and used the next day. 
 
5.2.7 Assessment of Seeding Efficiency and Cell Viability 
 Viability of seeded cells was assessed using an AB assay (Serotec Ltd., Kidlington, 
Oxford, U.K.). Following overnight seeding conduits were washed with phosphate buffered 
saline (PBS) and the washings collected for cell counting to assess seeding efficiency. 1 ml of 
AB (10%) in complete medium was added to each conduit and incubated for four hours at 
37° C and 5 % CO2/95 %O2. Duplicate 100 μl samples were removed and the absorbance’s 
read spectroscopically at wavelengths of 570 nm and 630 nm using a Labsystems Multiscan 
MS UV visible spectrophotometer (Labsystems, Ashford, U.K.). All conduits were washed 
prior to exposure to flow. Cell viability on nanocomposite conduits was also assessed 
following exposure to flow. 
 
5.2.8 Design and Validation of a Physiological Pulsatile Flow Circuit 
 To test the flow shear stress on the EC, a physiological pulsatile flow circuit was used to 
simulate the cardiovascular system (Figure 5.1).  
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Figure 5.1: The flow circuit comprising a variable-speed electromagnetic centrifugal pump, 
flexible plastic tubing, fluid reservoir and circulating solution oxygenated through a Maxima 
hollow fibre oxygenator with 95% air and 5% CO2. Automatic pH, pO2 and pCO2 controller.  
 A flow waveform conditioner (FWC) sited in series with the circuit is used to generate 
arterial flow waveforms. This was constructed in-house and consisted of a solenoid 
connected to an electronic control box from which the frequency and duration of solenoid 
occlusion could be governed. Instantaneous flow rate is measured using Transonic Medical 
Flowmeter (TMF) system. Serial intra luminal pressure measurements can be made at 
discrete sites along the graft using a Millar Mikro-tip catheter transducer introduced via a Y-
connection port. Graft radius, flow rate and shear stress are determined using an ultrasound 
duplex (US) scanner with a wall tracking system (WTS). All outputs are fed into a computer. 
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 The model simulates specifically a given artery such as coronary or lower limb flow 
waveforms (See caption of Figure 5.1 for further details). The flow circuit was primed with 
cell culture medium adjusted for viscosity. The whole circuit was kept in a sterilised 
condition.  
 Figure 5.2 shows a typical distension and pressure waveform generated from measuring 
distension and pressure versus time using an ultrasound artery wall tracking system (Wall 
Track, Pie Medical Systems, Maastricht, Netherlands) and Millar catheter (Millar 
Instruments, Houston, TX, USA).  
 
 
Figure 5.2: Vessel distension detected with ultrasound wall tracking system and pressure 
with Millar Mikro-tip catheter transducer from circuit in Figure 5.1. 
 
 Examples of previously generated plots of the velocity profile inside the artery and shear 
rate on the wall is shown in Figure 5.3. 
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Figure 5.3: A typical time dependent velocity (a) and shear rate distribution (b) acquired by 
the duplex ultrasound coupled with on-line vessel wall tracking system. 
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  The hemodynamic data including peak and mean shear stresses are computed and 
recorded in Table 5.1. 
 
Input parameters  Computed parameters 
 
 
 
Frequency of pulsatile cycle 
 
1 Hz 
 
Inlet length (mm) 
 
60 
Internal diameter of conduit 5 mm Peak Reynolds number 512 
Temperature 37 ± 1.4 Mean shear stress 
(dyn/cm2) 
14.0 ± 3.2 
Seeded graft length (mm) 50 Systolic shear stress 
(dyn/cm2) 
30.4 ± 5.8 
Seeded density (cells/cm2) 1.2 x 104 Diastolic shear stress 
(dyn/cm2) 
62.7 ± 9.7 
Pressure systolic (mmHg) 120 ± 5 Mean velocity (mm/sec) 436 ± 20 
Pressure diastolic (mmHg) 70 ± 6   
pH 7.3 ± 0.1   
pO2 (kPa) 21 ± 2   
pCO2 of solution (kPa) 4.2 ± 0.2   
Viscosity of solution (poise) 0.035 ± 
0.2 
  
 
Table 5.1: Flow circuit haemodynamic data including peak and mean shear stresses  
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5.2.9 Application of Shear Stress to EC Seeded Conduits 
 Seeded conduits were randomly split into two groups, static and flow exposed. Static 
conduits were placed in fresh medium and incubated at 37°C for either 1or 4 hrs. Flow 
exposed conduits were placed in the flow system and a set flow rate of shear stress was 
applied for either 1 or 4 hrs. 
 
5.2.10.1 Application of Preconditioning Shear Stress on EC Seeded Conduits  
 The experimental protocol is summarised in Figure 5.4. Seeded conduits were randomly 
split into two groups (A & B) where preconditioning was tested with or without a static 
recovery period (see below). Conduits were placed in the flow system and preconditioned at 
low shear stress rates of 1-2 dynes/cm2(low flow) and then subjected to pulsatile 
physiological shear stress of 15 dynes/cm2 (physiological flow). 
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Figure 5.4: A schematic representation of the experimental procedure illustrating a summary 
of the treatment carried out to each set of conduits. Group A conduits were exposed to either 
1 or 4 hours static (S1 or S4) or preconditioning (P1 or P4) prior to exposure to 4 hours 
physiological flow while Group B conduits were exposed to either 1 or 4 hours static (SR1 or 
SR4) or preconditioning (PR1 or PR4) followed by a 24 hour static recovery period prior to 
exposure to 4 hours physiological flow. 
 
5.2.10.2. Preconditioning Shear Stress without a 24-hour recovery period 
 To test the effect of preconditioning shear stress on EC function without a static recovery 
period, group A conduits were preconditioned with 1 hour low flow (P1) or 4 hours of low 
flow (P4). Control conduits were also included where conduits were placed with fresh culture 
medium and incubated under static conditions at 37° C and 5 % CO2/95 %O2 for 1 hour (S1) 
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or 4 hours (S4). All conduits were then subsequently exposed to 4 hours of physiological 
flow. 
 
5.2.10.3 Preconditioning Shear Stress with a 24-hour recovery period 
 The effect of preconditioning with a 24-hour static recovery period prior to physiological 
flow was investigated. After 24 hours of seeding, group B conduits were either 
preconditioned with 1 hour low flow (PR1) or 4 hours of low flow (PR4). Control conduits 
were incubated under static for 1 hour (SR1) or 4 hours (SR4). After static or exposure all 
conduits were then washed with sterile PBS, placed in fresh culture medium and incubated 
under static conditions for 24 hours. Post recovery period, all conduits were exposed to 4 
hours of physiological flow. 
 
5.2.11. RNA Extraction and PCR following Preconditioning Shear Stress 
 Following exposure to experimental conditions cells were removed from conduits by 
washing with sterile PBS and then trypsinising using 1ml of trypsin-EDTA (0.25 %) which 
was added for 5 minutes’ incubation at 37oC. RNA was then extracted by using a “Qiagen 
RNeasy” kit (Qiagen Ltd, Crawley, U.K.).  
 
 The RNA concentration and purity was calculated by measuring the absorbance at 260nm 
and 280nm using an Eppendorf Biophotometer (EppendorfAG, Hamburg, Germany). The 
quality of the RNA was assessed by 2% agarose gel electrophoresis. The mRNA obtained 
was used for polymerase chain reaction (PCR) of GAPDH, TGFβ-1, VEGFR-1, PECAM-1 
and VEGFR-2 genes (Table 5.2.). RT-PCR was performed using a one-step PCR kit (Qiagen 
Ltd, Crawley, U.K.). A master mix containing 10 μl 5x Qiagen One-Step RT-PCR buffer, 10 
μl 5x Q-Solution, 400 μM from each of the deoxynucleoside triphosphate, 2 μl Qiagen One-
142 
 
Step RT-PCR enzyme mix and 0.5 μM from each of the primers was added. 0.1 μg of 
template RNA was used for each gene and RNase free water was added to give a total 
volume of 50 μl.  
 
 Cycle conditions for GAPDH and TGFβ-1 were 40 cycles (94o C, 50o C and 72o C). For 
PECAM-1 cycle conditions were 35 cycles (94o C, 50o C and 72o C). Finally, for VEGFR-1 
and VEGFR-2 cycle conditions were 35 cycles (94o C, 59o C and 72o C). Amplification was 
carried out using a MasterCycler Gradient PCR machine (EppendorfAG, Hamburg, 
Germany). PCR products were analysed by 2% agarose gel electrophoresis and semi-
quantified using a GeneGenius darkroom with ‘GeneSnap’ version 6.02. (Syngene, 
Cambridge, U.K.). The GAPDH band was used as the internal standard to normalise TGFβ-1, 
VEGFR-1, PECAM-1 and VEGFR-2 signals. 
Locus Sense (5’-‘3) Antisense (5’-‘3) 
GAPDH  GAAGGTGAAGGTCGGAGT GAAGATGGTGATGGGATTTC 
TGFβ-1 CACCTGCAAGACTATCGACAT TCGGAGCTCTGATGTGTTGAA 
PECAM-1 GCTGTTGGTGGAAGGAGT GAAGTTGGCTGGAGGTGCTC 
VEGFR-1 
VEGFR-2 
ATTTGTGATTTTGGCCTTGC 
GTGACCAACATGGAGTCGTG 
CAGGCTCATGAACTTGAAAGC 
CCAGAGATTCCATGCCACTT 
 
Table 5.2: GAPDH, TGFβ-1, PECAM-1, VEGFR-1and VEGFR-2 Primer Sequences. 
5.2.12 Scanning Electron Microscopy 
 Seeded nanocomposite conduits were examined by SEM pre- and post-flow to visualise 
whether cells were present on the grafts surface. SEM images were also taken after 
trypsinisation of the cells from the conduit in order to determine that complete cell removal 
was obtained for RNA extraction. Due to the material nature of the glass tubes SEM was not 
performed for these samples.  
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5.2.13 Data Analysis and Statistical Methods    
 The experiments were repeated 4 times. All statistical analysis utilised the Student’s t-test 
comparing flow to static conditions. 
 
5.3. Results 
5.3.1 Optimisation of Conduit Seeding Density 
 
 
 
 
 
 
 
A)                                                                                     B) 
 
 
 
 
 
 
 
C)                                                                                     D) 
Figure 5.5: Alamar blueTM cell viability assay post HUVEC seeded on TCP and 
nanocomposite conduits at cell seeding densities of 0.5 x 106 cells/cm2, 1 x 106 cell/cm2 and 2 
x 106  cells/ cm2 after A) 4 hours, B) 8 hours, C) 12 hours and D) 24 hours of seeding time.  
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Significant differences (p< 0.001) in cell viability were observed between the TCP 
and nanocomposite groups at all seeding time points. There were no significant differences in 
cell viability in nanocomposite conduits that were seeded for 4, 8 or 12 hours (Figure 5.4.1 A; 
B & C respectively) between any of the seeding densities. Significant increases in viability 
were only seen at 24 hours in nanocomposite conduits seeded with 1 x 106 cells/cm2(p< 0.01) 
and 2 x106 cells/cm2(p< 0.001) compared to 0.5 x 106 cells/cm2. At 24 hours post seeding, no 
differences were observed in cell viability in nanocomposite conduits seeded with 1 x 106 
cells/cm2 compared to 2 x 106 cells/cm2. 
 
Figure 5.5 shows AB cell viability results of nanocomposite conduits seeded at three 
cell densities of A) 0.5 x 106 cells/cm2, B) 1 x 106 cells/cm2 and C) 2 X 106 cells/cm2 
comparing across 4, 8, 12 and 24 hours seeding time. Conduits seeded with 0.5 x 106 cell/cm2 
(Figure 5.5 A) showed significant increases (p< 0.05) in cell viability at 12 and 24 hours only 
compared to 4 hours seeding time. There was no significant difference between any other 
seeding time points in this seeding density. At 1 x 106 cells/cm2 (Figure 5.5 B) and 2 x 106 
cell/cm2 (Figure 5.5 C), nanocomposite conduits showed a significant increase in cell 
viability post 12 (p< 0.05) and 24 hours (p< 0.001) of seeding compared to 4 hours. Increases 
were also observed after 24 hours (p< 0.001) seeding compared to 8 hours. At this seeding 
density a significant difference (p< 0.01) was seen at 24 hours compared to 12 hours.  
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A)                                                                         B) 
 
 
 
C)                                                                         D) 
 
 
E)                                                                       F)                
Figure 5.6: LDH assay test measuring cell toxicity on HUVEC seeded on TCP and 
nanocomposite conduits at 0.5 x 106, 1 x 106 and 2 x 106 for A) 4 hours, B) 8 hours, C) 12 
hours and D) 24 hours of seeding time. *P < 0.05, **P < 0.01and ***P < 0.001 using one-
way ANOVA with Tukeys 
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Figure 5.6 shows the LDH assay for cells seeded on nanocomposite conduits and TCP at 0.5 
x 106, 1x 106 and 2 x 106 cells/cm2for A) 4 hours; B) 8 hours; C) 16 hours and D) 24 hours of 
seeding time.   
 
HUVEC seeded on TCP was used as a control. Differences in LDH activity were 
observed in all cell densities seeded in TCP compared to those seeded in nanocomposite 
conduits at 4, 8, 12 and 24 hours of seeding. 
 
There was a significant difference between 0.5 x 106 and 1 x 106 cells/cm2 post 4 
hours (p< 0.001), 8 hours (p< 0.01), 12 hours (p< 0.01) and 24 hours (p< 0.001) seeding time 
on the nanocomposite conduits. After 4 hours of seeding time there was no significant 
difference between 1 x 106 cells/cm2 and 2 x 106 cells/cm2 seeded on nanocomposite 
conduits. This was significant post 8, 12 hours (p< 0.01) and 24 hours (p< 0.001).  
 
Figure 5.6 shows the LDH assay for cells seeded on nanocomposite conduits at A) 0.5 
x 106 cells/cm2; B) 1 x 106 cells/cm2 and C) 2 x 106 cells/cm2 for 4, 8, 12 and 24 hours.  
Cells seeded on nanocomposite conduits at a density of 0.5 x 106 cells/cm2 (Figure 5.6 A) 
showed a significant difference between 4 and 24 hours (p< 0.01); 4 and 12 and 8 and 24 
hours (p< 0.05) of seeding time. There was no significant difference in seeding time between 
12 and 24 hours of incubation at this cell density. 
 
Nanocomposite conduits seeded with HUVEC at 1 x 106 cells/cm2 (Figure 5.6 B) 
showed a higher level of LDH activity at 4 hours compared to 12 and 24 hours (p< 0.01). 
This was also significant for 8 hours compared to 12 hours (p< 0.05) of seeding incubation 
time on the nanocomposite conduits. 
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HUVEC seeded nanocomposite conduits at 2 x 106 cells/cm2 (Figure 5.6 C) showed a 
significant higher (p< 0.001) LDH activity at 4 hours compared to 12 and 24 hours of 
seeding. Significant differences were also observed at 8 hours of seeding compared to 12 (p< 
0.001) and 24 hours (p< 0.01) seeding time on the conduits.  
 
5.3.2 Assessment of Seeding Efficiency and Viability 
 An Alamar blueTM assay pre flow following overnight seeding showed no significant 
difference in seeding efficiency (data not shown).  
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5.3.3 Assessment of Cell viability after exposure to flow 
 Viable cells were present on both the glass conduit group and the nanocomposite conduit 
group following exposure to flow or static conditions (Fig. 5.7 A (Glass) & B 
(nanocomposite)) with no significant difference between groups. 
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B) 
Figure 5.7: Cell seeding efficiency and viability post 1 and 4-hour static and flow exposed on 
A) glass and B) nanocomposite conduits. No significant differences were seen between the 
nanocomposite groups (one-way ANOVA).  
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5.3.4 Scanning Electron Microscopy Analysis of Seeded Conduits 
SEM images showed viable cells present on nanocomposite prior to flow (Fig. 5.6, A & 
B). SEM images also demonstrated cells to be present on nanocomposite post 1 and 4-hour 
flow (data not shown).  
 
 
A) 
 
 
B) 
Figure 5.8: Typical SEM of a nanocomposite conduit: A) unseeded, B) seeded with 1 x 106 
HUVEC overnight 
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5.3.5 Assessment of Seeding Efficiency and Viability following preconditioning 
 The AB assays performed pre-flow (following overnight seeding) showed no significant 
difference in seeding efficiency. Viable cells were present on all seeded nanocomposite 
conduits.  
 
 Figure 5.9 A shows EC viability post 1 and 4 hour static or low flow without a 24 hour 
recovery period followed by physiological flow. Conduits preconditioned with 1 or 4 hour 
low flow (P1& P4 respectively) showed no significance difference in cell viability compared 
to pre-flow. Conduits incubated under static conditions for 4 hours prior to physiological flow 
(S4) showed a significant decrease in cell viability (P < 0.01) compared to pre-flow, whereas 
no significant decrease was observed after one hour static incubation (S1). Despite a 
noticeable decrease in viability between S1 and S4 this was not significant. Comparing P1 to 
its static control S1 also showed no significant difference in cell viability. After four hours of 
preconditioning P4, had a significantly higher viability (P < 0.001) compared to time matched 
control S4. 
 
  Pre-conditioning followed by a 24 hour recovery period (Figure 5.9 B) showed 
significant changes in cell viability in all groups apart from pre-conditioning for one hour 
(PR1) to pre-flow. Control conduits not exposed to preconditioning (SR1& SR4) showed 
significant decreases (P < 0.01) in cell viability compared with pre-flow conduits. An 
increase in cell viability was observed for conduits preconditioned for 1 hour (PR1) but this 
was not significant, whereas preconditioning for 4 hours (PR4) showed a significant increase 
(P < 0.01). Very significant differences (P < 0.001) were observed between conduits SR1 and 
PR1 and SR4 and PR4.  
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Figure 5.9: Assessment of cell viability by an Alamar blueTM metabolic assay: Figure 4.9 A 
shows Pre-flow, S1, S4, P1 and P4 groups. Figure 4.9 B shows Pre-flow, SR1, SR4, PR1 and 
PR4 groups. Statistical analysis was carried out by one-way ANOVA (n = 4) with ** P < 0.01 
and *** P < 0.001 
 
5.3.6 Scanning electron microscopy following preconditioning 
 SEM was employed to further elucidate cell retention following exposure to flow. 
Figure 5.10 A shows nanocomposite prior to seeding. Figure 5.10 B shows pre-flow seeded 
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nanocomposite. Figures 5.10 C to F show seeded nanocomposite for treatments S1, S4, P1 and 
P4 respectively. Similarly Figures 5.10 G to J show seeded nanocomposite for treatments SR1, 
SR4, PR1 and PR4 respectively. All seeded nanocomposites show cells present on the conduit 
post-treatment in line with the AB results earlier.  
 
 
A)                                                           B) 
 
 
C)                                                            D) 
 
153 
 
 
E)                                                               F)  
 
 
G)                                                              H) 
 
 
I)                                                               J) 
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Figure 5.10: Typical SEM of nanocomposite conduits: A (unseeded conduit), B (Pre-flow 
conduit), C (S1 conduit), D (S4 conduit), E (P1 conduit), F (P4 conduit), G (SR1 conduit), 4.8 
H (SR4 conduit), I (PR1 conduit) and J (PR4 conduit). 
 
5.3.7 Assessment of Quantity and Quality of RNA Extracted 
 The amount of RNA extracted from HUVEC is shown in Table 5.3. The purity was high 
in all samples and in all cases purity was greater than 95%. 
 
 
Conduit and treatment 
RNA Quantity (ng/µl) 
(mean ± SEM) 
 
Group A 
 
S1 
4.2 ± 1.2 
S4 
2.4 ± 0.7 
P1 
12.4 ± 1.3 
P4 
18.4 ± 1.5 
 
Group B  
SR1 
2.7 ± 0.6 
SR4 
2.0 ± 0.3 
PR1 
28.7 ± 3.5 
PR4 
36.0 ± 4.9 
 
Table 5.3: RNA yield was measured at absorbance of 260nm and 280nm and quantity 
determined as ng/µl. Group A shows S1, S4, P1 and P4 samples. Group B shows SR1, SR4, PR1 
and PR4 samples. 
 
5.3.8 Analysis of GAPDH, TGFβ-1, VEGFR-1, PECAM-1 and VEGFR-2 PCR Products 
 Figure 5.11 A shows a 2% agarose gel of the PCR products for group A, resulting from 1 
and 4-hour exposures respectively to either static conditions (S1 & S4) or low flow 
preconditioning (P1 & P4); following four hours of physiological flow on all conduits.  
 Figure 5.11 B shows a 2 % agarose gel of the PCR products for group B, resulting from 1 
and 4-hour exposure respectively to either static conditions (SR1 & SR4) or low flow 
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preconditioning (PR1 & PR4); following a 24-hour recovery period on all conduits prior to 
four hour exposure to high flow for HUVEC seeded on the nanocomposite conduits.  
The mRNA levels of GAPDH remained relatively constant in static and preconditioned 
samples, and changes were observed in the other genes (see below).  
 
 
Figure 5.11A 
 
Figure 5.11B 
Figure 5.11: Typical 2% agarose gels of PCR products with a 100 bp marker. Each sample 
was analysed for GAPDH, TGF-β1, VEGFR-1, PECAM-1 and VEGFR-2 expression: Figure 
5.11A shows S1, S4, P1 and P4 samples. Figure 4B shows SR1, SR4, PR1 and PR4 samples. 
 
5.3.9 Intensity of Gene Expression 
 Relative levels of GAPDH, TGFβ-1, VEGFR-1, PECAM-1 and VEGFR-2 were 
determined using Syngene (Syngene, Cambridge, U.K.). After normalisation by the intensity 
of GAPDH mRNA bands obtained from preconditioning, the levels of gene expression were 
examined.  
 
Figure 5.12 A shows the intensity of gene expression post 4 hours’ physiological flow 
after either 1 or 4 hours of preconditioning (P1 & P4) compared to time matched controls (S1 
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& S4). Differences in gene expression were observed only in the expression of VEGFR-1 and 
VEGFR-2. Significant decreases (S1-P1, P < 0.01 & S4-P4, p < 0.001) in VEGFR-1 and 
significant increases (p < 0.001) in VEGFR-2 were seen after 1 and 4-hour preconditioning 
compared to time-matched controls. All other genes remained essentially unaltered under 
these conditions.  
Figure 5.12 B shows the intensity of gene expression post 4 hours’ physiological flow 
after either 1 or 4 hours of preconditioning (PR1 & PR4) compared to time matched controls 
(SR1 & SR4) with the addition of a 24-hour recovery period after preconditioning. PECAM-1 
expression remained relatively unaltered. TGFβ-1 expression was shown to be significantly 
higher (P < 0.01) after 4 hours of preconditioning (PR4) compared to controls (SR4). The 
expression of VEGFR-1 showed a significant decrease after 1 hour only (SR1-PR1, P < 0.05). 
Significant increases in VEGFR-2 expression were observed at both time points (SR1-PR1, P 
< 0.001 and SR2-PR2, P < 0.001).  
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A 
 
B 
Figure 5.12: Intensity analysis of PCR products to determine gene expression levels 
following normalisation for GAPDH: 4.12A shows S1, S4, P1 and P4 samples for TGF-β1, 
VEGFR-1, PECAM-1 and VEGFR-2. 4.12B shows SR1, SR4, PR1 and PR4 samples for TGF-
β1, VEGFR-1, PECAM-1 and VEGFR-2. Statistical analysis was carried out by one-way 
ANOVA (n = 4) with * P<0.05, ** P < 0.01 and *** P < 0.001 
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5.4 Discussion 
  The culture of HUVEC on flat sheets of tissue culture plastic in the absence of flow 
produces a well-documented change in phenotype; the characteristic cobble stone appearance 
being one such manifestation. It has long been documented that culture of HUVEC under 
conditions of shear stress results in a recovery of an in vivo phenotype and an alteration of 
growth pattern with cells becoming aligned to flow in a similar manner to that seen in vivo 
(Zaragoza et al., 2012; Dolan et al., 2011; Malek and Izumo, 1996).   
 
 A major problem with EC seeding of vascular prosthesis is that, when exposed to 
physiological flow, extensive cell loss from the seeded graft surface can occur and that this 
loss can occur rapidly thus reducing considerably the effectiveness of the cell seeding process 
(Dardik et al., 1999; Ballermann et al., 1998; Ott and Ballermann, 1995). Various strategies 
have been employed in an attempt to overcome this problem including modifying the 
prosthesis surface with moieties such as RGD or fibronectin to improve cell adhesion (Seta et 
al., 2012; Hoesli et al., 2014) or by the employment of preconditioning to reduce cell loss. 
 
In a previous study by our group, pulsatile physiological shear stress (~14 dynes/cm2) 
was shown to result in a significant decrease in cell retention for EC seeded on 
nanocomposite following exposure to 4 hours of physiological flow (Vara et al., 2011; Tiwari 
et al., 2003b). This suggested that immediate exposure to physiological levels of shear stress 
strips EC when seeded on nanocomposite prosthetic materials and is in line with the findings 
of similar studies by several other groups examining cell retention on a variety of other graft 
materials (Salehi-Nik et al., 2016; Xiao and Shi, 2004). It has been observed that cell loss 
under physiological flow conditions can, however, be reduced by exposing the cells to a 
lower preconditioning flow prior to physiological shear stress and that such prior exposure is 
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beneficial in promoting cell adherence(Baguneid et al., 2011). Therefore, we tested the 
hypothesis that exposure of EC seeded on cylindrical nanocomposite conduits to 
preconditioning shear stress may allow the cells to adapt to the material in an improved 
manner and enhance cell growth and adhesion. In order to test this hypothesis EC seeded 
nanocomposite conduits were exposed to a variety of preconditioning shear stress regimes 
employing either immediate exposure to physiological flow after preconditioning or a 
recovery period of 24 hours between preconditioning and exposure to physiological flow and 
compared the results obtained with those for seeded conduits that were exposed to 
physiological shear stress with no preconditioning. Conduits were preconditioned with a low 
flow of 1-2 dynes/cm2 followed by physiological flow.  
 
 The AB results prior to flow (pre-flow conduits) demonstrated that the nanocomposite 
conduits employed in the study were successfully seeded with viable HUVEC in a uniform 
manner. Pre-flow conduits were taken as a baseline, and the decrease seen after physiological 
flow was applied without preconditioning suggests that a significant number of cells are lost 
under these conditions as would be expected and confirming the results of our previous study. 
The application of preconditioning prior to exposure to physiological flow demonstrated that 
the seeded nanocomposite retained cells significantly better under this regime and suggests an 
improvement in cell adherence and an increase in cell numbers or metabolism following 
preconditioning when compared to the cells not exposed to preconditioning prior to exposure 
to physiological flow. The changes are more marked after 4 hours compared to 1 hour 
demonstrating that the effect is time dependent and that a longer period of preconditioning 
before the application of physiological flow results in greater protection for the cells. There is 
little difference between the cells exposed to physiological flow immediately post-
preconditioning and those given a 24 hour recovery period following preconditioning prior to 
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exposure suggesting that under the conditions investigated the recovery period results in no 
further benefit in terms of improved cell retention. However this does demonstrate that even 
if there is a delay between treatment by preconditioning and implantation of the graft and 
exposure to physiological flow the potential benefits of preconditioning would not be lost and 
that the positive effect of preconditioning lasts for at least 24 hours. The SEM studies support 
these conclusions regarding the relative numbers of cells remaining following exposure to 
physiological flow.  
 
 The investigation of expression levels for a variety of genes was the carried out in an 
attempt to build upon the information obtained in our previous study to elucidate the potential 
mechanisms behind the changes observed in cell metabolism and numbers by examining 
further genes and a wider range of exposure to a variety of flow regimes. In the case of 
TGFβ1 whilst there was a general increase in expression in the preconditioned groups this 
increase was only significant in the case of the 4 hour preconditioning followed by a 24 hour 
recovery period prior to exposure to physiological flow indicating that while TGFβ1 may be 
involved in the longer term changes observed in this study it’s short term effect is limited. 
PECAM-1 expression remains relatively stable under all treatments suggesting that the 
remaining HUVEC following exposure to flow retain their EC phenotype regardless of the 
application of preconditioning.  A significant decrease in VEGFR-1 expression was observed 
in both one and four hour preconditioned cells when followed by immediate exposure to 
physiological flow and after a 24 hour recovery period. This situation was reversed in the 
case of VEGF-R2 where a significant increase of gene expression was observed in the 
preconditioned groups. Both VEGFR-1 and VEGFR-2 are known to bind vascular endothelial 
growth factor with high affinity and previous studies have shown that VEGFR-2 mediated 
signalling can result in significant changes in morphology together with alterations in actin 
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organisation in EC with high expression levels of this receptor (Mustonen and Alitalo, 1995). 
Significantly other studies have shown that the expression of VEGFR-2 is induced by the 
application of shear stress associated with a reduction in VEGFR-1 expression in a similar 
manner to the results obtained in this study (Shay-Salit et al., 2002). This suggests that the 
reduction in VEGFR-1 and increase in VEGFR-2 expression may be associated with mature 
EC likely to proliferate in response to shear stress (a situation similar to angiogenesis) and 
indeed in the case of the PR4 group a significant increase in cell metabolism or numbers can 
be seen which may become more apparent if longer term studies were carried out. 
 
 In conclusion, the results presented in this chapter confirm that the previous findings 
regarding the potential benefits of preconditioning can be applied to EC seeded on the 
nanocomposite employed and demonstrates that preconditioning under the right conditions 
can result in a significant improvement in EC retention when exposed to physiological flow. 
This is a major benefit towards achieving a viable seeded conduit for clinical usage. The 
study also builds upon previous work examining gene expression on cylindrical conduits 
when exposed to flow by examining VEGFR-1 and VEGFR-2 expression in addition to the 
previously investigated genes and demonstrates, for the first time, that low flow 
preconditioning causes alterations in gene expression in this situation. It suggests that such 
alterations can be determined successfully and that further investigations into other 
potentially significant genes may well be of benefit in exploring further the potential 
mechanism by which preconditioning improves cell retention whilst studies into protein 
expression via techniques such as Western blotting would also be of interest. Such studies 
would also be valuable in determining the most effective method of preconditioning with 
regard to the optimal length of time for preconditioning and the potential advantages of a 
recovery period prior to exposure to physiological flow. Finally, it also demonstrates further 
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the suitability and potential of the nanocomposite for future use in tissue engineered 
cardiovascular devices. 
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6 
6 The Extraction of Endothelial Progenitor Cells and Circulating 
Endothelial Cells from Human Peripheral Blood 
 
6.1 Introduction 
 
 One of the most exciting and important areas of medical research in recent years has 
focused on the potential of employing human stem cells for a wide variety of purposes in 
both tissue engineering and the treatment of a variety of medical conditions (Sales et al., 
2005).  
 
As medical procedures get more complex and the population gets older an ever-larger 
demand for high quality synthetic prosthesis appears. Regenerative medicine is the best hope 
for providing high quality hybrid grafts (Baguneid et al., 2011; Motwani et al., 2011). The 
use of stem cells and adult progenitor cells in regenerative medicine promises access to 
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sufficient autologous cells for the first time. Previous shortages in, for example, EC’s limited 
the effective production of hybrid grafts (Punshon et al., 2008). The discovery of circulating 
endothelial progenitors allows regenerative medicine to harness the body’s own repair 
mechanisms in the creation of new medical devices. Regenerative medicine and the use of 
hybrid technology will result in a more natural ‘artificial’ implant; thus better mimicking the 
original and reducing failure rates of such devices. 
 
 The majority of this work has focused on cells sourced from embryonic tissue, bone 
marrow or umbilical cord blood. The future benefits of such work could be considerable but 
research using such tissue sources faces some practical difficulties. There is considerable 
debate regarding the ethics of using embryonic tissue as a source of stem cells which has 
been widely reported. In the case of bone marrow, the availability of samples of bone marrow 
for research is limited whilst for cells sourced from umbilical cord blood again suitable 
samples may be limited and the difficulty of donor and recipient compatibility would have to 
be addressed.  
 
 Following the initial report by Ashara et al in 1997 on the extraction of CD34+ cells from 
human peripheral blood (Asahara et al., 1997) there has been some interest in the extraction 
of endothelial progenitor stem cells (EPSC) from peripheral blood. There are several 
potential advantages to using peripheral blood as a cell source. Firstly peripheral blood 
samples are relatively easy to obtain compared to embryonic tissue, bone marrow or cord 
blood. Secondly the employment of peripheral blood does not encounter the ethical problems 
associated with embryonic tissue or the compatibility difficulties of using umbilical cord 
blood. 
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 There are, however, some major problems with peripheral blood as a cell source to be 
overcome. The major difficulty encountered is that it is possible to extract far fewer cells 
from peripheral blood compared to embryonic tissue, bone marrow or umbilical cord blood 
particularly if the blood donor has not been stimulated with granulocyte colony-stimulating 
factor (GCSF).  
 
 This problem is compounded by the lack of a universally accepted method of cell 
extraction and culture such as exists, for example, in the case of the extraction of HUVEC 
where the method of Jaffe is generally followed (Jaffe et al., 1973) which has demonstrated 
its reliability over a number of years. 
 
 There is in fact considerable variety in the reported methods employed for the extraction 
and growth of EPSC from peripheral blood some of which are quite fundamental as a result 
of which there is currently no generally accepted process for the extraction of these cells. As 
regards the source of peripheral blood used in studies the majority use ‘healthy donors’ 
(Fuchs et al., 2006; Shirota et al., 2003; Zhang et al., 2006a; Ingram et al., 2004) but often 
the age range is not stated (Fuchs et al., 2006; Salven et al., 2003; Yamamoto et al., 2003) 
and when it is there is a considerable age range from a mean of 23.05 years (Zhang et al., 
2006a) to 56.3 years (Hur et al., 2004). Some methods employ Histopaque for the initial 
separation (Zhang et al., 2006a; Hur et al., 2004; Ingram et al., 2004; Fuchs et al., 2006; 
Tepper et al., 2002) while others use Lymphoprep (Punshon et al., 2008). Some studies 
further employ magnetic beads to purify the initial isolate (Asahara et al., 1997; Salven et al., 
2003) while others do not (Hill et al., 2003; Fuchs et al., 2006; Shirota et al., 2003; Tepper et 
al., 2002). In the majority of studies a two day pre-plating step is employed in which the 
initial isolate is plated for two days following which the initially adhered cells are disposed of 
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and the non-adherent cells cultured (Hill et al., 2003; George et al., 2006). Other studies 
however allow the initial isolation to adhere for two to six days then dispose of the non-
adherent cells and culture the initially adherent ones (Zhang et al., 2006a; Hur et al., 2004; 
Ingram et al., 2004; Rehman et al., 2003).  
 
 One isolated there is further variation in the techniques used to culture the isolated cells. 
Some methods employ coating for the tissue culture surface using materials such as 
fibronectin (Hill et al., 2003; Fuchs et al., 2006; George et al., 2006), collagen (Howling et 
al., 2002; Ingram et al., 2004) or gelatin (Hur et al., 2004; Ghanbari et al., 2011).  The 
variety of cell culture medium used also varies with media such as M199 (Wang et al., 2007; 
George et al., 2006; Hill et al., 2003), EGM-2 (Ingram et al., 2004; Hur et al., 2004; Zhang et 
al., 2006a) and commercially available specialised media such as the EndoCult Liquid 
Medium Kit (Stem Cell Technologies, Vancouver BC, Canada) (Yoder et al., 2007) all  
having been employed in studies. Again a variety of fetal calf serum percentages have been 
employed, generally ranging from 5% (Tao et al., 2007) to 20% (Wang et al., 2007; 
Yamamoto et al., 2003; de Mel et al., 2011). The addition of growth factors to the cell culture 
medium is a further area of complication with some studies using supplements such as human 
vascular endothelial growth factor, human fibroblast growth factor, insulin-like growth 
factor-1, human epidermal growth factor, ascorbic acid and hydrocortisone acetate (Zhang et 
al., 2006b) while others employ supplements such as bovine brain extract (Wang et al., 2007) 
while some methods report using no supplements other than fetal calf serum (Hill et al., 
2003).  
 
 The differences in the extraction method and culture process employed in the various 
studies above make a valid comparison of results obtained from them problematic. 
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 This chapter uses as a base the process for extracting and growing EPSC from peripheral 
blood in Chapter 4. It then makes a direct comparison of some of the above factors in an 
attempt to begin to develop a consensus on the method of extraction and culture of EPSC 
from peripheral blood in the future and facilitate the successful employment of this source of 
stem cells in clinical practice. 
 
6.2 Materials and Methods 
 
6.2.1 Blood Collection 
 
 Blood samples were collected following consent from healthy adult human volunteers. 
24ml samples were collected by venepuncture in EDTA blood tubes (Sarstedt, U.K.). 
Following collection samples were mixed and used for cell isolation within one hour of 
collection.  
 
6.2.2 Effect of Cell Isolation Techniques 
 
 The mononuclear fraction of the blood was then isolated using either Lymphoprep (Axis-
Shield, U.K.) or Histopaque 1077 (Sigma-Aldrich, U.K.). Briefly 3ml of either Lymphoprep 
or Histopaque 1077 was added to each of eight 12ml polystyrene centrifuge tubes (Falcon, 
U.K.). 3ml of blood was then carefully layered on top. The tubes were then centrifuged at 400 
x g for 30 minutes at room temperature. The mononuclear fraction was then separated from 
each tube and the Lymphoprep and Histopaque 1077 samples pooled separately in 30 ml 
universal tubes (Falcon, U.K.). 10ml of Hank’s Balanced Salt Solution (Invitrogen, 
U.K.)(HBSS) was then added slowly to each tube and the contents mixed. The tubes were 
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then centrifuged at 250 x g for 10 minutes at room temperature. The cells were then washed 
twice by removing the supernatant, re-suspending in 10ml HBSS and centrifuging at 250 x g 
for 10 minutes at room temperature. Finally the isolated cells were re-suspended in 5ml cell 
culture medium (CCM): RPMI 1640 supplemented with 20% foetal bovine serum (FBS) and 
penicillin/streptomycin (both Invitrogen U.K.). Cells were then counted using a 
haemocytometer and samples of the cell isolates taken for RNA analysis and cell staining. 
Cells were isolated from four different donors (two male and two female) 
 
6.2.3 Cell Culture 
 
 Cells isolated by each method were then cultured for an initial two-day period in a 6-well 
plate (Falcon, U.K) at a seeding density of 2.5x106 cells/well in 5ml CCM (n=5 per 
individual isolation) following which the supernatant (containing the non-attached cells) was 
counted using a haemocytometer and transferred to fresh wells (Adherent Group (A)). 5ml 
CCM was added to the wells containing the initially adherent cells (IA). Cells were then 
cultured for a further five days. At this stage the medium was removed from the Adherent 
group wells and transferred to fresh wells (Non adherent group (NA)). Cell metabolism was 
then assessed in the initially adherent group and the Adherent group using AB (Serotec, 
U.K.). Two wells from each isolation method were then stained using Giemsa to visualise 
Hill Colonies. The remaining three wells were the cultured for a further 7 days after which 
cell metabolism was determined again in all groups and samples taken for RNA analysis. 
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6.2.4 Effect of Gelatin or Fibronectin Coating 
 
 6-well plates were coated overnight with a sterile 1% gelatin solution (Sigma-Aldrich, 
U.K.) then washed twice with phosphate buffered saline (PBS) (Invitrogen U.K.) prior to use. 
Human fibronectin coated 6-well plates were obtained from BD Biosciences (BD 
Biosciences, U.K.). As a control, uncoated 6-well plates were employed. Cells were isolated 
from human peripheral blood using the Histopaque-1077 method described above. Treated or 
untreated 6-well plates were then seeded with 2.5x106 cells/well in 5ml CCM and cultured as 
above (n=6 per treatment). Cell metabolism was then measured at day 7 and day 14 and 
samples taken at day 14 for RNA analysis. 
 
6.2.5 Effect of Foetal Bovine Serum Concentration 
 
 Cells were isolated from human peripheral blood as above using the Histopaque-1077 
method. Cells were then seeded at 2.5x106 cells/well in 5ml cell culture medium 
supplemented with either 5, 10 or 20% FBS (n=6 per FBS percentage) and cultured as above 
in the appropriate supplemented media. Cell metabolism was then measured at day 7 and day 
14 and samples taken at day 14 for RNA analysis. 
 
6.2.6 Effect of Media Choice 
 
 Cells were isolated from human peripheral blood as above using the Histopaque-1077 
method. Cells were then seeded at 2.5x106 cells/well in 5ml CCM as above but replacing the 
RPMI 1640 in the CCM with either DMEM, IMDM, M199 (all supplemented with 20% FBS 
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or EGM-2 (Promocell, U.K.) and cultured (n=5). Cell metabolism was then measured at day 
7 and day 14 and samples taken at day 14 for RNA analysis. 
 
6.2.7 Measurement of Cell Metabolism 
 
 Cell metabolism was assessed by AB  assay at Day 7 and 14. Medium was removed from 
the wells and 4ml 10% AB in CCM added. After a 4 hour incubation samples of AB/CCM 
were removed and measured on a Fluroskan Ascent FL (Thermo Labsystems, U.K.) 
fluorescent plate reader (excitation 530nm, emission at 620nm). Unseeded wells were used as 
a control. 
 
6.2.8 Giemsa Staining for Hill Colonies 
 
 Wells were washed twice with PBS after which 0.5ml ice-cold methanol was added 
(VWR, U.K.) for 5 minutes to fix the cells. The methanol was then removed and the wells 
air-dried. 400µl Giemsa stain (Invitrogen U.K.) was then added for 15 minutes after which 
the wells were destained in distilled water. Colonies were then examined following the 
criteria of Hill et al as described previously(Hill et al., 2003). 
 
6.2.9 RNA Isolation and Investigation 
 
 RNA was extracted from initial cell isolates and Day 14 cell samples using an 
“RNeasy” kit (Qiagen Ltd, U.K.). The RNA concentration and purity was calculated by 
measuring the absorbance at 260nm and 280nm using an Eppendorf Biophotometer 
(EppendorfAG, Germany). The quality of the RNA was assessed by 2% agarose gel 
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electrophoresis and the mRNA obtained was used for polymerase chain reaction (PCR) for 
CD14, CD34, CD133, Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1), Vascular 
Endothelial Growth Factor Receptor-2 (VEGFR2) and von Willebrand Factor (vWF). RT-
PCR was performed using an One-Step PCR kit (Qiagen Ltd, U.K.). 0.25 μg of template 
RNA and 0.5 μM of the appropriate primers (Table 6.1) were used for each PCR reaction. 
Cycle conditions were as follows: CD14 30 cycles at 94oC, 57oC and 72oC; CD34 35 cycles 
at 94oC, 54oC and 72oC; CD133 35 cycles at 94oC, 52oC and 72oC; VEGFR2 35 cycles at 
94oC, 59oC and 72oC; vWF 35 cycles at 94oC, 50oC and 72oC; PECAM-1 35 cycles at 94oC, 
50oC and 72oC and amplification was carried out using a MasterCycler Gradient PCR 
machine (EppendorfAG, Germany). In the case of vWF and PECAM-1 RNA extracted from 
HUVEC was used as a positive control. PCR products were then analysed by 2% agarose gel 
electrophoresis and a GeneGenius darkroom with ‘GeneSnap’ version 6.02. (Syngene, U.K.).  
 
Marker Sense (5’ to 3’) Antisense (5’ to 3’) 
 
CD14 
 
CCTCCCAAGTTTTAGGACAA 
 
CAGCTGGTGATAAGGGTTAG 
CD34 CCTCCCAAGTTTTAGGACAA CAGCTGGTGATAAGGGTTAG 
CD133 CAGTCTGACCAGCGTGAAAA GGCCATCCAAATCTGTCCTA 
VEGFR2 GTGACCACATGGAGTCGTG CCAGAGATTCCATGCCACTT 
PECAM-
1 
GCTGTTGGTGGAAGGAGT GAAGTTGGCTGGAGGTGCTC 
vWF TGCTGACACCAGAAAAGTGC AGTCCCCAATGGACTCACAG 
 
Table 6.1: Primer sequences for CD14, CD34, CD133, VEGFR2, PECAM-1 and vWF gene 
expression analysis. 
172 
 
 
6.2.10 Data Analysis and Statistical Methods 
    
 Data were presented as mean±SEM. All statistical analysis utilized one way ANOVA 
with post-hoc Tukey’s test. 
 
 
6.3 Results 
 
6.3.1 Effect of Cell Isolation Techniques 
 
6.3.1.1 Number of Cells Isolated 
 
 There was no significant difference between the initial numbers of cells isolated by either 
method. The initial cell isolation produced 26.01x106 ± 1.54 cells from the Histopaque 1077 
isolations and 26.98x106 ± 5.01 cells from the Lymphoprep isolations (n=4). 
 At Day 2 when the non-adherent cells were transferred to fresh wells again there was no 
significant difference in cells numbers between the two groups: Histopaque 1077 2.44x106 ± 
0.08 cells compared to Lymphoprep 2.46x106 ± 0.10 cells (n=20). 
 
6.3.1.2 Assessment of Hill Colonies 
 
 All isolations produced Hill Colonies. Figure 6.1 shows typical Hill Colonies from 
Histopaque 1077 and Lymphoprep isolations. 
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Figure 6.1: Typical Hill Colonies isolated using Histopaque 1077 (left) and Lymphoprep 
(right). 
 
6.3.1.3 Assessment of Cell Metabolism 
 
 Figure 6.2 shows the effect of isolation technique on cell metabolism over a 14 day 
period. There was a significant increase in cell metabolism between Day 7 and Day 14 in 
both the Lymphoprep (p<0.001) and Histopaque-1077 groups (p<0.05) adherent cell group. 
There was no significant difference between the Lymphoprep and Histopaque-1077 groups at 
either time point (p>0.05). Both the initially adherent cell groups (cells adherent after the first 
two days) and the cells which had not adhered after 7 days showed minimal metabolic 
activity at either time point. 
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Figure 6.2: Effect of Isolation Technique. Cells isolated by: Histopaque 1077 (H) or 
Lymphoprep (L). Cell Group: Initially adherent at Day 2 (IA), Adherent at D7 (A) or Non-
adherent at D7 (NA). Time point: Day 7 (D7) or Day 14 (D14). * p<0.001 L A D14 vs. L A 
D7; & p<0.001 H A D14 vs. L A D7; # p>0.05 H A D7 vs. L A D7 and + p>0.05 H A D7 vs. 
H A D14. 
 
6.3.1.4 RNA analysis  
 
 RNA analysis for CD14, CD34, CD133, PECAM-1, VEGFR-2 and vWF showed no 
significant difference between the two groups (Figure 6.3). Figure 6.3a demonstrates a 2% 
agarose gel of initial cell isolates by either the Histopaque 1077 or Lymphoprep method and 
Day 14 cultures examined by RT-PCR for CD14, CD34 and CD133. All isolations were 
positive for CD14 and CD34. The initial isolates were positive for CD133 whereas the Day 
14 samples were negative. Figure 6.3b similarly shows a 2% agarose gel of the same samples 
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examined for vWF, VEGFR-2 and PECAM-1. vWF was positive in both the initial isolations 
and in the Day 14 samples. VEGFR-2 expression was minimal in the initial isolations and 
increased in the Day 14 samples. PECAM-1 expression was high in the initial isolates and 
reduced in the Day 14 isolates. 
 
a) 
 
b) 
Figure 6.3a): RNA analysis for CD14, CD34 and CD133 on cell extracts isolated by either 
Histopaque (H) or Lymphoprep (L) techniques from initial (I) or Day 14 (D14) samples. N = 
Negative Control. 
Figure 6.3b): RNA analysis for vWF, VEGFR-2 and PECAM-1 on cell extracts isolated by 
either Histopaque (H) or Lymphoprep (L) techniques from initial (I) or Day 14 (D14) 
samples. N = Negative Control. 
 
 
B    IH       IL      B         IH       IL        B       IH   IL
D14H  D14L   D14H   D14L   D14H D14L
CD14            CD34         CD133      CD14     CD34    CD133
500
bp
B     IH       IL       B         IH       IL       B       IH  IL
D14H  D14L   D14H   D14L   D14H D14L
vWF VEGFR-2          PECAM-1    vWF VEGFR-2   PECAM-1100 bp
ladder
500
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6.3.2 Effect of Gelatin or Fibronectin Coating 
6.3.2.1 Assessment of Cell Metabolism 
 At Day 7 there was no significant difference in cell metabolism between the uncoated 
plate group and the fibronectin coated group (p>0.05). Gelatin coating significantly reduced 
the level of cell metabolism at Day 7 compared to the other two groups (p<0.001). By Day 14 
there was a significant increase in cell metabolism for the uncoated plate group compared to 
Day 7 (p<0.001) whereas the fibronectin coated group failed to show a significant increase in 
cell metabolism at the same stage (p>0.05). The gelatin coated group showed a significant 
reduction in cell metabolism at Day 14 compared to Day 7 (p<0.001). Again, in all groups the 
level of cell metabolism in the initially adherent cells and the cells which failed to adhere in 
the first 7 days was low (Figure 6.4). 
 
Figure 6.4: Effect of Gelatin or Fibronectin Coating on Cell Metabolism. Coating type: 
Uncoated (UC); Gelatin Coated (GC) or Fibronectin Coated (FC). Cell Group: Initially 
adherent at Day 2 (IA), Adherent at D7 (A) or Non-adherent at D7 (NA). Time point: Day 7 
(D7) or Day 14 (D14). + p>0.05 FC A D7 vs. UC A D7; $ p<0.001 GC A D7 vs. UC A D7 or 
FC A D7; * p<0.001 UC A D7 vs. UC A D14 and & p>0.05 FC A D7 vs. FC A D14. 
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6.3.2.2 RNA analysis  
 
 RNA analysis for PECAM-1, VEGFR-2 and vWF showed no significant difference 
between the three groups (Data not shown). 
 
6.3.3 Effect of Foetal Bovine Serum Concentration 
6.3.3.1 Assessment of Cell Metabolism 
 There is no significant difference between the three FBS concentrations for the adherent 
cells group at Day 7 (p>0.05). At Day 14 only the 20% FBS group shows a significant 
increase in cell metabolism compared to Day 7 (p<0.05). In the case of the 5% FBS group 
there is a higher cell metabolism in the non-adherent cell group compared to the other two 
FBS concentrations though this is not statistically significant (Figure 6.5). 
 
Figure 6.5: The Effect of FBS concentration on cell metabolism. Percentage Fetal Bovine 
Serum (FBS) 5%, 10% or 20%. Cell Group: Initially adherent at Day 2 (IA), Adherent at D7 
(A) or Non-adherent at D7 (NA). Time point: Day 7 (D7) or Day 14 (D14). * p<0.05 20% 
FBS A D7 vs. 20% FBS A D14. 
178 
 
6.3.3.2 RNA analysis  
 RNA analysis for PECAM-1, VEGFR-2 and vWF showed no significant difference 
between the different FBS percentages (data not shown). 
 
6.3.4 Effect of Media Choice 
 
6.3.4.1 Assessment of Cell Metabolism 
 
 Figure 6.6 shows the effect of various media on cell metabolism over a 14 day period. All 
media produced viable cells at Day 7. There was a significant increase in cell metabolism by 
Day 14 compared to Day 7 in the RPMI 1640, M199, DMEM and IMDM groups (p<0.001) 
and a significant decrease in cell metabolism for the EGM-2 group (p<0.001). Comparing the 
different media between each other at Day 7 the group with the highest cell metabolism, the 
IMDM group was significantly higher than the M199 group (p<0.001) which in turn was 
significantly higher than the RPMI 1640 group (p<0.001) followed by the DMEM group and 
the EGM-2 group (p<0.001). By Day 14 the IMDM and M199 groups showed no significant 
difference in cell metabolism (p>0.05) while both groups were significantly higher than the 
RPMI 1640, DMEM and EGM-2 groups (p<0.001). In the case of the EGM-2 group there 
was a higher level of cell metabolism in both the initially adherent group of cells at Day 7 and 
the non-adherent at Day 7 group of cells by Day 14. 
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Figure 6.6: The effect of various media on cell metabolism. Media types: RPMI1640; M199; 
DMEM; IMDM and EGM-2. Cell Group: Initially adherent at Day 2 (IA), Adherent at D7 
(A) or Non-adherent at D7 (NA). Time point: Day 7 (D7) or Day 14 (D14). * p<0.001 IMDM 
A D7 vs. M199 A D7; & p<0.001 M199 A D7 vs. RPMI A D7; + p<0.001 RPMI A D7 vs. 
DMEM A D7 or EGM-2 A D7; # p>0.05 IMDM A D14 vs. M199 A D14 and $ p<0.001 
M199 A D14 or IMDM A D14 vs. RMPI 1640 A D14. 
 
 
6.3.4.2 RNA analysis  
 
 RNA analysis for PECAM-1, VEGFR-2 and vWF showed no significant difference 
between the various media types (Data not shown). 
 
6.4 Discussion 
The use ECs in vascular grafts has for years been sought as an answer to the problems 
of thrombosis and intimal hypoplasia. Regenerative medicine suffered from the shortage of 
suitable cells to allow true hybrid grafts to be created in any meaningful clinical scenario. The 
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discovery, isolation and seeding of grafts with EPSC has allowed the use of regenerative 
medicine in vascular graft production to move out of a purely experimental field and to 
become clinically relevant (Sales et al., 2005). 
 
 There has been considerable recent interest in the use of progenitor cells extracted from 
human peripheral blood as a cell source for tissue engineering. Whilst there have been a 
number of studies published in this field there has been considerable variation in the methods 
employed to firstly extract the cells from blood and secondly to culture the cells once they 
have been extracted. Thus the process of isolating and culturing EPSC is still a matter for 
debate and further investigation to develop a consensus such as that in, for example, the 
isolation of HUVEC as developed by Jaffe et al (Jaffe et al., 1973). 
 
 The initial isolation of the cells has been reported by density centrifugation using either 
Histopaque-1077 (Yoder et al., 2007; Wang et al., 2007) or Lymphoprep (Punshon et al., 
2008). Some groups have then further purified the cell isolate using magnetic beads for CD34 
by positive selection (Asahara et al., 1997; Salven et al., 2003; Harraz et al., 2001). Various 
surfaces to culture the isolated cells on have also been investigated. Examples include human 
fibronectin coated plates, gelatin coating, collagen coating or uncoated tissue culture plastic.  
 
 Once isolated a variety of media compositions have been employed such as EGM-2, 
M199 or RPMI 1640 supplemented in a variety of ways with some groups using ‘simple’ 
media supplemented only with FBS at varying concentrations and penicillin/streptomycin 
while others employ supplements such as heparin, human VEGF, human Fibroblast Growth 
Factor, human Epidermal Growth Factor, Insulin-like Growth Factor I and ascorbic acid. 
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 Following isolation many groups use a ‘pre-plating’ stage after which non-adherent cells 
are collected and cultured to remove rapidly adhering cells (such as CEC, monocytes and 
macrophages) which varies from one hour (Asahara et al., 1997; Shirota et al., 2003) to 48 
hours (George et al., 2006; Hill et al., 2003). Others omit a ‘pre-plating’ stage and allow cells 
to seed for a variety of times ranging from 24 hours (Ingram et al., 2004) to three days 
(Zhang et al., 2006a) or six days (Hur et al., 2004).  
 
 Chapter 4 demonstrated that progenitor cells could be successfully isolated from human 
peripheral blood using Lymphoprep and differentiated into EC’s using a simple culture 
process on uncoated tissue culture plastic plates employing RPMI supplemented with 20% 
FBS and penicillin/ streptomycin as a medium (Punshon et al., 2008). Using this study as a 
base alternate isolation techniques and culture methods were explored and compared. 
 
 When comparing extraction using either Lymphoprep or Histopaque-1077 the results 
obtained in this study suggest that both methods result in similar isolations. There was no 
significant difference in the number of cells initially isolated by either method or in cell 
metabolism over the 14 day period studied. RNA analysis demonstrated that in the initial cell 
extract the monocyte marker CD14 and the EPSC/ mature EC marker CD34 are strongly 
expressed. The stem cell marker CD133 is also expressed to a lesser extent. PECAM-1 and 
vWF were also expressed in the initial cell isolations. RNA analysis of the Day 14 cells 
confirms that CD14 and CD34 expression was maintained though CD133 expression was lost 
which may be attributed to the conversion of EPSC to EC over time. PECAM-1 and vWF 
expression was also maintained and VEGFR-2 expression was detected. Thus the RNA 
analysis confirmed that there was no difference between the cell populations obtained from 
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either Histopaque 1077 or Lymphoprep isolations with regard to CD14, CD34, CD133, 
PECAM-1, VEGFR2 or vWF expression. 
 
 As Histopaque-1077 was employed by the majority of other studies it was decided to 
employ this isolation method for the remainder of the study. As regards surface coating of the 
tissue culture plates uncoated plates were found to be similar to human fibronectin coated 
plates. Gelatin coating however had a severe detrimental effect by day 14.  
 
 Examining the practice of using a ‘pre-plating’ stage under most conditions this would 
appear to have little effect as few cells which adhere in the first two days then proliferate 
further. One observation in initial studies was that this did depend on the vigour with which 
the cells were washed at day two and that if the cells were gently removed at this stage in 
some cases the initially adherent cells would proliferate (data not shown) whereas if a 
vigorous wash was employed the initially adherent cells would not proliferate. 
 
 The percentage of FBS in the media had a number of effects on cell culture. Using 20% 
FBS resulted in most of the proliferating cells adhering between day two and day seven with 
little metabolic activity being observed in the initially adherent cells or those which failed to 
attach in the first seven days. Reducing the FBS concentration to 5% lead to changed pattern 
of cell adherence in which cells appeared to adhere in the initial sample, the day two to seven 
sample (both of which failed to proliferate in the next seven days) and the day seven to 
fourteen samples. Employing 10% FBS lead to cells adhering in the initial period, day two to 
seven, but then failing to proliferate over the next seven days. 
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 Similarly the medium employed had a significant effect on cell culture. M199 produced 
the highest levels of cell metabolism after 14 days culture with IMDM and to a lesser extent 
RPMI 1640 producing similar results. Surprisingly in view of its employment in several 
studies using EGM-2 resulted in a low level of cell metabolism by day 14 despite containing 
more supplements than the other media examined. It did, however, have only 5% FBS 
compared to the 20% in all the other media so this could well have had an effect. DMEM also 
resulted in significantly lower cell metabolism at day 7 and day 14. 
 
 Taken together these findings suggest that it difficult to compare studies employing 
different culture protocols and may explain the wide variety of outcomes reported by other 
studies into the isolation and culture of progenitor cells from human peripheral blood. 
 
 The findings presented in this chapter also demonstrate that while the main isolation 
methods used to extract progenitor cells from human peripheral blood are comparable 
varying the culture method can have very significant effects on the final outcome. Based on 
this study employing fibronectin or gelatin coated culture plates would appear to be 
unnecessary and the medium of choice should be M199 supplemented with 20% FBS. 
 
 In conclusion it can be seen that while this study and previous work can suggest a basis 
for culture further work to develop an optimised and agreed ‘gold standard’ culture regime 
for progenitor cells from human peripheral blood is required in order to maximise the 
potential of this source of cells for tissue engineering and translate this potential into a 
valuable and viable process for clinical use in the future.  
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7 
7 The Effect of Varying Sterilization Methods on Nanocomposite 
 
7.1 Introduction 
 
Polyurethanes (PU’s) represent a large family of polymers consisting of different 
organic units linked together by urethane bonds [-NHC(O)O-].  Highly versatile, 
biocompatible and with excellent mechanical properties PU’s are amenable to a number of 
applications including catheters, biomedical implants and tissue engineering scaffolds (Burke 
and Hasirci, 2004).  However chronic in vivo failure, observed upon prolonged implantation, 
and primarily due to polymer degradation, is a major stumbling block for their continued use 
(Santerre et al., 2005).  The polyester based soft segments of PU’s are prone to hydrolysis 
whereas polyether based PU’s are susceptible to oxidative attack. 
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In order to produce more biostable PU’s our group tethered polyhedral oligomeric 
silsesquioxane (POSS) nanocages to a poly (carbonate-urea) urethane (PCU) backbone.  
Siloxanes are well known to be biostable and resistant to oxidation and hydrolysis due to the 
strong intermolecular forces between the constituent molecules and a strong framework with 
shorter bond lengths.  However, siloxanes are mechanically fragile exhibiting particularly 
poor tear strengths which make siloxane based polymers unsuitable for many applications.  
By covalently attaching the POSS moiety to the polymer network, our group was able to 
exploit the beneficial effects of improved biostability afforded by the POSS molecule, 
without compromising the mechanical integrity of the PU.  The polyhedral oligomeric 
silsesqioxane-poly (carbonate-urea) urethane (POSS-PCU) produced was found to be more 
resistant to degradation in vitro and in vivo, possess anti-thrombogenic properties, and sustain 
cell growth upon its surface;  a combination of properties making it suitable for a number of 
biomedical applications including heart valves, prosthetic grafts, and stents (Kannan et al., 
2005b; Kannan et al., 2007; Ahmed et al., 2011).  In conjunction with POSS-PCU, a POSS 
modified biodegradable aliphatic caprolactone polyurethane, poly (caprolactone-urea) 
urethane (POSS-PCL), was also developed for tissue engineering applications (Gupta et al., 
2009). 
 
The risk of infection associated with implantable devices is a significant clinical 
concern.  For example, up to 6% of prosthetic grafts can encounter difficulties with infection 
resulting in approximately $640m in healthcare costs (Darouiche, 2004). In addition, there 
are significant associated morbidity and mortality rates with amputation rates approaching 
11% and re-infection found in 18% of patients. In 17-40% of patients, graft infection leads to 
death.  Direct implantation of device with microorganisms attached is a common and 
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avoidable method in which infection can occur necessitating the need for effective 
sterilisation methods (Nagpal and Sohail, 2011).   
 
Sterilisation can be achieved in a number of ways including steam, gamma irradiation 
and incubating with ethanol.  Whilst numerous investigations have characterised microbial 
activity following sterilisation, as a marker of efficacy, the impact of sterilisation technique 
on the material bulk and surface properties is often ignored; whereas it is often the material 
bulk and surface properties which determine the success of the implant/device.  The 
sterilisation process usually involves physical or chemical treatment which results in the 
elimination of organic macromolecules and/or microorganisms.  Given the nature of their 
action, the techniques can also react with the biomaterial.  Steam sterilisation can lead to 
hydrolysis, softening and degradation of the polymer due to the high temperature, pressure 
and humidity (Zhang et al., 1996).  Gamma irradiation is known to cause chain scission and 
cross-linking which can adversely affect material properties (Haugen et al., 2007).  Further, 
both steam and gamma have been known to deform and yellow the polymeric materials.  
Immersing in ethanol is a milder technique used in vitro to disinfect the polymer sample.  It is 
particularly useful for disinfecting biodegradable tissue engineering scaffolds, such as 
glycolic acid based materials which, by their very nature, tend to be fragile  (Shearer et al., 
2006).   
 
The purpose of this chapter was to evaluate the impact of the sterilisation technique 
on the bulk and surface properties of flat sheets and porous membranes of POSS-PCU and 
POSS-PCL polymers developed in our lab.  The treatments include 70% ethanol, steam and 
gamma irradiation.  Changes to the molecular weight, mechanical strength, surface chemistry 
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and cytotoxicity were evaluated and compared to an unsterilised control.  The effectiveness 
of the sterilisation method was also determined. 
 
7.2 Materials and Methods 
7.2.1 Polymer synthesis 
7.2.1.1 POSS-PCU nanocomposite 
Polycarbonate polyol, 2000 mwt (Bayer Material Science, GmbH) and trans-
cyclohexanechlorohydrinisobutyl-polyhedral oligomeric silsesquioxane (Hybrid Plastics Inc) 
were placed in a 250 mL reaction flask equipped with a stirrer and a nitrogen inlet.  The 
mixture was heated to 135oC to dissolve the POSS cage into the polyol and then cooled to 
70oC.  4,4’-methylenebis (phenyl isocyanate) (MDI) was added to the polyol blend and 
reacted at 70 ºC for 90 minutes to form a pre-polymer. DMAC was added slowly to the pre-
polymer to form a solution which was cooled to 400C.  Chain extension of the pre-polymer 
was carried out by the addition of ethylenediamine and diethylamine in DMAc.  1-butanol in 
DMAC was added to the mixture to form a POSS-PCU solution.  
 
7.2.1.2  POSS-PCL nanocomposite 
Dry polycaprolactone diol (2000mwt) and POSS were placed in a 250ml reaction 
flask equipped with mechanical stirrer and gas inlet. The mixture was heated to 135°C to 
dissolve the POSS cage into the polyol and then cooled to 90°C.  4, 4’ 
methylenebis(cyclohexylisocyanate) was added to the polyol blend and then reacted, under 
nitrogen, at 90°C for 120 minutes with catalyst (Bismuth neodecanoate) to form a pre-
polymer. Dry DMAC was added slowly to the pre-polymer to form a solution; the solution 
was cooled to 40°C. Chain extension of the pre-polymer was carried out by the drop wise 
addition of a mixture of ethylenediamine and diethylamine in dry DMAC.  After completion 
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of the chain extension, 1-butanol in DMAC was added to the polymer solution forming a 
POSS-PCL solution. 
Unless otherwise stated all chemicals and reagents were supplied by Aldrich Limited, 
Gillingham, U.K.) 
 
7.2.2 Sample preparation 
7.2.2.1 Cast Samples 
The 18%(w/w) solutions of polymer in DMAC were cast onto glass petri dishes and 
left in an oven at 60°C overnight to evaporate the solvent.  The resulting solid sheets of 
polymer were then sterilised accordingly and used for future experiments. 
 
7.2.2.2 Porous Samples 
Sodium bicarbonate (NaHCO3, 50%(w/w), 40µm particle size, Bruner Mond, 
Cheshire, U.K.) was dispersed into an 18% (w/w) solution of the polymers in DMAC 
containing 2% Tween 80 surfactant. The mixture was mixed and degassed in one process 
using a Thinky ARE 250 mixer (Intertonics, Oxfordshire, U.K.) resulting in a viscous slurry 
which was then cast onto a stainless steel sheet and placed in distilled water for 48 hours at 
room temperature.  A sheet of coagulated porous polymer was formed via the immersion 
precipitation process as a result of solvent exchange with distilled water.  The polymer sheets 
were left immersed in distilled water for a period of 48 hours to ensure complete removal of 
solvent and NaHCO3.  The scaffolds were then removed from the steel support, air dried for a 
further 48 hrs, and sterilized appropriately for future experiments.   
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7.2.3 Sterilisation 
 
7.2.3.1 Gamma irradiation 
Samples were packed in sterilisation pouches and irradiated with a dose of 28.4 kGy 
at room temperature, using a 60Co gamma-ray source (Isotron, Berkshire, UK).  Samples 
were exposed to the source on a continuous path for a period of 10 hours.   
 
7.2.3.2 Autoclave 
Autoclaving involved exposing the biomaterials to saturated steam at 121°C for a 
minimum of 15minutes at pressures of 115kPa.  The samples were autoclaved and then left 
overnight for cooling. 
 
7.2.3.3 Ethanol 
Polymer discs were incubated with 70% (v/v) ethanol and left in a roller mixer for 10 
minutes or 24 hours. Samples were then washed (5×) in distilled water, and stored for future 
use. 
 
7.2.4 Material characterisation 
 
7.2.4.1 Tensitometry 
 Samples were cut longitudinally into a dog-bone shaped specimen, 20 × 4mm, using a 
sharp cutter and mechanical press ensuring a clean cut with no flaws or stress aggregation. 
However, due to the random nature of pore size and porosity in the coagulated samples, 
variability is to be expected.  The thickness of the samples was determined using an 
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electronic micrometer.  Stress-strain profiles were characterised using a uniaxial load testing 
machine (Instron 5565, UK) and the Youngs modulus, ultimate tensile strength (UTS) and 
elongation at break obtained (n=6).   
 
7.2.4.2 Attenuated Total Reflectance –Fourier Transform IinfraRed Spectroscopy  
The chemical structure of the PU samples, following exposure to the various methods 
of sterilisation, was evaluated via attenuated total reflectance Fourier transform infer-red 
(ATR-FTIR) spectroscopy (JASCO FT/IR 4200).  30 scans were taken for each sample 
between 600 and 4000 cm-1 (n=6).   
 
7.2.4.3 Gel permeation chromatography 
Solutions of each sample were prepared by adding 15 mL of Dimethyl formaldehyde 
(DMF) to 30 mg of sample and left to dissolve on a roller mixer overnight.  The samples 
were analysed using a PL-GPC 50 system (Agilent Technologies) equipped with PLGel 
column guard and 3 PLGel 5µm mixed bed-C columns (300 x 7.5mm). The measurement 
was carried out at 50°C in DMF and the eluent was pumped at the constant flow rate of 1.0 
mL/min.  The system was calibrated by performing Universal Calibration with single PL- 
polystyrene standard and a set of PL-EasyVial PS-H polystyrene standards of known 
molecular weights.  The detection was done using a PL-BV 400RT viscometer and a PL-RI 
differential refractometer.  The data was been collected and analysed using Varian ‘Cirrus 
Multi detector’ software (n=3).  Results are presented as percentages of untreated control. 
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7.2.5 Cytotoxicity 
7.2.5.1 Endothelial progenitor cell extraction 
  Blood samples were collected following consent from healthy adult human volunteers. 
24mL samples were collected by venepuncture in EDTA blood tubes (Sarstedt, U.K.). 
Following collection samples were mixed and used for cell isolation within one hour of 
collection.  
 
  The mononuclear fraction of the blood was then isolated using Histopaque 1077 (Sigma-
Aldrich, U.K.). Briefly 3ml of Histopaque 1077 was added to each of eight 12ml polystyrene 
centrifuge tubes (Falcon, U.K.). 3ml of blood was then carefully layered on top. The tubes 
were centrifuged at 400 x g for 30 minutes at room temperature. The mononuclear fraction 
was separated from each tube and the samples pooled in 30 ml universal tubes (Falcon, 
U.K.). 10ml of Hank’s Balanced Salt Solution (Invitrogen, U.K.)(HBSS) was then added 
slowly to each tube and the contents mixed. The tubes were then centrifuged at 250 x g for 10 
minutes at room temperature. The cells were then washed twice by removing the supernatant, 
resuspending in 10ml HBSS and centrifuging at 250 x g for 10 minutes at room temperature. 
Finally the isolated cells were resuspended in 5ml cell culture medium (CCM): M199 
supplemented with 20% fetal bovine serum (FBS) and penicillin/streptomycin (both 
Invitrogen U.K.). Cells were then counted using a haemocytometer and seeded onto polymer 
samples as below. 
 
7.2.5.2 Endothelial progenitor cell culture 
Cells were seeded onto polymer discs (n=4) in a 24 well plate (Falcon, U.K.) at a 
seeding density of 5 x 105 cells/well in 1ml CCM. Cells were then cultured for seven days.  
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7.2.5.3 Assessment of cell metabolism and viability 
 Cell metabolism was assessed by AB assay at Day 7. In brief medium was removed from 
the wells and 1ml 10% AB in CCM added. Following a 4 hour incubation samples of 
AB/CCM were removed and measured on a Fluroskan Ascent FL (Thermo Labsystems, 
U.K.) fluorescent plate reader (excitation 530nm, emission at 620nm). Unseeded wells were 
used as a control. 
 
7.2.6 Efficacy of sterilisation 
All samples were tested for the effectiveness of sterilisation.  Sterilised samples were 
immersed in tryptone soya broth (TSB) and fluid thioglycollate medium (THY) for 
cultivation of microorganisms (Wickham Laboratories, Hampshire) for a period of 14 days at 
temperatures of 20-25oC for TSB and 30-35oC for THY. Sterile broth was used as a negative 
control and unsterilized samples as positive controls. The broths were examined 
macroscopically every 1-3 days with clouding of the broth indicating contamination and 
inefficient sterilization compared to clear broth which indicates no infection and sterility of 
the samples (n=3). 
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7.3.0 Results 
7.3.1 Visual inspection 
All samples withstood treatment with EtOH well, irrespective of incubation time.  
Whilst the POSS-PCU samples were unaffected by the autoclaving process, the POSS-PCL 
samples were destroyed; therefore, it was not possible to examine the autoclaved POSS-PCL 
samples further.  Both the POSS-PCU and POSS-PCL samples held up well against gamma 
irradiation with slight discolouring/yellowing of the cast sheets of POSS-PCU being 
observed. 
7.3.2 Mechanical test 
Figure 7.1 displays the stress-strain curves of the materials following exposure to 
EtOH, autoclaving and gamma irradiation.  The quantitative values are presented in Table 
7.1. 
 
 
Figure 7.1: ATR-FTIR analysis of (A) cast POSS-PCU, (B) porous POSS-PCU, (C) cast 
POSS-PCL, and (D) porous POSS-PCL nanocomposites after sterilization with EtOH (10 
min and 24 h), autoclave, and gamma irradiation. A summary of the changes in key peak 
intensities are inset (n ¼ 6, p < 0.05). 
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Sample  Sterilization 
Technique 
Young’s 
Modulus 
(MPa) 
Tensile 
Strength 
(MPa) 
Elongation 
 at break 
 (%) 
POSS PCU Cast Control 8.61±0.81 62.35±6.71 823.96±28.03 
  EtOH 10 min 7.75±0.47 56.48±2.98 875.36±47.01 
  EtOH 24 hr 7.75±0.64 66.67±3.73 828.59±29.09 
  Autoclave 9.16±0.62 62.39±5.72 904.86±37.40a 
  Gamma 6.49±0.46a 48.87±5.04a 853.24±51.02a 
 Porous Control 0.35±0.02 1.08±0.08 440.76±11.66 
  EtOH 10 min 0.32±0.03 0.98±0.06 449.33±25.45 
  EtOH 24 hr 0.32±0.04 1.07±0.07 437.51±31.43 
  Autoclave 0.33±0.04 0.97±0.05 382.84±35.46a 
  Gamma 0.35±0.03a 1.22±0.05a 407.03±9.87a 
POSS PCL Cast Control 6.91±0.93 57.71±2.32 885.73±85.00 
  EtOH 10 min 5.61±0.82 55.05±2.42 938.88±54.99 
  EtOH 24 hr 5.92±0.60 49.55±4.18 968.32±40.45 
  Autoclave n/a n/a n/a 
  Gamma 5.03±0.278a 42.89±4.82a 865.69±114.47a 
 Porous Control 0.28±0.04 1.36±0.13 593.76±38.85 
  EtOH 10 min 0.22±0.03 1.04±0.11 581.87±29.58 
  EtOH 24 hr 0.20±0.01 0.97±0.04 577.52±12.42 
  Autoclave n/a n/a n/a 
  Gamma 0.23±0.02 1.03±0.07 581.74±31.31 
ap < 0.05 
Table 7.1: Mechanical properties (Young’s Modulus, ultimate tensile strength and elongation 
at break) of POSS-PCU and POSS-PCL samples after sterilization by a variety of techniques 
(n=6) 
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Both POSS-PCU and POSS-PCL tolerated ethanol treatment well – both for cast and 
coagulated samples.  No significant difference was seen between the Youngs modulus, UTS 
or elongation at break in any of the samples following incubation with EtOH compared to the 
untreated control. 
Autoclaving the samples of POSS-PCU did not affect the Youngs modulus or UTS. 
There was a slight significant (p<0.05) increase in the elongation at break for the cast sample 
of POSS-PCU, compared to the control.  Autoclaving the porous sample caused a minor 
decrease in elongation at break.   
The porous samples withstood the effects of gamma irradiation well while the cast 
samples suffered a decrease in their mechanical properties (p<0.001).  The UTS for POSS-
PCU decreased from 62.3 ± 6.7 MPa to 48.9 ± 5.0 MPa whilst POSS-PCL went from 
57.7±2.3 MPa to 42.9±4.8 MPa (p<0.001).  The reduction in UTS translated itself to the 
Youngs moduli which were both significantly reduced for cast samples of POSS-PCU and 
POSS-PCL. 
 
7.3.3 ATR-FTIR  
Attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy was 
used to analyse surface chemical changes upon sterilisation with the results summarised in 
figure 6.2.  The peak assignment was as follows: 1100 cm-1 (Si-O-Si), 1240 cm-1 (urethane C-
O-C), 1400 (C-C aromatic ring), 1540 cm-1 (N-H & C=N), 1589 cm-1 (C=C aromatic), 1632 
cm-1 (NH2), 1736 cm
-1 (C=O).   
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Figure 7.2: ATR-FTIR analysis of POSS-PCU nanocomposites following sterilisation with 
EtOH (10 mins and 24 hrs), Autoclave and gamma irradiation.  With each spectra is a 
summary of any changes in key peak intensities (n=6, p<0.05).   
 
Ethanol treatment had no significant impact on either of the POSS-PCU or POSS-
PCL samples, cast or porous.  A slight increase in the peak at 1100 cm-1, attributed to the 
POSS moiety, was detected for the porous sample incubated in ethanol for 24 hours. 
Meanwhile autoclaving POSS-PCU caused a slight decrease (p<0.005) in the intensity of the 
ether peak at 1245 cm-1 for both cast and porous samples. 
 
Exposure of POSS-PCU to gamma irradiation led to significant reductions in peak 
intensity at 1245 cm-1, 1540 cm-1 and 1740 cm-1 on both cast and coagulated samples.  There 
was, however, an increase in the intensity of the peak at 1095 cm-1 for the cast POSS-PCU 
sample (p<0.001). 
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Similarly, both POSS-PCL samples demonstrated a reduction in peak intensity, following 
exposure to gamma irradiation, at 1730 cm-1, 1540 cm-1, 1240 cm-1 and 1165 cm-1.  However, 
the cast sample of POSS-PCL also exhibited an increase in peak intensity at 1100 cm-1.   
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7.3.4 Gel permeation chromatography 
GPC results are summarised in figure 7.3.   
 
 
Figure 7.3: The percentage change (compared with unsterilized control) in number average 
(Mn, top) and weight average (Mw, bottom) molecular weight of POSS-PCU and POSS-
PCL, both cast and porous samples after sterilization via a 10-min incubation in EtOH, 24 h 
incubation in EtOH, autoclaving, and gamma irradiation (mean ± SD, n=3). The molecular 
weights of the unsterilized controls were as follows: POSS-PCU (Mw = 108 500, Mn = 
42,600), POSS-PCL (62 800, Mn = 31,200). 
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 The untreated POSS-PCU was found to have a weight average molecular weight (Mw) 
of 108,500 and a number average molecular weight (Mn) of 42,600 whereas POSS-PCL had 
an Mw of 62,800 and an Mn of 31,200. After treatment with ethanol there was a negligible 
effect on either Mw or Mn regardless of incubation time for any sample. Autoclaving the cast 
POSS-PCU resulted in a 9.3% increase (p<0.005) in Mw but no change in Mn possibly 
suggesting a degree of cross linking. No changes in molecular weight distributions were 
detected in autoclaved porous samples of POSS-PCL. Exposure to gamma irradiation had a 
significant impact on all of the samples. The Mn of cast POSS-PCU increased significantly by 
21.9% whereas the Mw decreased by 12.3% (p<0.001). Meanwhile for porous POSS-PCU 
both the Mn and Mw increased by 27.3% and 17.1% respectively. Both cast and porous 
samples of POSS-PCL exhibited a significant (p<0.001) decrease in Mn (11.2% and 7.2%) 
and Mw (13.4% and 10.4%) respectively after exposure. 
  
7.3.5 Cytotoxicity 
The results of the AB assay are presented in figure 6.4 as a ratio of viable cells compared to 
control cells cultured on the tissue culture plastic, following seven days of incubation.  Whilst 
no significant differences were detected between cell viability on EtOH treated and 
autoclaved samples, sterilising via gamma irradiation reduced cell viability by approximately 
50%, compared to EtOH treated and autoclaved samples, on both cast and porous POSS-PCU 
samples.  Sterilisation technique had no significant impact on cell growth on the cast samples 
of POSS-PCL samples and no cell growth was observed on the porous POSS-PCL samples. 
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Figure 7.4: Cell viability after 7 day incubation, as determined by Alamar blue assay.   
Results (mean ± SD) are presented as a percentage of the control cells grown on tissue culture 
plastic (n=4, * = p<0.001).  Gamma irradiation appeared to reduce the number of viable cells 
by approximately 50% on POSS-PCU whereas no significant differences were observed in 
cell growth on casted POSS-PCL samples.  No cell growth was seen on the coagulated 
samples of POSS-PCL. 
 
 
 
 
 
 
 
 
201 
 
7.3.6 Efficacy of Sterilisation 
 The polymer materials were incubated in TSB and THY to test the efficiency of 
sterilization with the resultant level of bacterial growth reported in Table 7.2. 
 
   Growth in Media 
Sample  Sterilization 
Technique 
TSB THY 
POSS-PCU Cast EtOH 10 min 3/3 0/3 
  EtOH 24 h 2/3 0/3 
  Autoclave 0/3 0/3 
  Gamma 0/3 0/3 
 Porous EtOH 10 min 2/3 0/3 
  EtOH 24 h 3/3 0/3 
  Autoclave 0/3 0/3 
  Gamma 0/3 0/3 
POSS-PCL Cast EtOH 10 min 3/3 0/3 
  EtOH 24 h 3/3 0/3 
  Autoclave n/a n/a 
  Gamma 0/3 0/3 
 Porous EtOH 10 min 3/3 0/3 
  EtOH 24 h 2/3 0/3 
  Autoclave n/a n/a 
  Gamma 0/3 0/3 
 
Table 7.2: Bacterial Growth Observed on Each Sample After Incubation in Tryptone Soya 
Broth (TSB) and Fluid Thioglycollate Medium (THY) for Cultivation of 
Microorganisms. 
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 THY is a viscous growth medium with reduced oxygen levels which tests for the 
growth of anaerobic bacteria and other organisms capable of growing in reduced oxygen 
tension. No evidence of bacterial growth was observed after incubation of materials in THY. 
TSB is a general growth media for aerobic microorganisms and is designed for the growth of 
aerobic bacteria, yeasts and moulds. The materials sterilized by EtOH incubation were not 
fully sterile and sustained the growth of bacteria for at least 2 out of 3 samples tested of each 
material. Autoclaving and gamma irradiation appear to be far more effective sterilization 
techniques based on these results. 
 
7.4.0 Discussion 
PU’s have found numerous uses as medical devices primarily due to a combination of 
biocompatibility and suitable mechanical properties.  However, degradation through 
oxidation and hydrolysis, once implanted, has limited their use.  Siloxane based polymers, on 
the other hand, are resistant to oxidation and hydrolysis, and also show good 
biocompatibility; but they are not mechanically robust enough and are prone to mechanical 
failure.  In a bid to utilise the mechanical integrity of PU’ss and the biostability of siloxanes, 
our group has tethered a polyhedral siloxane cage to the PU backbone.  An in vitro 
examination demonstrated it to be more resistant to hydrolysis and oxidation, results which 
were later confirmed in vivo.  
 
However, the impact of sterilising technique is as yet unknown.  Sterilisation can be 
achieved in a number of ways including steam and gamma irradiation.  Depending on the 
chemical nature of the material and the processing method; sterilisation techniques have been 
reported to induce changes in material properties. In this study we investigated the effects of 
sterilisation on two POSS polyurethane nanocomposites: a non-degradable POSS-PCU with 
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an aromatic hard segment and carbonate based soft segment, and a biodegradable POSS-PCL 
based on an aliphatic hard segment and caprolactone soft segement.  Further, we investigated 
the effect of sterilisation on phase separated POSS-PCU and POSS-PCL.  Phase separation is 
a popular method to create a porous, 3D environment for tissue engineering applications (Wei 
and Ma, 2008).  The properties of the sterilised samples were compared to untreated controls. 
 
The four samples assessed were incubated with 70% ethanol for a period of 10 
minutes and 24 hours.  ATR-FTIR analysis indicated that no changes in the surface chemical 
composition took place.  Further, there were no significant variations in molecular weight or 
mechanical properties suggesting that neither surface nor bulk properties of POSS-PCU or 
POSS-PCL were affected by ethanol irrespective of incubation time.  Whilst ethanol has been 
shown to be useful in disinfecting lipophilic viruses and gram-positive, gram-negative, and 
acid-fast bacteria; hydrophilic viruses and bacterial spores are resistant to the microbial 
effects of ethanol making it unsuitable for sterilising biomedical devices for in vivo 
applications (Holy et al., 2001).  However, in this study no signs of bacterial infection or 
cytotoxicity were observed with cell growth being in excess of control cells cultured on tissue 
culture plastic following 7 days of culture for the cast sheets and 75%  for coagulated 
samples. 
 
The process of autoclaving requires samples to be exposed to high pressure saturated 
steam at temperatures of 121oC or more.  The combination of high temperature, humidity and 
pressure has been shown to be quite detrimental to PU’s with decreases in UTS, hydrolysis 
and oxidation being reported in polyether based PU’s (Simmons et al., 2006).  The 
caprolactone based POSS-PCL also could not withstand the effects of autoclaving with 
extensive deformation of the samples being observed.  It is likely that the aliphatic hard 
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segment of the POSS-PCL decrystallises and loses its structural integrity upon exposure to 
high temperatures.  The result of which was that further examination of the autoclaved POSS-
PCL samples was not possible.  
 
The non-degradable POSS-PCU samples were, however, relatively unaffected by 
exposure to autoclaving with the cast and coagulated samples retaining their shape and 
structure.  GPC analysis suggested there was a minor increase in Mw of the cast sample 
which may explain the slight increase in elongation at break experienced by the autoclaved 
POSS-PCU.  The small changes in behaviour may be due to a minimal degree of cross 
linking experienced by the material.  The coagulated sample of POSS-PCU exhibited a small 
decrease in elongation at break alongside a reduction in ATR-FTIR peak intensity at 1245cm-
1.  These results are consistent with chain scission of the hard segment.  The porous, 
coagulated sample has a significantly increased surface area, compared to the cast sample, 
offering a possible explanation for the difference in behaviour between the cast and 
coagulated samples.  Chain scission may be induced by the moist environment at the surface 
of the material as opposed to the high temperatures being experienced by the bulk.  No 
significant changes were recorded in the molecular weight profile of the coagulated POSS-
PCU sample further reinforcing the belief that chain scission is a surface effect as opposed to 
bulk.  
 
Mixed findings have been reported regarding the effects of gamma irradiation on 
PU’s.  Whilst some investigators have found no change in material properties following 
exposure to gamma irradiation, an equally significant number of publications indicate severe 
degradation of material (Haugen et al., 2007; Simmons et al., 2006; Grad et al., 2003).  
Gamma irradiation is advantageous in that it is a rapid and highly effective sterilisation 
205 
 
technique.  However, in the case of both the POSS samples that were tested it caused severe 
damage and displayed cytotoxic effects upon the cultured mononuclear cells.  Whilst cell 
growth on the POSS-PCL samples was unaffected by sterilisation technique, gamma 
irradiation reduced cell viability by more than half on POSS-PCU.  Whilst the exact 
mechanism behind this observation is unclear, there are reports in the literature of PU’ss with 
MDI based hard segments releasing 4,4'-methylene dianiline as a degradation product 
(Haugen et al., 2007; Tang et al., 2003).  Aromatic amines are known to be highly cytotoxic 
and gamma irradiation has been shown to release 4,4’-methylene dianiline previously giving 
rise to cytotoxic side effects (Shintani, 1995; Golli-Bennour et al., 2011).   
 
No changes were observed in the appearance of POSS-PCL samples after exposure to 
gamma irradiation; however, the POSS-PCU samples had discoloured and became yellow.  
The difference between the two samples is most likely due to the MDI in the aromatic hard 
segment of POSS-PCU.  Exposure to gamma irradiation may have oxidised the central 
methylene group of the biphenyl leading to a highly conjugated quinone chromophore (fig 6).     
 
Analysis of the surface functional groups of the cast and coagulated samples of 
POSS-PCU via ATR-FTIR provided further evidence of material degradation.  Reductions in 
peak intensities at 1245cm-1, 1540cm-1 and 1740 cm-1 are all consistent with hydrolysis of the 
hard segment.  The significant reductions in Mw for both samples, as well as Mn for the 
coagulated sample would appear to corroborate those findings.  The Mn for casted samples of 
POSS-PCU increased suggesting that cross linking is taking place.  As Mn is a more sensitive 
parameter to the lower end of the molecular weight distribution, these results would suggest 
that chain scission is taking place followed by cross linking of the low molecular weight 
chains of the casted POSS-PCU.  An increase in ATR-FTIR peak intensity at 1095 cm-1 
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would reinforce these findings as ~1100cm-1 is the region where we would expect to find 
ether peak as a result of cross linking.  However, it is difficult to assign this peak with any 
certainty as the Si-O-Si of POSS is also expected in this region. 
 
There is no evidence to suggest any cross linking is taking place in the POSS-PCL 
samples.  GPC data showed significant reductions in Mn, Mw and Pd for both the cast and 
coagulated samples suggesting severe degradation of samples.  These findings were 
reinforced by the ATR-FTIR results which found reductions in peaks at 1730 cm-1, 1540 cm-1 
1240 cm-1 and 1165 cm-1 indicating chain scission in both the hard and soft segments.   
 
The effect of polymer degradation was seen in the mechanical testing of the samples.  
The UTS and Youngs modulus decreased significantly for the casted samples of both POSS-
PCU and POSS-PCL.  The coagulated samples did not display any significant changes in 
their mechanical properties.  This is probably due to the highly porous nature of the 
coagulated samples meaning that the true cross sectional area upon which force was applied 
was considerably lower than the measured area resulting in lower than expected values.  The 
force range upon which the samples were examined may not be large enough to determine 
any detrimental effects on the polymer chains.  
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7.5.0 Conclusion 
Sterilising POSS modified polyurethanes via EtOH resulted in no observable damage.  
Whilst the high temperatures involved in autoclaving, destroyed the biodegradable POSS-
PCL samples, the non-degradable POSS-PCU withstood autoclaving well. Gamma irradiation 
however led to significant degradation in both samples and had a cytotoxic effect upon cell 
culture.  The results indicate that autoclaving is the optimal sterilisation procedure for POSS-
PCU; however, more suitable methods to sterilise biodegradable materials is needed.  Tissue 
engineering scaffolds are purposefully designed to degrade over time; however their fragile 
nature also makes them unsuitable for the standard forms of sterilisation.  Therefore, new 
methods capable of sterilising without affecting them chemically, mechanically or 
morphologically are needed for in vivo use of biodegradable scaffolds. 
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8. Summary 
 
Over the course of this thesis the aim of the project developed and changed as the work 
progressed. Initially the project was designed to look at the possibility of developing an 
improved scaffold for use in vascular prosthesis using the novel nanocomposite developed by 
our group and seeded with human cells derived from a human umbilical cord source. 
This series of experiments has demonstrated that it is possible to extract stem cells from 
human peripheral blood and seed endothelial tissue within a reasonable timeframe.  Flow 
circuit studies demonstrate that cells remain adherent on the graft surface even simulated 
physiological flow. 
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It is generally acknowledged that in order for a vascular prosthesis to approach the 
patency of autologous saphenous vein the development of an endothelium on the prosthesis 
lumen would be essential.  
As the project progressed it became apparent that both the single-stage and two-stage EC 
seeding processes which had been attempted by a number of groups including my own 
previously were not, when translated to clinical practice, very successful. This was due to a 
number of factors including the difficulty of obtaining an adequate number of cells to seed 
prosthesis and the requirement to undergo two surgeries in order to obtain the initial cell 
sample. Other challenges could include cost, lack of specialist facilities/staffing, regulatory 
matters and ethical issues.  
As a result, it became necessary to consider if a different approach to the issue of cell 
sourcing would be more realistic. During the lifetime of this thesis, there was increasing 
interest in the new field of stem cell technology. While many of the most commonly used 
sources of stem cells would face the same problems as the cell sources previously 
investigated for vascular prosthesis seeding (such as lack of availability for cord blood and 
the difficulty of extraction for bone marrow derived cells) one other cell source, peripheral 
blood derived endothelial stem cells, appeared to be very promising. Peripheral blood is 
relatively easily obtained from patients with minimal risk and inconvenience to the patient. 
It was therefore postulated that it may be possible to design a practical process to produce 
an EC seeded vascular prosthesis within a clinically realistic timescale and this became the 
revised aim of the thesis. Such a process would involve initially extracting a sufficient 
amount of blood from the patient after which the EPC and circulating EC’s would be 
extracted in the laboratory. The extracted cells would then be either cultured until there were 
an adequate number of cells to seed the prosthesis or seeded directly onto the prosthesis and 
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allowed to attach firmly. If necessary, the seeded prosthesis could also be exposed to pre-
conditioning prior to implantation. Once successfully seeded the vascular prosthesis could 
then be implanted into the patient in more routine clinical settings. 
Such a process has many theoretical advantages. As the cells used would be derived from 
each patient individually there should be no issues with immune reactions to foreign cells. 
Should insufficient cells be extracted or the extracted cells fail to progress then either a 
second blood sample could be taken or the patient could still have an unseeded prosthesis 
implanted in urgent cases. In either case the patient would not have been exposed to a 
preliminary operation with its attendant costs and risks. 
The work presented in this thesis demonstrates that the nanocomposite used to 
manufacture the vascular prosthesis is suitable for cell seeding (Chapters 2 and ). Chapters 4 
and 6 provided evidence that it is possible to extract sufficient cells from human peripheral 
blood in a suitable timescale to seed a prosthesis and that the cells so extracted and grown 
demonstrate EC properties. Chapter 3 examined the possibility of modifying the surface of 
the nanocomposite to improve cell adhesion and growth and this is an area in which much 
further work could be carried out. Finally, Chapter 5 investigated the effect of flow on seeded 
nanocomposite both with and without preconditioning. Chapter 7 examined some potential 
methods of sterilizing the vascular prosthesis prior to cell seeding. 
Given the above it can be concluded that the postulated process for developing a seeded 
vascular prosthesis which can be implanted into a patient in a realistic timeframe is a 
potentially viable approach to the problem and provides a solid base for further investigation 
and progress to clinical usage. 
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All of the work presented in this thesis has been published in peer-reviewed journals as 
has much of the work on which it is based. A full list of publications is included in Appendix 
A. 
8.1 Further Work 
 Vascular disease represents a huge healthcare burden. In the United Kingdom, there 
were more than 1.6 million episodes related to cardiovascular disease in NHS hospitals, 
accounting for 10% of all inpatient episodes among men and 6.2% among women. With a 
mortality rate of 28% and a cost burden to the NHS in England of £6.8 billion in 2012/13 
(British Heart Foundation 2014) there is sound clinical and economic reasoning to pursue this 
area of research. 
There are numerous areas in which further work could be carried out and great opportunities 
for further progress in the field. The area of surface modification of prosthesis is a vast 
subject with numerous new approaches being investigated constantly. There is still no 
generally accepted method of extracting EPC from peripheral blood and this area would also 
be very interesting to investigate further as would the effect of age and other health related 
factors on extracted cell numbers. There are also still some practical issues to resolve such as 
problems with using non-human licensed tissue culture media and supplements (such as FBS) 
to extract and grow the cells as well as making available the facilities to do this. 
 Finally of course eventually there would be the need to assess the process in a clinical 
trial with human patients for safety, quality of life, cost effectiveness and other clinical 
outcomes. 
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8.2 Conclusion 
The work presented in this thesis demonstrates that the development of a two stage seeding 
process for peripheral vein grafting using autologous peripheral blood is a viable possibility 
according to these early experiments.  
Challenges remain in developing this methodology for clinical use. Given further work, these 
challenges such as the cost, ethical and practical issues could be overcome to develop a 
clinical solution to the burden of cardiovascular disease in future. 
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